var title_f19_7_19568="Apical 4 chamber view";
var content_f19_7_19568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical four-chamber echocardiographic view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 311px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE3AWADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooq1Ba+aitvxk4wBk0AVaK9J8BfC6TxSAZ9SlsBjJH2JpT14wNy5zXaaj+z/ZWMSyT+L5UVugk0kq2fTHm0AeBUV1PjXwovhmWOEXc11MSd/wDopjRR7NuOT7YFc4sQx87bG5wCPagCGinkKD94kfSpYoFdctJtPUjHQfXNAFeirDW4yu19wIzkDtTTEoYgvyOoA5z6daAIaKsfZiOroCOuT09KSKEPnLkcgZxkZ+uaAIKKtG127tzkEDkY5B9DzTZLfauQ/P8AdOAf59OKAK9FPdAqoQ2dwz9KZQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUowepxQAlFWBHEwXBcE5DHqBQtv+8KkE+mOg+pxQBXruPhxof8AbeowC5SSS2gO/bGuT178/WuStLQ3NwqLvK7wDtXJwe9eyeGFttB0iO2to5pLxSWdsHehOSMDIFAH0H4OtPDNjZRhbd4pxwPMYMwBH6CtrxDZaHqdjtM8S5XaMDdgfTnv3r58t/GM8mY447dSmGIkGWPuDnk/yqe58YPbI5mKxkAAL5hYsfQHpgn8aALnxG8CWclu8treJIB8u1VycjtnBANfPGqaU+mz3UV1MI5omwoKNmTPXBxj869ik8aNOSW075JHyVDHGR7YxWf4i0rS/Elj5mlW93DcAgs1zETgkdM7TkccGgDxok4OC23p/hUiSbARyGX7oOeD6+xq/Pot3bahLbTosBQMQ1wfLUge571nlGTKtnaP85oAdv2ksrNjIIOTke/B600sWUtzkdBk8e9KdpxtYhiQeOc+/wBaYVKsc4GODg0ASE4RtpCgdR3+g79qcJip5fHBIGOPp16dqijwZAOgY44pwRim4beW29QOf8OnNACmQtGiA5OSSWx/nFS5JzvPAxkMMN1z+XNVlO1fr/n19KkVmLKNw555IOfr7UARy4DYA4HHTB/GmVJL977249Cc5yajoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKmtEV51VyQDnkdQccVDT4nMbhgWBHdTgigCWZ9uAqqAO27OAe1NDlpMcBiwxjpxxTxj5WwqrtClse36k969M+HPgFr7y9Svbcuh+ZYHAC7PXPegBfACW+ij7S0kTvJhceUWf2+hz07VuajHJqeoy3K3FxFAoHz7TkfgP4h3FJ4k0q2tLll0+3tox9x8LuK+nbrTNTki0zwyiCJYr5xl5SpB6/3cYDf5zQBkSamu9YEDuF4V48hnHfv19ayNU1NGgEHlShjkoQ/THXndjn9Kxk165t9Sa4Z453j3BW+bGe233Pes/UNSnuJ3aVsCRic4OB2OOaANG01JwplWWRlGcB2GF/X9a3tI1q8tQ6tIFLkJ8rgnGB14PHXpiuN0m6aCYxIod3BT5sn8ByKveU8M6tdbYA4ypj+ZUyOvU8UAdb4k0aXUrJZ5rjzHVT5YZ1474xjOfSvO3tJFn8lUzLu8sKMk7v7uMda7OwVJ0kigG4IuPMkfHmH0BzzUfiDSW1BY5rWCYTqMZ28YA6YxyffPagDjZbeeCUpLE8UikqQwxg+n1pqqXKmTdg9Mck/Sl8t0Em4BSvyncPwx9aRSCuHVtw4GB79KAFVQWLc7ck/Lwe/So/4QQSSMgj0H+TSDG0/y9aceQRgeuQOvXp7UAKAWZSCzSHn/JpFcjGzbwep70Pk4LDHGenX/wCtSHdtbJ5zyMc/jQAsz7jwzEZOA3ao6cT2znHem0AFFFFABRRRQAUUUUAFFFFABRRRQAUUVIsMjuqquWYZA9RQBHRTlUscCkx16ce9ACUUpFPSKR8bI3bOcYUnOKAI6KdtPHv0pCMEg4yPQ5oASinAc44/OgIefu9M9RQA2ilxxnjH1p5iYIWO3A/2hn8qAI6KXFO8t8A7Tz096AGVJDkyKAMk8Y9c03acA4wDwCa0ND0yfUtRit4hwzBWOR8oPf6UAdB4E0B9d1eNT5/lK4JEafIR0xnp2/HFfVWmaTb2WmG0uI5IRBEGJc4UoByeoOevHtXO+BdN07RNLgg02K3ubqPBLOAM4ycnH4YrpPFeol9JMk9nJFK67FAXd2z3HU5PFAHm/iARXuo/ZrchI4pSIhGfLYcZzyTnNc18RTpwQPfrJJKU8sFpgzZ9P589K0be2a91AW9r5rzOMJnLsvchVGM+9ct490/VbSYLfqki4/1casNnqByePUnvQB5tdRwbz5RJQ4Cg/e44x0/Wq5YHa0nOMAYGAcfhT7k5lORgkZIGcDngcnp71Cdu75dhznrxj+lAElqyC43sSMH+Ae/b0rS+1S6jKkUpUe5Yrj+mfasksEb5CCMDgjOfr+NXrK2mmJdSo3cdO/Ht1oA39CvRYXLvEFebaRG3mfJ6HHPP/wBeut0+/WUwztesEjzykgTk9UGScg+v1rgDdG2lCIis28OjsuM4HQcD0GRXrfhf7NrunvcXAtbNIUBWPjMreqr1A596AOC8Q6INSt5tStJUba2ZIwQM+nf9a428uZ7iTfd3EkxChQGbJ4P3TXth1QaZH5FvoolWUHe8ZbaFxyenA9+teX+IdJkaSS+t7O4Fs7EjfkkcevHy570Ac24Xls5GeuMZ/wAKTKjBUc993NW5pyLaOJobYNHldwX529zz27fhVQltqnJwOnsaAAJubCMD6Z4/ClBHLDAx6jj6UnCk8Z6j5h0pOSO2KABvTBGOx7U2lNJQAUUUUAFFFFABRRRQAUUUUAFFFFABXX61ous6Ta2l7q2jz2dtMD5Ek0ZAkXrn6DPFchXpvxI8aaX4i0jSrew022iubdT50yw+WST25Y5HvxzQBw95qIktliisrS3RiH+RSWOOxJPQ9fwqs7BWeRgGZ14Lc7cj0x9fpUTud+Y8g7eeMHH+fSnFdgJ/hJzxkj2z7UAOWdkQRpIVhbqM8/j7+lPlklaLyhM5RRlgSSAen51F92QKG8rI/wA5p8Pl+SokcA8j73TrQBCwCyMFXC453DJAOKfMHbK/MDnoT19D9aayEgYQg9MEe3060qOFVlYc4OAe2M9fxoAA6liFjBX6c+n+f51MyoQVRG+VuSpGfb+tUwDjg8nt6/5/pUuR7sCMYHGenHTtxQAKSUZd5/d55zxjpgfXNMfBIAGSRwATxSM7EZPptH4U52bYwwoXOeMfpQAOGJDNgqRxzx/kVJkNCQQMDJGF5/D2460wy7uWG5gMA5wR/jTerbVK89ScAf8A1qALUGcokTMJGwoUZ5/Toe9e3/CnwPFNbxSSzLFdNiRpd2Ao5wAMjK9a8l8K6f5t7byy4MYbeucgH15xXt2giOznE13E6QM+EdBynT0GcUAelX2lR6Hp7S28KS8hXIfaSvPIGefpXG63rlwikp9sggT7wm2uD9PQ/wCeK6fT/ElqsTp9pjmNvlk83OBx09fp9K4bxZ4hk1LU0geXyrYg7gAMEk+uc/TNAEHw98VwJ4jkim09JnibKui4ZQB95TjAPc+tUfid4oEmrO6Sh2fBkDYwwGePu8Y70eAoY7TxK8unXsgj2s37yHzCcdhzkGp9Y0ybVNdvbm5ls7SNx8806gEAdMD29KAPEtd3G4MkYjCsd25AcEfljHNY2CASASoxnNd94qsI7ZjHa3P2iAZIdbdVU993uO2PauKmj2bjtLMCGOR+ZPHQ0AVgAW2jHPduMVbtmmGCkuxeB1AGB9T7GoNpVz8jAAjqSAufWpIsHPleZ3HIyBnt1oAvaXdQwyTPcW8V4rjAjcgA49s5ruPCbW11q8EkVvpUMX3gZZDt9DkZz+Gea4C1LxPJNPG+MYznAIPbJNdRoZWGN7lp4555cboXP3QDgNw31xxQB6l4ggsLq6MtrYGcsCiSQJxKwHUYHTtj8a5++jns7Rrcv5gdMi2eA7Rn/gPT/OKtaJq11f2jReZJ5kDbR5aD93kdevBHpVeaDTbO7RnnuJpS2XLHJBHsf5UAeUa7pM9hPl7eaNHPBcH+eBVHzIRbGOaCQ3AI2yeZgBfTbjn65r0DXrm11H7QjyNbWIyyKEBbd2yMVwN7bCEts3bM8ZGCKAKuaUE8kFumPwqWBYDFM07yKwH7sIoIY+hORioQMkD14oAVieN2eB39KbRRQAUUUUAFFFFABRRRQAUUUUAFFFFABV+UANkEZzwoA+hJ9jVCrc6SpMf9lsjJ9x+lACSKcuzhiqgAAkdPTio1YqpLHJycqcf1p6IoYk/LtXk9m4PvUsKRNvCnaxGQG/D+dAFUPkAHII7jr1707KncJPvZznGO/Of896fNA0K7l3EfdJOOD3GKgJ4AOOPSgB77s8AgZ4yMEegzTSSVJYn8uv8AnNKAQeoUjv1H6Uj4LYChPXrxQA7J2jaQQvOPT+tMBHcfkaBjHJOfpSg8rjcT2x/SgB2447HdyQB0/wAOlNyCcHoe5/h5pAQGzzj2PNKOTlchuvFAADjPTB9eas2FsbieIYBBPbuc9DVb74AHX/P5V0/hsK6CNrlYmDblXkI2PfPJoA6DRdIVLiG1nSSNHTK+YflPPqM4HtXVR3MOl3EEVpJHJMpJdSSAPxC8rWJJI1w/7q9eTZhjEJNxc+oBOBg9qrWsRZpDbKom3DejyLu92y3bjoKAOh1PWboXokjSFfM+cmMHcvGOcjp6Ae9V/DbWuqasVt5mlvcFhE24DPfOcfhWNqM07QMZYVEiKQDCVOBjq2B0/GrXg3XI47yIPbWgn3gb5QSV78BRmgDtLa4lOpqIrWOC8BKBlViFI47Nyao6nqdrFfH+2Jxd3Cn5t03lgkdtueo9O9dRpGvyXGtxRWEsb3sYwo8oxgjuDkflTPHlpr2pyTXNxpVtMzYdpIrf5wF9fmH6UAbup+H9H1bwrbazbWkNva+VvcvAoZvcDPHv618/XfhS51641uXQUgW30a1N9cPLJgmMZyV45PHT2r2qHx55XggWGoXUKyIcCJIQXI91LYHPbNcN8OdX0G11Dxxaa5q8ekR63pZt4LiWLcoZs5O1SfXOMigDzODwzqV/4PvvFECQyaZp9xHb3CeZ+9jL4wxXH3CSBn1Psaj8T+GNR8MwaO+omJG1WyW+hiSTc6xPkLvGBgnGe/55x6J4Kv8Awp4N8V6l4e1LxDFrHhDXtN8i9u7aCRFglBYodpBJZccEA48wehrj/in4lj8XeO9T1OzULp+4WtmpHCQIuxML/DnG72LGgDk1dwvLymPPyAHrjgVr6Zqlpb2/ltBcPdkY3F/kz15HtzWGeMrkA4wRjjOcf5NSR+Y0m5M7n6ED8+MUAeo/Dm8h/teBdbkvFtycM4clSfViD16da6vxhFDf3kn9l7TaQJuaYy7AB/eAz8x/KvGNLZrZ/MmJRSQXUOQSM4wR2ODxX0Do1zpt3pELWdjFDBHtQvOp3yt3Oe5x2oA8g8RXaXUcUcMLx2kXVvQeucnJPpXPXts9wu5ysSqDjJztz0HBOf6V9C3egaj4t06aG0khtrBVz5iR7Rgf3eeT0zXgPiKw+w3slvH5h2PtJXPT/Yyec96AOdmUK+Bj8DkfgaksoRcXKRmaGAHP7ybhR9cA06RCyEHJZRgYBIx6Dn+lVyAB15FAA4AdgGVhnqo4NNp4QlwiAsx4wB1Pt60SxSQuUlRo3HVWGDQAyiiigAooooAKKKKACiiigAopSP1pKACtJ1znBCrn5iRk8nt6+lZtbNyV3OrZBznAY59z78igCs5G39yoyDklfx5prOMIqIyuq5DE5A//AF/pSyBdq+WGjI+UkDoPx/nULFyJeSMMPmHA44oAdBK0ezcWUbiMdByMHimtHlg0JynPUjKj0x+NQ7gAQUAYH/PBoVgMZzj6/wCe1AC7+ML90c+me3rSNjPBHAx060pw2SAoBPU9jSlCh2lTvzwSOPwoAjOehGCOOlSbWKM5I64ODz0/lUeP0p6AbSWUkDuOn0NAAygbenrz/I03PPPPalPzHdwTnG2nKuSGVSUJAIx+JAoAtWcSAHzVwMck5H4dK2454IwvyJKmMtsYjg9+g5rHtDCMl4RIG6ZPIHp07etbNm9oq5mURqMAMmRuGeh+X8aANe1EduIp4ZZtygZZs5bPTI3dRVnWb9XwyTwBkYAuoKgH1IzyfasyE3Ck/Y3MkR+bJJVT9flAzWfdXaoxivGV8ncyljn8fegB11fTwlydwLDcWA4HqxGeevSqlreATGKUZAPy7MFgOpw2Dyf0qA3BMkm4MFcdckn/AHgCc5/SpdPkiFyhy6plVJjPIJyfx560Ae7fBq3gEZM+jrcDAP70/MFz6heR71tePdGS51Nmkj1FbRwHZuqhfTp27ZqP4XBNHc3Fteq+5fL2MRGCCOjEk8c/Wm+PriCAXCRQm4jkIDKjiTnrgnGQKAPN9d0Jrm0ml0y6We3hOG3x7GOOxYd68yvA/wBocSHadxChQck/hjmus1fV5LeOaGJRGjMdiBANo47beenWuQuJbqV1MhkOAcA9h6dOvWgCnuJ6cAdBnp9KUnJ4wO3B6dffpQEkBXKuOeOKPKII53AjgqM54oAlEgHRQTjZgnj3HXp70RTKh3ldxJxnIBH0FMXIYc4DcDOcEc/pmnp8zknDBeOD2/PpQA3aJSzLksWJIJAyM9h/npXpnhTX7ODSFsbczI4/dyMIdwPcYOMBq8yfaScKB8oIyfp710fgy8kNwLKOGBlmYBlI5f04zz+FAHrNzqFpp2jTrb6xKHlxmKIbdx9OnB68V5Dq0s805EWVSQAkjPT0XivU9J0uw0PUUuvENvHdTybREmwDDemM8Hir/iDwjZGwl1TU7qCzimDNFb/LvY9gOPzA/OgDwW5K79ztIduRyeG9McdKhdAVJXGR1Azz7j24ra8Q2yC4X7HA4jIJV3TDSYPYY4FZSR+YzNLuClc5Axkeo46CgCuozlAASf4qbwD6/Wp7lIhIfILuuOuMc+vTpUR4GAQfcd6AFljeMDfG655ywxnNNznqcYH51LPdXFwFE88soUBV3uWwB0Az2qCgBxGcYABPvS5yCxUHtnPf1puecnn696UsT1/H3oAEBLDGfXjqKCflxk49O1IaAcHI60ABozxjt/Kl5IAySM8DPek7UAOcg8qgXPPemU4/d9Pw602gAq5cs/3EyQTnOOc+1U6nuuJcF94x27e1AEZJLDODjtnjHpQWwMDOPrnimnk0A0AB6+lJRTugIyPyoAMkY57etOOc43ADGRg8DIzim+hI4Ht1o4A6nnqBQAd8Z4PWkPJo6kkk0HHGCaAHJ8zqCVHP3m6VabaqBFJUEbQ5OD7456dahQozEBeeTzjn9OPpVliJVYkAN0JzjqeDkD7tAD4vLQsHmyhyM44I9Bz0zWg0mYo0juGlDAERkg7fYA9utV40jJiXzODn5Twc+gHTFStaOJd/lyqvzDcqjIOOo54HFADk8+2UnzUX737sjIOeuBjFfQfwnu4rb4W+GmfXrXQvteuyWzCbTReC9LEfuSSP3ecY3ZA96+cyY0gjVoVLrhQ4P6e/1qwdZvorK2sI724Flaz/AGqKHfhI5eMsgH8XHUdKAPbJ/DNn4sn+IvhPTdEttP1+z1mK+09UwpETMsT4YdECnfjplx6VwnxcvtP/AOE+ksNGht4tN0iJNMgMYA80xZDsxGMkuTk9eBXLW/i7XbXxFNrkGq3SavKCr3qsDI+QAVJ78Y/KsyCOS8u3CRPK2/cdq5Zj9cfn60AfQPwGvvtV99n1DVGt94zFDtOxgOwOfu/41q/Eezt/DWoS2gtPMgmO9pIhtYAnOSxbpz1ryPwfr194fu0hvU2Qk58qRDEceoOKveNNc0+6kLxed8+MrtYKTxkBj1H4UAcx43nhW4DWzzHBAO9gxGPfPauRIaUK2TK/Q+wrc1a8N3sCSMqIAFUZAAPUdfw/lXdfDr4Wz+LPCMniDStRs7y5s7wRSaRJlWmUEFl37hguOgxg8/NnoAeZW+j6hPpFzq0FjPLpls6xT3CqSkbN0BPY/wD1qpsAQT19CBjd9OOK+yPF1hoXh7Wr+4gtIU8KamIdL8RacEEaWnmKPs94qYwgGQpOBzz1Br53+IGn+CtPt4tM8LXl3quqwzsLvVZP3Vu6gEbETnpgfN6jqQRgA8+BHDZ2twRx3z/KkYjdghRzkntj/CpHLrLvDNncMMBz/wDr9qjkHJJ/A4xkUAIqs4IUE4568Ct3wxNdWc8s8e5ARhiOGPNYjMxQKdmM5GAo6/8A6q19HthKVdo5Zdn8CHCkccnj3oA9ct9fgXSEi020vLmcgfNtLs3chjnj2P0rIhk1R5jfatDdM6gmP7V823A+oCnnr3qWPVLeKySQahHDFAvEKheR7/LyP1rM17xBqWuaUY4VijsIv+WshK7V7cYGaAMbW9UXVriZ2gVCTje5AOPU88e3auXuJIANrO0r5ywAwpOMbuvX270txKZMRSOPL+982cjtz7dcYqpOQsjbfMC5GVfO78ff0oAlZzuJATGcheN2fXHr7VUYAHAORUpIBPysGz3/AJ/WkwRxJuxu+Y5/l79aAIif0qY3MhtlgKxbFJIPlLu5/wBrGf1qI43e1NoAXJ/pSVPHLEttKjwb5WxskLkbB3471BQApxnjpRmkpc0AByeTnnvSoNxx37CkJJ680Z/WgBSCFHBAPc96bTy2VxgDnPA60ygAp7EhnB4J4P50ynMxY5Ykn3NACDHOaM8Y7UlL2oAByaXgDBAz65ptPAXb3LA8gensaAG44z2o9amkUEt91QMnB4wfT36UwIxQEA8njjrQA1TjJzg4qTIGDgnB7nBPH1pVjYf8syRjkMMfrU8UQ2jCKVByN3c+5Hb0+tAETpJKw4OT95m7n39KtSGFByvJ564ywx1/GnHCLIJH3gADDHqPft6VHGS7jYzY27sE5A684z7c0AbGjm282JLtyhc7sqoKjPfGK63UNCvPsB+wSC5i/hlVjkfTgfjXBaekizf6tGbbwcjAHHrXX6NeaaJIvtpkt5VkDB1GV46ZwOKAOXv7O7t7jaYJI3JBDFW4Hc5rOSJ2VcZwM5x2zk5XnpxzXqnizxBa3FmltNAkwAxG6qDjr04rzadI0xsGd+SoABPHYDstAEEBKfOko24ycjg88ge1XHukZvPjIikH8QOM4PrmqI3q2WYAEbskHGOgP6imOGJK9R1Ibvzj/wDUKAOt8OtL4jmW0vtVWMSYGZQpY9hkjmtPxT8P59LX/iWzSaizcfJAduPTNclopeKaMvLCvzDIeTGeO5yOfxr1G0SzuoY3W5iFzkDZHehVPuQSf50AcLpug6lpWoWN9rOh3N3psMyy3FtIpQTRgjcu4DgevFfRXjDxB4U0K3gvLY2dw97CYJbTStqi9tCoZJPkGIWhkbCMfmwp6k8ee+I/EU9tp8WnxJbokwwSswOMepGfyrzzUtRis1jntGtraYncY4o1bcR/F/8AWoA1Nc8Tal4ju0n8S6jI9wLaO2YeUUWSOMkq0oHDnLk5Pc9qw7qHTZXbyZ5Wd2wZACFY9Pmx09q0/h3p9t4w8aW665cpBpFnE+o6jNMQubePBZQBycnC4GTgk9q9u1Xw7oHimaG51IaAz/b31OeXSwpCaQg2wxy4IDSSEIFJGcE4+6RQB886t4Za2IEF5FduyjcI1LFc9N3fd6Y//XUPhnWEJlfT7pFXne0ZwvHUn19vavefGPwne28TeKte0OW18MaDpUQltxLFlbmQRhpNo6qmTgHn5uFHpg+IPGXiCy8P2dlqWnXlpd3lusqiTavmRt91sDqeDx7c0AeMS6Y8apExJkztCFQOvpz174zXU6f4LuI9KN3f6pp9rjhbYzq0kg9eGwO/Fb/h/RZdavYITZSyXU5wCg+6T7+vXJFepQ/DHSvCNh9v1m7hjmkHFvMpbIHpg5yKAPnm3uI7a5KWyDAGRgowPqec810V7oWrXem/arxF0+xCBh5rqGA/vY68g8VreJ9Z0+4vjLaW7sFb5ZEjKq3vjjpXIT3U2rPJHdX1xECciNnYqExztLNyfagDm72CJLh/s7x7E78MADwD05/pmqnJGEVcLnnGTz7966ptDjjhaW3jkfOT9oZuEHYg5x+NYF3tR1SFUUA44YMQfbnmgClt2hwc8YzzjnPSk67mYg55J/p060+VEGQHU4GeDnb14Hr9ajwATnGOwzmgBcA44LHPO3j+lR07Az1yKONoHegBDyamtBbmXF48qRYPMSBjntwSKhIwcHrSUAFFSW8ayzJG8qQqxwZHztX3OAT+QomRY5GVJUlAONyA4PvyAaAI6XJ9T6UpGcng+uBTaAFJycnrSUUUAFLjjPakpTyaAEpwOSSee/Pem0pFADwmSfutxwB1P0pythtvBAz6kD6e1R7T749uacjndkZB/h29jQBPtUqV+Qk8Lg5CjryakjKsWdsqcg7h6enT6Go4xF5pJ2kEgEY4z6VoRwoFOW+boMsD2z19KAIFVUQqyMRw2NvA6deO/p79qcq4Y7RznBGPXn+tKT5YZpACP4D24qv5rglM7WJxxzzjjPFADnZgsu4yABs7myefQ9s1I821D5nynkYJ5579c5x2qNpXLqY9p2sVA6c/4+9JKxKuM5bILBl+YHH86ALWlXBinVWeNVGPlb5h+PP+eK6mPOowiOYwJF0Eowc++2uShVdxBiDMR8rensOeTzXbeBvCV14rstVu7fVrDTLHTI0e5udQmaJRvJC9M9x378dxQBx2pxm1mKxFGTAJI5JH17VSNwvPChyM7iOT/wDWxXd698PtYsvGWjeGt9jcXWrLFJaXNtKZIJYpCQJA2M7RgknGcDIrG+IXgy+8DeIpNJv3gmkREnhniB2TxsMhlz6NlT7j8wDBR8rn5sk8D1/Tp0pZHJlUEupB4+Xj3HToeo/Gotkbly0n3TkAAHAH9Pap7dVSQsqqCrDA3Zx/+vt6ZoA7X4eaNHc37vqOm3bx7cK8a71H/wBfmvRFjisb6a2hksIIztAF0hcD8N2Q3X9aqaLP4VHhxX1USJcKp2CK4BO49uF61x11rE1pcyf2NHcGCQ4QuckcdPu9fWgCHxpePBqFxHm1nQnG+Hcqg9sfN+dcPcK0kijzVMgHzAsOuOPrV/Vr68v5na4kWRmBOQ3HPbge2TWNMoWbYAsgx1yensc9KACG5khnRk2Blz1AYHPrng9a3NB8T3uiyCWwu5ImE0E8kOSYp2ikDp5qg4cBumfWudZiWG0FfQZ6UinG0noD69KAPf8Aw98Tbfx1e6fonjO5SyttQ1D7TrF3NIFglij+aC0jH/LOLIGcnrkk5Y10es6deaj8SrzUfG0NrFbXBAsVMqvE9sPuCNgDkYIOeOWPFfMcXzD95JsAHysGyVHoBmt3R9QmguoHS6iKW/CiVjtA67V9BnnPvQB9u+FrfSdL04nTHtFVWODtAYDGcZK545riPFttH4nvpY3SW4RQfNlGX2ntjA4+lch8MvifoiSeRrT75XUZh2BkckdNxP5Zr1TRNZXxH5ttpnh8WllJ827Cp5w/4DQB4lrPgy5to3ttHtbi4eXnzQdiK/TjK8DrnNee6t4cv9Duf9KljeaU5kVQSiMMYy2MH6jFe+fEzSPsIjS3a4xvBVLZwQD6tgE8eleJeNVmTILRyLty4TahB9SGGf8AGgBtxqAtdNEdzK11MUHyoSixr/nua4C+uzLP5pAycj5W6D2579/xp86zBW2lfKHG8jg++SKoEAnczLzkcAj+lAAJMA4UA54wTwOcj6c05drRqBw5bGc9B6fTmm7OMqMjg8g8+tLJlgCTjBxgjp/n+tADQMjOF5OBz/8AXoBwvbPUeopTkLjggHOMfTn6Gm87f9nNACGkp3IyD+VNoAdtO3djjOM0g6+tBpKAJ7q3ktnCzKqllDAK4bg8joTURABIByOxptPeN0VGdGVXGVJGAw9qAGUUpyODnjtSUAFOY5JPQk9B0ptOwFcgtx0yOaAG09doI3AnrmkC8ZJGPrSDgdTmgBygZGVZh3wcf0pYgCeRnnoOvelSPLYbOckYH+fXFPWIcqxB4yCO/rzjsKAHhlCHar/J1G485z6dBSvKWUEOyErk7W6j86axLLs2gA85Axz/AIH0/wAKVwqOq4YEAsDnOD/hxQA1pt775Ms/Rjntn9aYzuIlXaAoORxnrUhRFjJGRgg5zzj1/wDrjNJvCgEH5gBg8np1HFADo03HcFUY4GCMden196GKiRlOTIuV54P8utNVAA7gK3GXA6KO3fmmeZtLAopYcZB4x0x/9egC0kpUDYJcngAHIB78Y+93r0n4XeM4PC/h3xrG0kX9oX9rCtjHNb+eksiSNuBUgr0bPPH14FeXJKVYoBtzxj29Pr71OkzlQF2u3c7Rz04HHH170Ae8n4peGZfHt14xksdQnvYdDjtLSzlBQNcklZCjAkRoFOMjrljjNcz8SvF+geMfA/h2Sws10nVtLkazj0/zZLhvsZUbG81gMgMuMEk9a85EjSIm75XI+XC9cdhgVRkZfM42hgM5BOAPb29qAF3hD8oGceZkLnPvyeKZI0gZWZlbaAdy847UsMuxAp2qAecEjHt79/ypHMYhyoAU9Dgk980ASbmYjdJhsKoGQCDnsOn41J5lxFIwV/LJJUAkDd7e3/16rbGADDhmxgL3Hbv0ppBKA4wpGcfjwDz0oAllLYaRzyw6LwDjg8Y4/rVTIJxjPrt79fyqxnacyLkP/C3Gfrzkf/WqJ1YeZk+5yBnOf060AMwBgEEAjv8Az+lI2O3Xuexpxyq4BXBAJx/nrSNwBkYOO1ACs5dRuJPUZJqWGSPcpkDlFHKKevt9PWoojt3HarDGMkdM96awCkjIPoRQB3eja3pNtblLfS/MlGAC7twT/wAC6e9eyeEvF08Fksep6l/Z1lGuxDJKWP8A46xP0zivnCwiDzL50giUjHCEsfccc9q9J8OXEcO5bfS7m8kbje0GfxbK8+2KAPQvFPiLTZ4YZbLUb5Zs4M0pwuD/ABEb8fT1rzPXLTT7+aS6n1wkqAWGAWJ9Qd3LY6Cuxn0W3urQyz6dLCScxpJIwJP+0OmfSuB8UrptqjxPEIz0AZiQD3zt6t7/AJ0Acrq4t/KC2txNMu7J3bcgepAPWqK7bZ2bau7A25IYj8M09pjB5ghcrFJg7gDn9e9Lc3ME+AlniYqFdjIzc45YDjB475FAFN2V2JORxngDr/hQShC/K2QMHB60hUDuT6kDj2pCBgYz70AC4yM8e/XmgqQSCOR1pB70lABTht2853Z6dsU2nc7c8Y6UADY/hJP1GKTjHvRmkoAKmknkkhjjeaV1ThUYkqo9uahooAXPGO1JVg3UpshaEp5IfzAPLXduxj72M/hnFV6ACnEenPGTjtTac+NxwQfpQAIeenr071NvXyyFBU9A27B56jGenXmogwwflHXP/wBb6VI6lY0Lt2yoPf8A+tQAjMMABnOR8wzx16fSnO5WJU3Egjnnke1C4Pyxrkntzhv/AK3+FMdShIXcAOckEE0AOMhuJGadsuxyWOBQGwGBIVioXnn+Qpgy7HALDnqcc460rEd2+fdyQP1zQA6Nz5gVUBP90jk+o9u9X9Pi+0I5OFIyQT37du9UiygbY1G4cg4wR9c0sc3lSAx4TgYIIOPXtQB0ej6Ct1I6B5I9y4+VScjHJ57VHr/hyWwG9JfPQZG3oQB269PeodN1WS3lMsbOjE/I6fh146V2+meI7XVz9i1yP94Fyk8RCtjqBtA5zQB5a3mF1UqWyBwD1HbvTkdedpbB45/iAH8Qz/8Arr26y+GWka+GS31aGxuDztdjIHz27Y/CuI8W/DrWPDJQ3KRzxdPMTJG0Z6jFAHIx3CjbllkUgFiwHbofXjPTvVYSozscAHIb2J6/hU0NvlzGxaMngO6tj8fTpxUcsDRTAlg54wRnBPTmgCPZulUsCxbnr27HNSBUB2uyrjBOSMcjB4x/ninFg7gyrllbGR3J5688/pT1LfZ2TCEH5tzLll47HPB4HtQBGVZgHIDM3CqV6gd8+lMZ2kdUwpOc5PTr6/3abllgbhccjBPIz/8AqqLAy2eeMgr0oAsNlSfNVuoyW4DfX19q9Y8Z6Dc33wY+Gcuk6TcXE7Jfee9palyR5q4LlR7cZ9DXkOApJUZwM4bnHTn9a6PTPH3izSNPh0/S/EWp2tlCpVIIbhgiAkk4A46kn8aAPoLwH4Oii+F9j4R1EaZFdeJbWa9uTcXKR3UM52m02xk7mGEJI7En3z8vXlvPZXk9reRvDcwSNHLG4w0bqcMCPXIOav3mtavPqsOqXWpXUupRFNl08jGWNkxsw3UYwMYqhcTzaheTXF3NJPd3EhkkkkYs0jsckk9ySetAEKscgAkegHrUkL4dSODnAUDPHtk1HhSOoHPXPH5UpCruGSRjKnGMn/OaAO78GaXpjziTUgVVTuR4XBbPfjcMAd69Qt/FOhaNEitOhiC7FYTE7RnqeentXzw7sPlVmUE53MeT71o2rxG3G5ZWnIzsjY7vwPNAHrutfECxnS5ttwvjghX2opH5nn6mvG9XvXuZmWRFTaThdoyvPQkdeMc024v7go0QUQLzkJlSfrz/AJyapE8DcT04JoAN4KgMCSOO3T8v1o455B+nce3FHy7iWBAxnH+e1LvHPAP1H6UAIcgdiD7UgHTg89B60mRjGMEd/WnbuD3z6j+tACMOTzu7k0h4HQ5pc8n+LPc0gODkdaAEpcnpk46UlFADgeCOn9aQdfWjFB4GCMUAJRS8EnsPege9ACk5AFNoooAKXjHvSU5uuc5zzmgBtS+YdoCrgAc55zTCRngcUhJY5JJPqaAHqf7wDEY69unWhnO9mAIDc4z1/wAmk3EHkYI/DB9aTJU8Ed+aAA/c4+7n9acMbcsDt/r/AI009s5wMcZqQuMgICRjbz1IoAHJOVUfN0bOMk/5FCI2VLBcN0DcA8deKZuwQBggHPKjmpGYsFMoU4+UYIH+RQBft2D23lptDk5Z2c/NgdOtX00aT7OJ5bWfaPnZ4vmX6+x9j71gRs4kO3C8n7w6f4V2fgvxRc6JOwZt1u33lcbh6nsec0AdF4G8XRadex2+oDfHtCgyryg9cgdfavT9Y07T/EukgaXqFm45bypZVBbPv2rEsbrwR4iy99EYLk5LNGHBkc98Y6/hite1+H+mzTC60C+WSRCrKkm5GXj1JxnvigDxnxV4T1PRbyU3Nm0cTAbTGfMDf8CwM9M+1UtFi+13CwsiySMQgUYLD/6/XntX0hcaWk1q1nqk7WckQ2NLKC0ZJHbmvGvEvhq/0uR57S5S7gVjsMD4yM9kznFAHoPhv4Radeack5gMEjrgmWQTfoRgV57498Dw6NftDGiqE4EjAoGPJ6AYBqHwx8QfEXhdZUcytEePLEu1cf7Wc4FWtd+ItpqyyRXmn2UkjH5nEYJI6bc56enFAHlV9E0MwA+9nkpnGT6cCqyFkcFR83bj1rS1CaxnmaaKKWIE4AUDjH44pDjyfKAsyzcK4xuH14oAzy7BRgn13Z798fnSxu5KANypwoP16UOMyAbcHoRkDkdfpTD0BI6igCUNhztb5R0xnH69s4zUbL8xUDBB59qUbCnHByBzz+P+fWkG3b1x7f16UABG0fdBGetSBswIhIxuJxkD8T6VHjDAH5eh+YUmGx0OBz0oAczDnPIxxxjHvxSbz0DELuzwKQhshSDkdsUg5wADmgAJycnrQD69KSl455+mKAFOTzx602ilOM8dKAFU4ORjjnmkzQDjkdex9KUHtkgd6AExxntSUUUAKevpSUUUAKaBwaSlGO/T+dABmjNGOM9qSgAopcfLnI+lJQAU4Dc2ADzwOabSkYOKAHBCTjIB75OKQjPT7o70nGPepANyE/LgD2B/zxQA6VGBHLFWPTkkH396au4lRsfAOAFJ+9/jStwNrINx+6B+H555pWceYwUuckkYOMZoAFAZvmI+pPDU6TADBuHVcYGf5/j3pNo/hbjorH8/8mlfzMnaBwMnHTHt7UARv8pcMu0n0P8AnimEYHXnOKnlydrqAO7HH+eKjX5l5YnA6YJ49PpQAsUgjzjBHow+9/hxVlBh1EeEkXgbjgA9f1+tVOWHL5zyc54+tOK+WGwS2PYjb7n+lAF2yupoJlInCOo4BXJ9hn15r17wJ4x1G1hWO8jEsQHzSR7W5+pBxivGIZikjZc5J5DjOfXnsa6XQtWghQrseIc7kRiS7Dvhmxn2oA9o1Txlc28e5FjljVQVjbAOfUEjHpWfpnjRdRvGt7mCJrnq25RnHXIIXGK861PU4LtZHubmQMcBAygsPXAztBrM0O3D3ckkExkIJZjJ8px2Y8/oKAPctS0OyubGRYIo4HYF2kjygyPdgQR9K8Q17RrmK9uUu1liiLFhK8TYb8hz7VtN4jv7FEgN/P5XPCvDtx7buce1Vb/xLa3lvHGG3TE4zIV57enGR+VAHJ3emrHlY7hSoxkNkEH0I9aptCfMK27M7ZwoUH05/Hitx5omMYksFQE4BRlbt6/1qBLOJnkQ+UGJ2KBCxOD9O/vQBjSKQ4bDfMcccZ9fx5prqcLgZz0Pc1Yu7R45yAj7CeMptzUByTsz0GD82B+tADd3HAA57E0A4DFid3BAI61cs7N7pkSBHklfkqqEjHqMfjn/ADj0TwZ8KtZ1u4iYWUqRhgS0ox68hcdB6UAec29q05Dq0UYJ6k8LWvZQaPZMz6kbiUg5UwKMenB3Dqe/ava/E3wpt/DekG71PWhYKBjzCTGuc9OByO1eHa5BAskwhuxcY/j3cnHTPtQAmpajpzkpp9hhcY3yklv5msiZ1kCbI1Ttwf8AP5moySMgZUEDIz1pCCM5B44NAATSk4yAQQQO1Jn9aV2LHJLHOM5OaAEPJpRyMc/nSZ4x2/nSlicjcSM55oAQYzz0pKXjHvTpHMjlnwWPtigBlFFL2oASiiigAoopScnJ60AJRRRQAUUppKACnZ54JGB3NNqRxtxjb1OO+f6UAR07IBPHHbPahzk9APpScdj+dADkkeP7jEU5cIN2AytwVzzjP/1qYq73CjjPHNSqGU/OSp5ySM8ntzxQAiOm7CpkngZP6UxMEgbc/j7U8Bc9ckjJA4z7f5xQEOQCSRggYU598UALM5dSWVOSOQOenSmPgY2fdx1/DmnFXibbv25JA7d+vtTtygiRGHy8EZwec9PagBg8vaoORkckc053VlCt0Awpz0+tN3FwcnGFxn15oK43FSMADnkUAN5IyAMDsO1TEEbACRhcjH1/mfWmquVOV4BxjqR+HvSS4LEMVBxnjJx1+UUATpO235SAWPUEgk8Drjj+VSQXt3BlYbhgG+ZSp5Jx6/zqgNu3nduz0HpTxtJwob5hwCAcn60AW5ma7U5LFsbgxGAQOpFErKY/l2OVzhgD+JJqAyrsKrzu+8SPxz161oHTrcIDBdyyEENgxhcf+PHntQAQNcyOn2mNkRAFBbcFAPPOK7fwP/YYuWOpXG95DtaO3Zs8e7EY/CsPQzqMEyxzC2MH8P2nbKnPOMHrn9K9M0DwJqPiKQCM+E4jtyMxJGcemVU56UAP1fwhp+qWyvpEWoTt1Adoypx2PPH+elefXfg65+0GNdLvFkX5ZCyhRx9T1r6I8MfDbxX4dJlSTRryIr/qLcmP9SuD+dbMn+gzeZ4mSWz3nOzy0dWPQAkUAeS+BPAHix4ozDZrFZScYdN3HPJIPB4r6C8JeG59Lth+7tYZvvEqjgk/ixqK1+IfhuOGKGK/VigxgoV6deAMCnXXxG8PFF8qaacHn93GDj86AMb4keHv7e0ua3mhuTOqlopDeRhFPqAevrg18aeMNIudG1A20kquEY/KrBsE9sj7x9fTpX0p8TviNp17E0NpayxFhwZgFxxw2BnB+tfOes2dxqszTWTRSKhL7UkbOOORkACgDlTlWIPBHBoBJIHBHTn606aNoZCkgwwppOe3XrQAh4NBHcdKmtoXnLImMgZPOOO5NNmjaNiHYbxwV7igCKil64HA96UggZoAbS8Y6c0Y46ijPGO1ACUvQcg89KBjPPSkoAKKKKACiiigAooooAXHGe1JRRQAU5m3NuYkknmm045yQeOelACHGeOlOPzHOCsefqBRxwvLc9j1pcEAFQR35HIH1oARRhS3rwDml3txhiPl2/h6UpG3dt2jHfdkmmZwxI/DHSgBwx3yRjnb9KVWBySoJzkjHX8e1LGA/L7cDJ5OM9OKRcIVdMEc8MP096ABmLn5vmJ/DPFNPzLgY+X25I9TSZ6Y4I70ZBOTknPPNADvlbCruPXjHU/5/lStwAhPK9c4OPpSh4wV+VxgY3AgHv8A/WpUZUPylm44IbBHrQAhZVChcZHORzj2/lSFhyw9hg/ypvUgJu4Hc/nQjbenGRgmgBvbNK3XnqOOuacH2bccgZ79f/re1KBkkcAAcnnnp1oAWJygYBlwcEgjOfanNNuMY2qoHdDgn3JPekRlAJkjEmO+Txz3xRtDEoyMsg4HXPXv+FAG5pd1ZQxKLi2i80NjDKxxnjqOMV0ema4YJhJa2823ghIpCgAx6Y4HtXBTbzGDI7bRwFII3fT86tW9wVhaQybW42gs3bsOaAPsj4QeJLnUbdRqYEahdpVg3y/j0r0mGPSoblpGvlkdjwktyGC57AZr4Y8K67qIcQKZwjcYSRvx6sCBivePA+marNb+aZLW3hUbj5u2U568/MT/AI0Ae63TaM8Z+0vYFCMEsyD9a8Y+Iw0bT5J7q01VxcE5EEEhYN9AO/pVLxlqPiWISW2lWdvMnGbhYY8DnPOT0/lXl+va9cLut9ZisI5ehkliZSo6HlTQBznibxgMSW9tZRAk8yyIQwI9z3rjZ9Y1C5Yh7qYK3BVWOP51Z11oJ7hpkvYJlJwFijZSBn3H61m3IiwjQmQgjkvgfkB9KAIv3khVfmY/wjr+VOjQeaoc5HU7PmJ9qYRzt464zmpkhlJVsDJOFywHT/P40AStLGqBIY2OcnMnp16dAPf2qmeuSOvNOfJJLYz1P50ygApSMHB61bOn3Y09L54JFsmfYsxXgnvj16VVGD1oAXhs8gYHTFNxxkUEYz0496BQAlFFFABRRRQAUUUUAFFFFABRRRQAVLNuDtlSuSevp/WoqtTSKZHEgk4ztGcEe3/16AIN5GNvy47gmk5PzNkjPr1pzgErtZTkc9sH0oUlSuFyemPX8KAGkAZ5HH605VKMpK59jg5qwqhMqzffB5ORu+uf89KicBWIyoBGSMHqc/ljNADSFyOT5Z6Z6j3oI+UDawyM4zx9aUsSx5yBkqScYPr/APWpAxTPA56FeMH60ANGQV+7xz0zj603GMg8EdjTkxkDBzz0PJ9qfGhM6BQrEtgDsecd+3vQBGASOBnJ4oOVb0I9OMUMMEZHHoP6U5sE5ypx9enpQAjEHbnPuc5zzQnzfKFBY9MmhyQed2CO/U/40byFCjp16dfr60AOlTY59Qe+MHv/AIcU7y8IGOO2SR93/GogWK7R064p6ysrbs5JOTmgBikgcAcc9AalCkcna27IBxnOP89abvRpCXTCn+71FNZyScDap7f5+lADe1Svkj5hlzkn/PbH+elM+XkDk54bOKehVmG8ksx539Cc9SetAGhpiRTzKZ0MoJz/AKvnj3/pX0D8N4LWS2Edro05ZQMywxhW+ufXtXh+i2bXc0aWEFt5pyQDO2Tj8Md67LTItf0+ASpFcWQYhfNhnDLkdiCeD7470AdV4/u0sNwt/wDhJLWTuqXQC8+gA5968Y1XV3md4y942D/y8TCTHr27/pXQeKr26nl/0zXGZ+ux/wD6w4ri53UuAwV8cFl4zQBGnJO3+LjH49K2tI0Vb+QK9zYWysR8014g2jPcZrEIIHQEH5sgUqMYzzzkZ4P8/wDCgDodc0TTNNdVh1u3uyRgmFQ4zn1DfrWAxDMcyP5edu7bx+VRrwQcjr3Gat3Vys0CgvI7+6quOnUjk0AVGGD3x1GRim0pOTk9aSgBcnjk8dPakoooAUn9KSilzxjtQAlFFFABRRRQAUUUUAKAT05oAyPekpRjPPSgBKKXjHQ5+tJQAVJKpDsTjr/nio6tsp3SFiQcj5sA8Y9PyoArEnoeM84xinqybxndgevepo4sHcMFs5GRxnPX6UjKryjbGFDHJx0/DuB70ARSPubn7pOcnPP1/wDrUw9Tuzuz3qxIm9sEYwpwVGQcHr7DrUbxlc7Qdh5w3BHbmgCIjA5/KnKQuT+XPNOwrY2kb8k9P6VKqJhGXli33umPbHTNAEeRuDKCpBHt9MehpMMQ0ZYnaeg59v607yyuQMFhg4Xt+PrUkSsrhnAkHYj6HpQBWLEjnn09qQn9KuIFEgBPzY428c4yMe35VG8W3aBncwJIH0PT29qAIM5GW54wBnpRuwCF6c8460+QKxTYAu7+dOZWXBIClTnIGcfUj3oAiyDy2SSeeaOM5wdualEahH3hlOAQSOh9/r0oQBWyYmIPygHjn60ARqQAQR9ff6cUhA45HuauFF3NuzuIwNy557YPr69qhEauWwCTz9wcf/q9aAICMf4+tGKtRw5l+Q/MOoI7jnOPSomjJCj5QvXOOg9T7UARHHOAfalBK8gkN2INSuhUAE7SPvfKQRn19qjxg9eMZPbigBXkkdQHd2UdMkkUztmnbSCAV5zyMH8qTqM8Aj9aAEHBpKkHONuS/baKZ26/hQArAA4FNpw+6CDyDngdPxpBjPPSgA7UlKaPSgBKUmlUH3HbNIQR14oASilAyccficUrKQASMAjigBtFOzxgZ2+me9ICR04oASiinMCMcHkZ5FADaXH6UlKCR04oAMHnPBFJT/ut8vX25xRs6DILHPA5oAb2zSU5gOqkkd+O9NoAK9T0v4OeOtWtoruy8PsYXAZZJLiKPcvqMuDXllbdt4o1e0UrY3tzaKcfLBPIgGD6BqAPRz8CPiB986DEZO+L2Ac+3z8CqH/CnfHyXssa+GbpWiyd6yx7T3IDbvm69BXKjx/4nAG3W9SUgg5F7N/8XQPH3iYCIf2xf4iO5P8ASZRg+/zc8+uaAL/i3wJ4i8MafbXms2LW8U3ylzjKk8bWx34xiuejsZnRGWGYbeQWjYA9hz/KtfTfiJ4m07Ujf2+os12WLl5kEoJ/3WyP0rso/wBon4gIMG8sGHvZpx+VAHJ6R8PvE+swCfTPD+qXMTHaJVtyACOvJxz05rT/AOFSeN1yV8LapwM8opx+vWs+/wDip4zvdTmv5NevIbiX732aRoF6AdEIHQVGPih42AwPFGsf+Bsp/wDZqAL9x8MfHkELyP4T1PykyMLHlsHp0ySfpRafC3xdL54k0G/s3jBlVLiMx+YAOQgPUjPbNULf4n+NoZFceJ9Wkxxtmu3kU/UMSPxpLr4meLru0ht7vW7ydYZDIjyyMzgnr82c49ulAGCtt5DsjBPMT5T0yCCc9/zpXjjfCptDBcYHJ446+nWuwk+MHieTw7Nosi6S1nMpR/8AQIwxB69BjPvjNQeG/ir4h8O2ItNOh0cRDoX06JmH44zQBU0bwJ4s1WFLqz8N6vPb4zGws3KHjsfTPpViT4Z+MUn8qTwpq5ZgMBLRjgeuR9Kbe/FfxrdXktwPEN/bmR95jtp3ijB9kUgD6YqQ/F3xybT7P/wkmoY3l9/ntvz6bs5x7dKAFf4c+MIwZpvCmtkd3e1ck59QKqReC9bfSLrUmsWjtICY5fPcI49flYg/jirNt8XPHVvv2+JNRfcCP3k7NjPcZPBovfip4nvdah1S4mtHuIohCENshiZc5wyY2t9SM0Ac3HbldqscY+XjDHOOg9+a3rPwR4qls3u7fw1qktntJMwtHwAMnI47V1Vn+0F4ttYgkdl4fwOAfsG3H/fLAVzg+LnjUXzXK65cqGdnMCsRCc9vL+7j2xQAtt8OvGNxGs0XhfWniOGU/YnG7vnn+VOPw08aRlWbwlrZBHGLYtg9cnHvUNz8WfHM87ynxLqSFjnbHOyKPooOAPamxfFfxzHu/wCKm1Rtwwd1y5/Ec8UASwfC3xpOHjPhu+hkSMyH7TH5Iwf7u7AJ9uo9K5C9t/s5eKX5JYyQY9wO09/rXUyfFPxlNbxQ3OuXdwsUvnIZpC5VsY6k8j2PHtW9p3x08VWEPlw2ugn/AGjpyA9MZ+XGTQBwGl6Fqur3X2fStOvb6f7pit4Wdl57gA4rcb4Z+NYghl8K60FkYKMWrEn2xitbXPjP4y1aGNFvLfT2QlvN0+EQSH6sOay4vij44iSZR4p1dhKuw77p3Kj/AGck4PuOaAGS/DLxrFBJLJ4V1pVTqfsjf4ZrD0jRby/1OCzERhaV9peZdqpjg7iemD61tr8TPGoY7/FGsSqRgpLdu6n6gnBrbufjV4wudLuLCaXTWguIjDIfsEQZlPB5A6+9AHEa/o9xomoSWd6oSWPrgg5Hr/LFRaRpGo6zqEdjpNlcXl3IcJFAhdjxntXdaL8aPF2kW6w20mmuFUKGlsY2Y46EtjJxjvUniH43eNNc042c95bWyZBElpbiKRSOhVxyp+mKAMWP4ZeNJXVI/Cus7myRm3YDA4649atN8IfHw4/4RbUs4z9wY/n+lUbz4k+L7wP52v34LBQWjlMZG3pgrjH4de9Vz4+8WGMo3iPV2UkH5r2UkfQ7sj6CgDYt/g/49mUsPC+ohRwd4VCPwJyaz/GXgjVfCd5FaX8bM88YaIIN2e5HSq7+PfFDS+Ydc1AP/s3LqOmOgOOlTeGPiJ4n8MTNLoupyQSN1LqJc9f7+fWgDITQdWcArpl85x1Fs5/pXZWHwZ+IF9YR3sHh2R4pCAN9xEGYHuVL5x09KuH4/fEYrt/tyPGMf8ecOfz2VwyeKtbS6kuU1O8WeRizOJnG7JOcjOO/pQB6Db/s/fERwN2k2sY6/PeRfnwxqtF8DfHTXssTWNpAyMV3SX8Qycdvmyevp+VeenV7wkfvpMDsJX/+KouNZv7i3WC4uppYF+7HJIzBfpk8UAdzr/wo1TSdOQebHd60jhJ9OsmWaRAfusApJb39M1Sg+EPj6bATwvqIBIGZEVP5muRtdWvbS8+12lzNb3X/AD1hldH/ADBzW5/wsXxptZf+Es13a3Ufb5cf+hUAdRpvwX1jzVj8Q6xoPhyZlLrBqd2I5WUHGQuMEfjWs/wS0yIFp/iT4UWNV3SFZwxX043f4V5He6ld38olv55bqUZG+aRnbHpkmoFnK4xHFgf7PX/OKAPZJvg9oQtxLD8TPD7wJ8srKuSjngAgMeD6nH0NVn+EcOnWMEOs65YxapeoXtHiu0MDY48t2PKk5BB6du1eSGbJBMaEjuQf19aTzhx+7j46DB/xoA7/AMffC3UPBnhm21i81XR7uKe5W28qyuDK6sUZsngDjYRweprzuns+VwFVR7ZplABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical four-chamber view from a&nbsp;two-dimensional&nbsp;echocardiogram. The display shows the apex at the top of the screen with the left ventricle (LV) to the viewer's right.",
"    <div class=\"footnotes\">",
"     aML: anterior mitral leaflet; LA: left atrium; pML: posterior mitral valve leaflet; RA: right atrium; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19568=[""].join("\n");
var outline_f19_7_19568=null;
var title_f19_7_19569="Female genitourinary system";
var content_f19_7_19569=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Female genitourinary system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 477px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Female genitourinary system (GU). Anterior view of the female genitourinary system, including the ovaries, uterine tubes, uterus and bladder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LifeART. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19569=[""].join("\n");
var outline_f19_7_19569=null;
var title_f19_7_19570="Hypertrophic osteoarthropathy 1";
var content_f19_7_19570=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophic osteoarthropathy - digital clubbing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDtNw70hb0FMPU0mcCvRMhWORUMkIfnFKzUBqAKFxpySA/LWFf6CjknZ+VdaD1pSqt1ANBNjy3UfDQOcKawrvw9JHnANe0TWaN2xVCbSlf+EflUShGRSbR4nPp88Q6NVN45UzlP/rV7Ld6IjcbBnFYl54eUqcJ+VZvDroUqltzzHecfMCKeJO1dddeHTk7VOKpN4efGNprN4eSKVVGBv6c1IGxWt/wj0vYGnroE23oc/WpdGRXtUYzMCMVGz9q2W0K454P1xUL6HOOxNT7KQ1URlh8MSKd5hzV3+xrnsp/Kg6PcgDCnPel7OXYr2iKJbPJNRFuSMCtM6Pc9gcH2pn9jXG48H1zij2Uuwe0iZ4YfjRuA5zWgdGlPY07+w5uDg0/Yy7B7RGesuehNSLIT3rRXRWAywII5q5baGWwdufwpqhJkurYwd55phDMehrs4NAViCy8elXI/Dq4yUrRYZkOscA0L7vun8qeLeUrgK35V6TF4eU4ynUVbj8Pxg/cxiqWGXVk+2PKWtZcH5TxUL2EjnOwmvXv+Eei5OwE0qeH4tvzRqDVfVokuqzyGLTph0Q81MdOmHOw/lXryaFDj7gpx0OMDhRT+ron2rPGJLKVTnYw+tIIJAPumvXLnQ4ieUFU20CLH+rqXhuzKVY8t2P8A3SBQpb0Nelt4dj5byx+VVH8Pxk8L+lZ/VmUqxwkb46mpDLwOa659BjB4QVWfQgOi0vq0kP2qOXMvNOjlxxn9a6BtCOPu1H/YZz9zml7CQ1VRjmb3FOWVQOTW2ugMR9386DoDjopxT9jIftkYvmL6g0vmDGc1sDQJM/dp6+HpT2NHsZE+1RiGQEUhkAFdAnhx+eCKG8OSejflTVCQe1RzvmilEvvW3/wjsuehpy+Hpc/dp/V5B7Ywml46A1CznOa6lfDrkZxSnw63cVX1eTE6xyTO+elJvcGuuHh1sj5OKsp4c77M0fVmT7a5xQZzzg1FKkh5w1egjw2uAdopH0BQuNn40/qwe1PWSepNRsc0ueKaetbktjWPIo5pSKEHBoBCdKkU5FMxSqwFAyQnjmk3U0nIzTeT0NADmAYDcM1DJCjA8VLk9McU4LQFjObTo2HSmDSo2J4BFbAGelLtp3CxkDSEz92pF0ZSD8oH4VrKQOoqUN8tAzBfRU9OKhOjRjjaDXQMwxjNQu3rSuyWjD/sWPHCimvoiEfdH4CtzzAO1MaUZ560hWZinRUU9BUMmkIM/Lk+tbbz4Haq5ueuAM01puCRiPo6dcYNKNIjUcjmtV5iaY0uep5qtBMzRpUfcCp4tPSNQSPyqyX7ik84A4JxxSEEVtEnJA/Kp1SL2zVfzhg4IqFpcghicnuKYGknljnFPMiYOMVk+fjgHJqN52B9RQDZqtNGOgFIbhQOgrKMrHBwKUOx6jg0xXZpSXaAcCo/tqgGqbIzKMdKjKNQIttcq3UDmlEiE8iq6RZHPFWIISc0hCnZzwaiKRsSNprQW3GOhpy2wPbmgdjJFpGQQQcmmtp6Hov6VuLa4IzUyQKTjFF7jsc+mmRk4IPr0qcaVF6VvJbqWqYQKPr60DsYK6RGccU9dHj5GOK6COMA461KsSk9KVxpHOLpEWeFzUyaNHn7uK3FiRBwD60/aCeDRcEkYJ0qIHoKDpkXYD8q2WUZ6801qQNIxzpUWPuj8qRdLiHRa1mIHNNLjHB5oFZGZ/ZsQ/hHPtTG06IfwLWk7A+9RM3PAoFZGW9koPCigW6jJ4q65OeuKaORxVBYqeSuBmo5IlINWpBiq87hV4BJJouSax4o7UknSkyTUmgtLTcgHFPQDqO1AIPzppXB4FS7frQooK1REAfTilwak704DnpQMaqnFPUU4HHUUjNwM4H0oHcUHjijIqFpPejzOOtBPMOL4NNMwFQvLg1BLKMdaA5iyZucjmmPICOTVIzY96Y8+72oFzk8s208E1Wef3qvLLnPzVA0mDTSFzMtNMSOORUIdgeag354B705nwvJ5p2JuPeU56imhyDkmqsknvik8wDvTsK5ZaUE4U1G0h5yc+lRB+1KeaGguKHOODUqAtyagUjd16VYR+aAuOMYzkHmnwx5ODjFODEqPWpIT7CjUVyWOAYwFGPpQ0KjtzTxKVPFPWTOCcZ9KVguhnlFV6c0vk7h/OpBKoyT1NSKRjKjigLoijiG3IBqaMAYwOtBINPhHNA0yxHgirMca5FVACOhp6TYHNJjLhQelR8BvvZ9Ki+05prSZwc0IbZZUjNSnGOtUfNwOtNe6HrQx3L2cHANKJCD1rPN0pPJqN7njgmgL2NTzf8AaNRmYBetZRuyMnNRtd5AzQieY1TPzxTWnFZf2g44NH2kkdaGFzQeXjjpUfmiqnmBhyaaZPUn2oQXLZkzSBqqmUDGM0hlx0bNOwmyaV9pqHztp5P4VVuryGJS0sqLjrk1y2t+OdI0/gziRx2U5o2DVnYySdc1n3t/b2yl55kUD1rx/WvijeT+YljF5adAxNcNqOtahqLMbq6kcH+HPFZSrRRSptn16wyPWmc44peM8cUoFXYY0DPJFSKcUjDigdOKAJQfahmHbmoWfHHtTRJgUASluOlNEgHfpUDzcGq0kxDcGgTZeM2DjNMebPes+Sc5BHWojcHsaEFy+ZQCcHimtNxnOaz/ADTimvKQOKYuYuSXHGelVmuBn72KqtNwearPJk9aaQi7JcDsfxqq9x83B/WqskxHGeKg3EnNMC8ZC30pXc4IxVONj36VKGBB5oQXDzATx1pGcnucUiLgEetBAA4BppCuQnO7kkingU/bUmFHB60WER45qdQMD1pvAyW4qWIA4HpTSJbGGP5sgU5VKnJHFQ3+pWdgpa6nRO+Ca5DVviNp9udtqhmIPXpUuSjuNRbO/hyRyMCncrkg814ve/E/UZARawxwj1xk1iXPjnXZ2JN4y+yjFQ68CvZSPoUM3cjNKhbAr5xHi7W8c3059PmxTo/GOtIxIvpR680vbw7D9iz6QD+tCuc55r50Txvri8i9kI96sRePNdjYZuyfqKX1iIexkfRSSHvmp4pfmHpXz7D8SNcQj97Eceq1qW3xWv0AE9rE4HccZp+1gL2Uke5iVfWmSMSMjmvKLL4r2jsourV0J6lea6bT/H+hXgCtdrEx7OMVUZRezBqS3OpMzDIY4NO+0Ejg5qtb3lldqGguIpAehVgacYh1BzVk8zRKbvjHeoGuOTQ0RPTj3qGSAnnGTRYOZjmuR261A1y2TinG2IJwCKieJ0PzChK473FM/HORTTNkgA0vksy9ODR5JHXr9KdhX7j0lOcgcU4TnPJFRlQoJOOfWsrU9ZstMUtdXCKOm3jNKyQLyNwTimtcIuSWAH1rzXWfiXaQIVsU81+ntXBar4t1bUJGzclEboqnoKzlVhE0VNyPZ9X8a6VpQZZJwzj+FeTXn/iT4ozXKmLTIzEP757151IkszlpHJY9yalFm4QFdrfWueVZvY0VJLcmvdc1G+Ym5uZWDdgxqgUbrJnce9Si3dcsCMdxViNVyAW496xlJs1UUirHHn39qc0Ad+GAI6irZhwAVHBpVRQQUwP1pbjR9cFsHFLvwP8A61Rb+ccUx34969BI5rkpk5pPM/Cq29geajeQZ60xFkyZz601n7ZGahMgxmq8kx5ANFgJZZc5GelMDBlz71UabBJ7U8TYXrjNArkkhwCKqySBcBieTjpTnmBHPBqFnyOtNIVyTzMA+lQyyUxsY4qMnjOc07BzDGcmozn1pzHFMLgDjrRYVxj53eo9aFwOaY8mBl+B78VnXes2Nqv7+5TcOw5JodluxWb2NVl70Acda5O78bWyKVtoXkbsW4FY83jDUJP9TGkY+mazdemuppGlN9D0hSSvpQ8sa/6yRR9TivJ59Z1KfPmXMmD2BxVJ3uJT80jn3LGsvrceiKWGfVnr0uo2EAJlu4VA/wBrNY+peLLC1IMLGc/7NebrCOQzZOPrUscAYnOTSeKvsP2Fjb1jXr3VJB5UphjH3VU4JrDvdT1iJCDezqo6HdVmCHDcIeKuz2pubVzjkL8wxz9aj2kmP2fKcTeXt1cuTcSySN/tGqgTLY5/GtLULbY4Kg4PWqQVuRgYrFt9TVJWIdozjgUbck5FS+WN3XFTLCvILH8KBlYRZ7UeScZxVsLUgjBwB3oEyj5PGWGB6U82zEBu3bFXAh44pdmOhNAymkQBwxx74oeIBiMjj071dWPJO4ZpkkXfGPQUgsUni4JphByBzV/yScZYDNMliAbgH8aAsNgurq2+aCaVMY+6xFdBpfjvX7AKFuzMi9FkGawfL/d5J69qd5SKgPbvj1q1UlHZkuCfQ7yz+K+pQsPtVpBKnoCQRXRWvxY054Q81jcKejEcgGvGwm6M4Ulh1xURjCFOchuoHY1oq8iHSiz6D0f4h6BqbiMym3lPQSjH61vT6hYiAzG6h8n+9vGK+YDGTkgfdGaV5ZmjEXnSbP7m7j8qtYjuifY9j6Al8ZaDAxV7+LI/unNcp4i+J8UOU0uPzD/fPSvJPILL+7bn0NDjzCEIAK/hRLES6AqS6nRXnjjXb5iFuCgPZBWHcTzXU5e8mZmz3OaqiOSMEqenWpYH3KxdRuA4BrFzct2aKKWwqQZf1Xt2pphOflbkVYRduPMGAehJ4qZYQVUJhgecgdKhlLcis2XfiUZq2wQ4aMMoHXHaqc8TpknBA7ipoZZYlwwByPxxQNiuqDIIyCO1JHDyCo+U9AetLMxESsRwT1FOMoHlAhiW/hTrikA5gF+8MqfXqKSNFV9zY69+3vVh8HdICm1SCN3BJ+lNMJZt6kNz19KTGj6mCEHNNkXH1qcsM8VDLIM4xzXpnIVXB57VWPXk1YnkAGQKpPL83AxQSx7uQAB0qqzEsQamB3c9jUZi+bJzQhXI2j4znimgknGamYEnBFPWNRg4phcrMrYHB6VHypq8z8EECs++uIbaIyTyKiDqSapBe+w5iMciq8kgj5Zgq+5rktY8b28AZLBPOf8Avn7orjdR1vUdScm4mZUJ4VeBWNTExhtqawoSluei6l4i0+zyHuAzD+FOa5nUfGkj5WyhCf7Tda5IQlmycmrcNqWxgfgK5J4ub20OmGFj1Fu9Wv7xj507kHtnAqAW7kB5FYg9Cc81o29m24HbyD3Fa1091eiNbltyoMKoAAFc0puW50KlbY5tbc8cc5q1HbnHT9K1o7ELg96nW1HpmkmV7Mx1tHxnHFKLM5roIrZQDnrjin+SMD5cmmHIYSWZByBVhbI5IGeBzWoY8HkfrU0EBdwqrhm4HNUiJQMlLQgg5q5bwNwAxUHgkdKtCPJBUcj17VMFlEewcR53Adia2iZSicT4itZILhwgBRGIBNc2sbHdjOQcYrv/ABGizkpIpExbccDrxXORWTK5wF5HcVE9yI7GKIcYJBz7VIEU9a07qMxnIw31qicZJBP0pJ3G9CJYwDkZJ7U8rgcZJqQHkD19KkkGAABnvmmJFUFvTmnj5h1w1TlAe3NATnHT3xTFqJHESxA4FDpggdQPWpQpAySfrTSBwWJNF0OxC0QLdDxSMgH3s1MBk7l7dqbIQSAetSMgMQIJBOTTYoxkq5OT0xU5Gc7Tg4pi5BByMjtQMhSIrMM5wOuOtMnRckAfmOauyIWJXn1qtNG6uA3U9DmhNCsKtsRbiZFbpgk1Glt5kbEcMOfm4z9Ku6Y2dyOu5gMdM1NNF5UOCxO7BwDkfiO1VpuLUopAgthNEACDhweuaqToVbeQDyB161ox5jMiAkBxwGHftzVGWFnmGB04I9GptqwluOSBym9eF7k9BVW8tVRA6zKzHquOlan2FvKcklvLx5ntn2qtNAjA5JXnGNpxSGyvBIJIyhYAgA8irsUewg428ZG7iqBhWN0fJGGxn2rQgjWTa7TqCOQ7N09qq10TsOkYSRLu+7kgbR396rw4WQqWBIPUc1qJYJeWzSQyAlTyp4P5VQa3ME7iXhVxkilYe5Xm3KsqggoxByeop9mFYu528jCk9QPWm3OChYAAc8d6ZbArDG4YN2FQyi+6bYt54Q8ZFFoxCjeMgZH0pfOJUqGIBHIUcU7TyzXLBjkKNzDHYUDPppieck1VuJSM46Y/WppCR2zVdxlskV6ZxNleR3K5AqsWJPPWtAoMHioGhy4wOKdyQgX5SWYkn1qQjOBT44x6VP5fHFAFIp75A70jMVU5OBT9QuoLCLzJ5FXHb1rzjxT4xaUvBZ4BP8QPSonUjBajjCU9EbXiHxJBpqFIWEk3oe1eb6tql3qkpMsrFey54/Kods11IXnYszdTmrtvY5UHBxXn1cS5bbHoUsOomZHaluuRV2GyJA4P1rZt7AAg4FXUtwMZA/KuVyOtUzJt9Pxy1aENmB/CK0I4cdBx71OQOpNCLUSisCgAY4p4iB6L0q0oz05pyxsegpl8pXKinLGAMn8quR2hdealFqD0FUkTylJQATgZp0cZd+BtXGSa0Etgpp3kgNwR+dUibamWY2JyBx709IpAPlNaAiUn8PwqRY1ZeF/GqREjNEDkgE4qcQMqDGcjnI7Vd+z8glTg1ehsppoWMULvGvyMccc9s1rAwmjkdfijF7KjHBIyHPHUVyDSsszDaAOgPUGuy8Wxbid6Yk2DGOvTk1x3lDIO/Hse9KpuYx2KlzG7EnBGagaAhAdvHTI7VoSyRLlAeT6ioWjDlf3p9eKmI2UniZACOM9KYu5uxNaDKB03MV9s5qLBL8Aqc4ANUxEPltjA4B709Y2QgbsD3FWYj8uckn0IpssRJDKCv16VLY0iJs9MjFMdcjp+I70942Jzt6flQUIAPY9DSuBEg+oqNlYNzn61MVBzuGCaYd27AJI6UAIVBjHBBo8pWXgdBk7iKkKZxn7uO1QyZYYU5PrQFia3QsilT0O0k0zU1Clc4DAdVyM/X3qbTGeOXbz83T61NfoGhDMBuPJGMYo2GzN0+MtM48xVTuWFas0CBWIzyMgHJyao6OHN0Y4yoZl53Y6VpzSlFIbBKDsMCmtUIyr1WMDyuhIGMOSetQwxt5XnSbiHb7yjofarVxcu9i9pG+UeXcVx6dKYsWyNQFB2nqcj8KZNtSW1jheeRpZGCshZSf4sduKiePI38jIOQp6Htmobn5Y0ZVCnPZs/pV2UpJFtjMhwgzzwT34FVvoBk3KPOA8pXPI6elQ2blolCnbjgmrN0DCSrpuPDHcOtN0xAkD7QC7H5eAcDvSTCwTSNGPkbJ7cdqarMXLuSzHHzE1LeJ/D96QkcZ6D2x1qwYz5SxomI8c89/6UhlKYusZyFw3Bxjj3psa4h2qoxncD/OppIi0qQh1JzwQePzq2scaFokKsfU9PwqWAyDaYY/uFuQRzx9adM5V0IBRjweMBlPtU1lCn2iUksYkXc2am1ALMd8rbXZRzt4HHAFA7H0fMVU4GaqyNzxSyklielNCcZ616hwsbyze3epkhAOc8U2EfP0wBVphnaSaAWxGI+eDWTr2t2+kQkswMvpU3iTWYtIsCSw81xhRXiWt6rcajeOzsTkn8Kyq1VBeZpTpc7L3iHxBPqU7MGbb0AzWNbWrSH5vxxU1nZ7m3NzW7aW4VV4rzalR1NWenTpKK0K9nZgEEitOO3VRjH4VNFGFPang8/LyfYVgdMYDVTb060oXso5qaOBycuTz2FXYLfacYxQaWKkUbODngd6nhtfqSKurEen8qnjjOOBj0FaILIqrBjGQAMU9IlH3eatGMY65NCKM+lMViBIznG0HPepvKOOSM1JkcbutBIHY57VW4hiQjHNP8pOeBTg3PIxSkckY60yWRiNBkcVIqgAYxSEDIzinlDiqIkrj1+cqvVz0HSt+Z/I05IY9yxY6ep7k+9YUSGFVmdPl/hYmr8kzzW0eGPo1awOap5HCeJLVp7q5jikG6NPM5OMj0/KuGu90bg4IGOTuz1r0PxK/2fUJGMWVkhwcHHQ15/cqu9VlZAu0bSoP6+9KaTV2YLRmUz7pCM9TyfSpoCRxuwOmaQQsSTGpI9xilQFWCkYx/DUoC9EuEIjc9f4ScGlEckm4je5AwT14piOwhyAq84xmrUEmxeWbJHVR0qkrgUSWU7dntmmSeYQMBiOlWNpQnDn6+1Gx25bnJzyalqxSIF3hTkDbTwuVyMDPalG5SegGeB1pduXDdCPbpUvUrlIXG0nIyfXsKa0UrK0kcRdOhKckfUdathBggcMfWmKvlsSrMre1LqNq5VyuB7jmmiMY3DpVgx9ecHtxVcZUkg80h2G72jZGxtIOc1sX8e+IOFcxsMrvNZgCuvTnvWza3CvovksmWjyAwJz+NNK4mrmBLhFWRFw6noKsXZluRD5SkPJHuI3cHr+XShoAyEMe2VOOp96I5m329umyOSIsgYDsx/Wqi9CGh2iLtt3bykd36O3GwZ7epp8lt5JOAC4JPHc/Q1tWNi9sGR1aOMDOWAYEf3h7VQuEdCxIDSByh29KvlsiLnP6jhUHBB3YIyOPwq9asotEiBy3U7hwM+nvVTWeCi4w7N0PUfjWlpquwiQv5iBcso5A9qI7jZmX6BIXTDAgHDMMfhnvSaYqx2oy2EZehJHP1HWpNaZEPkxhWyOg4AP09auadYSm1iJkVN5C5bAA9s9qLa2EYznMiqvTPJ6VeiQiRTKwjQHlm6AY9KjMMKalsZ9wXqVOcn61cKr5KuM5yWII4I6YqRoyrna95hMkL0PrWnax7fLdtoAIHzVXtE3Xs0sADKDhcjPH+NaX2STG6RcA/d9z+FS1d3GQzF5bmXykd0kZVZ0U7TjPy/WtC8sY4kMDrPFMiDf5qbcSc5UD0xjrVyzmg1TSrDT4NSg0+S1kfdHPuCybjnerAfeAyOa0fFOowutrb29493DDCqSTsCDI4J5yeeMgZ9qFsWetTcDA7U2FsnafWrN3FycVVijYNXqHn2J1Q7iQePSpwP3ZY8BQSc0kS4IzmrF2qrp9wc9Y27c9KGJo8P8a6hJqmvvCjfIvyqc1jw2PlN8474JrdaygW8kupmxh8bRyTxxSRQAFxIccEj3NeVWk222enQhZaFa3hH92tBMJj19KhVWBwg4B5NWYIvm3HmuZHfGFiWOMuMk8Vbgi28gEfWkhwBg5/KrSg8Z5z2oNFuLGiqxGM1ZjQ55JpUXb0xg0ueapIbHqFH+etSjBByelQbvfmnJu7Dk1YrDs7jxyKOQM4wKUAg8j8KlVCO340ySEnd3/SnIvcZNTiPLDNShNrYHQ1SFYiWMkgEYFSmHgEkc1IOnQH9alVN+OKZPKVREu3J5p4jAIO3OOcVZaLnOQM9KfFF2DZz2pktFqaWO4gZXAjA5VM+tV4UCxkkBgCCQT1qxcBpREHx8i4GBTYrffbyEH2z6VrE55RON8X7ft4DACNoZAQDgDpXn8qqJlPmCVSMAAYx7V3fjSNGkRi+0eWw44OeB0rhoyNoKopK9f9qlN6WOf7RRulwD/DnrUcG3A4+X1NF1JiTb1bPKilSCW5fc53BeM57VEd9RSLRlJASNEBA7ECkjt5ZJAwmRGA53Nj9alhtkwAqEepJ5q1Fal8kFcgdCavURT2NkGQc9yT1qYW4fLAkYHQ1eX5IUZXVs9V60MFRsrscPzhc4FSzSJn+UpBG4+nAqBhtfA5U+/StSSAyr5gDcdRt7VWkgCjBUH26E1BaGxRBxzgfTtRNAUB54HOTTl2xpkDr2NLLcBoyGGRUsZly5BAPeoCpLEAcjtVx4ssCobGaY+MDJOR37ihMCBMBwDgBupatG2nkit54QRh25HY1SID5A+96dqTBFoS2eWPHXpTTEx0rGTCr2GSPWqlpEZ9UQbtgPzF2OABT96MuGyDUVrL5dyuEBJ4G4ZxnjNNESO3vYBZWvkuBJJs3GQv1B7AYrMtGd7OSBcKkTeYC2C0h4H6Va0QvPLBMRJfXccm0QOu5ZFH49q3NbijvoLu60qxW2ktokml3feXP3sDpjjI9jXRe+xk9Dy7WZCbhBu3fN1b1rrNA0yaZIUtygicANLLhU3Ec5PpXJXjG41aNFTdluBjOTnFeuyahZ+HPB6QXpt5G8357J0zIXwMYYdB3pU1eTbCTPO9Qtmstb8y/VXhhPCk8Ofb1/CprW8l1JgkKiKzDMYoCflDHuSaoz3D61qJubgMI9+FT1rUvjEmkGa2tTbGNvLYgk7snihPqtgt0MHToPOuLnc2GLfLgccfSrV95ttagS8c8ZPTFamjaY0NoHu15cea5B+6D0Jx0rI1ktNL5UZLYGTyCAPWoaaiVFXZY8N26SLKSwLgbth/iz2+tW9SX7NESofzH+RVB4B78V0OhW1uuiWilxb3IAKXAH+sJGcfh0qK9NlqPiGGeF18uBFkljnxzID8ynHUcZzT5bR8xrcuaLZ3lp4e0ptPuLS1YSy/a1aSMPJk/KQW7DpiqPjRbxDEdQnjuJZIwI/KKlQuT128Zzmruva9ZnTItmg6UoU/u1Ktlh64zxVF86hc20ps7azghj2iNMqhbG7dz35FZ6fCaJdT26dDu61EBtbnFXLhGGTUEUfmfe616aZ5wqYL5PSqniO9isNHuJywBCkDPfNXfL25HavF/i14hlmv5NPtnYRxD5sdzSlJRV2FruxalCxXcU6hWA656exqxbW0N9HfTyL5Sxr+6VBne3+FZfh6Z9V0O3llILoPLkx146H2rX02IpcrbuZkil4PlDLYrzZo9KkyqkI2AnjjmnJ97bH0xVi8aBrl/s0bJb9EEh5OOp/GoiygALketczVj0IO6JYugFWA4Uj2qorg9D061MhGfekaosq+epNSKd3fAqGME5Aq3FCe/wCVUgJETJHTAqUR4anohP0qZYcEZ5FMLDEVSOmQOlOEbFRVhY8dSAtSBVGACDmmhWIFhB+9yfSp1iCjAHFOBxgDg1MFIXJ/OrRLViMRj1UD0qaNVX3pFCdRVgR5Hyrg980xMh2xkE45BxzQFbdwmQOlWl2hCD1zTTt42kj6CqIYwblXlQOe9PE6xxSpKOGGQR1BpzbH5LH6YqtfDbBuz1OMsMCrW5z1Eee+MLrdqgUHhUC+3OSf6VzN0Fig3lgGbnaOv1q7qkovtbnkOWjDleOc1nalnGXIPsBilPVnMtDPjt1kBc4UDqxOf0rRgjUqCBnHrxVOIbmHJC9+nFaNuI9zEEPj14J+gq4pEN3JI4AWy0Y6dzgn6VLFCVILR4H8LMeavJ5J+SWyaO47qMqAMcEDrmrSWrmRSImDkcIyFSR688VdkIyCknkKCqkA5BUVWZ2SRhgYH8J6Yrdu7RSEMCyEMORLxz3wR/WsyaycSMzByigZKnB5+tDjcd2UBKd7mNyu8Hg54qQZKLvJbjn1AqQRukp2+YFXkZGSKehRslt6HHpwaynGxpF9ClcrhMqDt+lQxxkHJ4wOh71pSRK5yw+UjoOTimRqoOTtK+/esmaWKPlg7sMMnpTJiFBXaAT1HY1ddPmwQME4FQyIThASeePWp1HYzkGw5HGfWlC5WTb0PHAqeZQXO5TgeneoihCqyk4zz3zRcLFJ4yrH5cqB0JqSwWE6nB9r3LFn5ivWrMSLJISp+U+vaq0aFr4CJWMuDsA5NWmYyj1NPS7w2s9xFA7q7ndC6nBBBrTh1HF+jXaiIpGS8kSc7cHI9Dk9c1zUDBbxXuGckNkkDtWl4x1BnaIiIxyPFjCKFG0/dxj2rWMrJ3JktjE8PLHLrDzu+1kx5eOSXzxgV0l3pcuo3d3qOqyosmCwQAhdwOMVi6KbnQby21LyzIiKcAnHLDGf1rq9MtGazN5chrkI4JtwTlwxycH+tVT1VmQx8tnHHZR/Z47fzlTG0Rsd/ctk8Cs6C1/tDU7K3nIZZpOY412M4AODjp1712ulxG+sg0ka28USlEhjOAHJ439T068VheOlg0q7hhs/s5uySEaCQsi5GGBz09auVkrjSuykJIbZtTntWcQW7LGDjPy9CT2OSKz7O0ik0++1G7ZBcyhikQG0gdj/APWp0WnvcGOyUpHbxLucswBkbqee4q1rsrpbxaVbXSzhQCREvyoMcDJ69aybtqy0uiLV9c2tv4csrOEvc3phXJkkylvnqAPWsnQooIra6WZVmLMHLKCcAc5z2qxaBZdKkWGHcY1+diACGY0XMDWWhgWJ/dXbbVVs7ieMkH07fjQ317DW9i3qMEF7odi1su+V5hHhAxwSD8v16HirNzYBhFJeWtzaRwFYp2ncEE4OPlwDyMd62Vl/s3S9MsVEkl5ZQyyJFBDuXzHGA7MOm0Z61sa/YvPZ2lvaXbXPl2gV9sZ3PjJLHdyMZ4qbNstbHdzgtkhevaoYY8tgVbucBuAcUQIAdw4r0DzbGR4hvU0fSLm8flo1JAPQntXzdq8sl9qUk0xwZzuOPWvcfjBIV0GFEcjzJcFQPvD0rxO9gDlR0YDrXPXlbQ1pRvqavhnWU0/y7R4o1j3BWx95z613YM1rc+dDJtkXhXAzwRXlEiiW5jdBtlUA/wC9jvXdaJrarDHY3UgmTgrNyNmf4T7ZrnupaHTFuJPcOS5Lck81GC38R4NXru2YuWAUDGevWq0cZLg7cdiTXNOLTPQpyuLEMMcc5q9FwuMDGfTmmww4GRj61cityFyeag6IixLkZAx6VdijJ7gfU1DGuOgwRUyt0BqkVYsxAkD171ICPf8ACmRFdp5O/HY1Pbsq5bbk9hTQDdpxg8c1IOQBjp3p6FpGOFwTViO2ZsGTO09hVWFcgABBGfmz9eKtR28zRkrGzKMcmtKy04s4KR5JPcVtJpczKygEgDOB0q4ozlI5+20+RsbyFOOBVxbBGIVmYgdR71sx2SrAZDksuCeaeFjDYJG0nPHWqSIbbMlLVGKqI8nsO9SSWMioW2AAnAGKuSSm3uWKMGRug44qOO+fy2Tb1PODVIhlL7IVcFlAQjp6Vz/jeaG00K6kQ7XKbQPUnoRXVSyifGxG3jkYOa8o8fX8t/qCabC4SJGO/I5yf/rVRhUehzVorWGkNKXUvK2AuMkjr/k1zs5Mjl2GeT+ZrpLgm+mitbOPzCMIiqOvv71pCx0Dw7Fu1kS6lqZx5dnAwWNfd2/pU2bdzneisctYWM9xkW9vLKfVVPH5Vvx+HpLVS9y0ELMODJcAMvvtHJpur+KNXvwtuBFpengfu7W2QIij3PU/iaprprAxvcbZHcBlJbcHH1HT6VtFEG3Ha2jj5NTgeYDOYkkY8dyccYpBM4kxNK0u0fK2MB/oSc496p3yR25jj8r7PuAZZFQIR6g+1NCYdXhdvl+8GO9T+nFXYLl1T5k/mbVCt0iLEkY9CKc0mCxhAJZTlVJIb8xUKI0ZLLIVOeqjpQoHzEOp9CWxn6VLZpFFC7hBYSRo2APmyMEGqZVlIZB1GDg4xWxIV3kgld3Hyn9PaqEoVm4xkHBIPf3FZSLSsRmVUU4BU9xjkGoJVUMowAD0AFWpLfax+bJIBIx2NNZUZT27ZIrFmpi6vI8dmWtm2yM6qMDPU1Njkgg8cAk1YuIAu0kBwG4yOh7Gotwwo7dxUsTIJlCknPzdyO9VplKnG4kdvSrrjJxjJ9T1AqGaIoR5in09DQhFMLjIbjd27/hUHnPHdx3HIK/dZTjkdxUkqsHzuOP6UwAeaGKbhnIz3pomSLF7LHPNJJyNq4y3JLdyT7mq9tHJqd8kt07GGMbNxbngcAVHOJN2wjBPBUnrW/ZtDa28dtLgwswZ9uGZD/n0q17z1IasW7XS4tT0+aCXYI45cGQv8x44Cr7YOcVc8Pao8WmDT4oUa5hfc0xA+4DgfhzUmham1nqd+dPQzo7fJuYIVHc49cVk6ncRtfvc2yqZbhWRlLY2j+8ccZre6SuRymxrwupE85LhI7hlMzrCmx2U+uOoxXOaZKdV1aK5ula5S3wPLB+Zl9a0o7gNo9zJqNtJJdB0jjdJCoIwRjjkirfh7TIbfRor2G3muHJY3AJ2RqAfu7j2xUvVopLQkv8AxBZwC7+xQRrJKyiIKMiLjBIOOSfSq3h8vpdzho4jdzplZG52k+/QUkUaX+rTXi+THCuGQRHIj9FJ/wDrV1jxyzWaapdPHuwxkRlGxgB8oJGMDimve1C1tjAL22nS38aeZOjYWVXwMyZzk8dB2rI0xP7U8QQqxSC1t/m2eZkLgZOCepJrWlJexGoS/Zy8alxtYBy3Ybe/1NQ+DbGB2luNQs5JopXIDqMgcHjPQcnqalq7SKWiOs0a+C2dvLaXsMFxGLlTHM6o0pYYjY84IA4qprkOqDT4Z8iWNbQJcXUUo3TNkkID1KjIGR1xWlbaatvYwrDpWn3l1HkEOokMfIwrEDqRzn1p2pQf2oG09NPtoBb2qSDy1wIpmc4Q465B6HpSe92NI9Pvbfap6Zx1rO2OeQQBWlcnzUbB4rMEMgztbIrvRwSOE+LcpbSbVDxtlLfWvImUBtp+Yg9TXrvxUJTTbQNtOXPXr0rylVLZPqcdK5cSaUVZFCWIb8jI2nIxV+xMasDOVVT19x6094RjbxyOTUZiUKRgtxXHzWZ18t0buh6xFHMLDUSxtzwk45Kfh6V0722Om2SPAO9Oa8yCvuZW646DvXSeGtWmsYn2TboxgNavzvHcA1omp7lRbg7HZx22VGw8Dt60EkAjGMVZhKXMaPbFonkG5beUYcj/AGT0NNZlbKEbccHd1zUSgdNOoQKOeWo5z/KpWtjnav3atw26lVVR171m4nTGehBaoWYlm2gc5xV62UM52HJz1qxa2nzgZAiZcNkZ/GtCytYoog23JUiqUROZLaaZIYdzrtVjwx71tw2ttFt85hhTkgHJOarT3PmW6EkKq54X+tVobiPzMDaTjOTWiJtc35bqNBtgjHORk/MR6fSoXv5pIVXcFUfoazZblmUFR/8Arp0KuyfO2M/N0p3Jsiwsg89h5pIPzHHHNRXcylQzZLZznNRRR7pi5OVHAzSShC+ADjNMBskykdPyqXT42u5HCEKqDJP0qAKGY54HQDFa+myW9rb3RlfawTKjtj1qkZzbS0Kmt6xY+GdIv5ndmkSP918v3mI/lXhOnx3OoXlxcXUscbTZeR2P3FPOa3PHniI61c7FkK6dbkrH6SN0JP8ASuRvdYla1+y24EMLgB9n35Mf3j6e1KUlsckndmhcaoyTLp/hyEqWO0zoMzSnvt7gVNYeGVS4P9pSCOQH54i4MxPp6A+5qpoaaveeXa6LavAXBAeBcPJ25kPOPpXXaX4J1iEBpLmwtixwZJk34/F+BWkV3MpDRoFpGolzYWdru2K81z5kj++1eM/pVWe1020Ctb6nprvkgkyFmHPBBAOKuah4LsbRnnvr+OdejM0oQlv9kdMVX03RtLmVRbod0TZZ26MPYY5rTmYuXUge8s0TE19Jcz8FfKRmHPb5uM/hRNqV0r5iBMWNhMybMfWti/06FWzabwNmV+Qcjvnpmqf9nztEdsrNGq7jtypHHfPFDbsUo2ZmR3m5AlxHHERhWMB5PPXHQ0ydImUtb3AmjAzgqAy4HTFI9nIQqB2DZJ3ZG05H6GoZ4pFiGSu4Ajj1FZybsaRKs0oCg9HGCdwwVz3pk6pIpLHEicDHfPcmnyM7sBKAzHChvX1oVUOQvKjqMdKzkUkV0xkqzNhMc0skbRbmDbgOtNmWMqWj3Bs9VPBHYGoysioCDkE84PSsmWhXzu2ghgR+tV3Rd4G7jscVIztEd3BNOkbIAwpI9qm49yqdyswByp5NMcBoiW5bpx6VakiLp5jDaHB2lfWqzqVzjlsUElGSNncrngHPtUO1RvAHU7Q3Qe/FXmZgS/HXBx9KiLxmUlQCOg3DpVITKjxl7iPP3m/u54HTH1rbs2CJdQPDtlDAiVv4Bn06npVexiV2kuGZUWPgDIyW7cU940UIVk+aX7wb6c/h7Va01My3oJ+y6ulwq72IypY4znIzn0ro7nWI0tRa6va88i3a2xjcPX1HSuf1GG4NhYCTyIYMtGhjXDDofx61fjNw17FpszAJAjAHZnK/3lz+HStIvlVkG5kXBaX7ReTTxCPcHWIDHzt2H0FbWoXdu0AjspHjefYxi3sVY5568VmpCEuoYLyCJkEmUdTxzwCfbvXXaZpNi2s3UupKJLJIcxtIenTGF4yaIq4Kxmac7Q2bwW8ZjeX/AFshAKhR91jxwOSarX1x5LMdR1Dz3uf3YjMYCbBgZOP6Uy6CWWutNc2ksNjJJnyXTBCjJBx0x3p8X2i91UalKqyWFuwRZCnDADOCB7dfwpt9BXKev6hG1hFaWln5EUipnzUG5sHgjA6ZyPerlhqMq6Zb2VmEB2svmeTkEk9c5/LNWdUtTPqtjNF9n/s9S1z3IUZztOf5U9dRj0/X7m5tGtJbSRRuQglY2PUr75qXpK5S1Om07TrXQdNth5M02qXglyRKV3lQcLgeuOKdcaPZxaTDJpKyWN/OolKvJyHB5LE9eeh+lFvNpOmaXaahd3t75ru1yrxMS4kB2gLuHB5+mKzLia31q+GpaleXRtnK8XjgvjkZ+XgDgUW1Gj2+4SMxYYYHris5IIwGAOQa2ZFCqC+Cp7VnyxouTFgjuK60ziPK/i5AsdlaSZJCykD8RXlsY2Pj14r2b4nIZdAlZAp2MGPtXjandubGTnpWNfculqWliDqSeG70CHnG0nipLT5sK3XOOa0oYQ5wR+NcbVzugjDlsSgyVGKpyQOpJ6N2YV2D2Z3BRggiq1zZpt5OT6L0o1RbipIybbUb6BY4ZZXZITlFLfdz6GulttcaeENcLHK6cKQSGx7nvXN3kUjE5AU9W96qpM/Ih2KF4YlsU+cjlcdzvrfXLc/67cjY/i5FXbe/jLBkkVueMGvPUv1jiCucNnnuD+FbGh2Y1AMwuRGcZCjAJ/OldvQ2jKx3sOoJESAc56itKLUoZFfeANx+WuPisry0G8yebGp4IYMD+RrRtLqO6Yxu4tZAedwyKrYpSTOphia6tmKumOyBhT7C1+TJ5L8bRXLSI0Zk2XMT4xhkODV/TtU1O3i+Tc8YBGGGeP50XNOmh04iKsFVQP6U6RgRwCGJ2isiPxB+5IntXibn5wM5PfrUMesPKV8lPMlb7qg/d/8Ar1SaJs+p0DPFBEFQnPXGaq7uPmILe3Ws10uioadWizz8/Ap0ce/cDOwUfeIHSqC9i80qRvl3QN2Gea4jxh4he7kbSNMjllLttmeLr/ug/wA6g8U6/YRym1sWmK52vKOR7gH1rnzrP2NSul2/lhuQz9T7/wD66Tml1Mpu+het/Cks6faNavYNPtY13BRhio7AD196zm1Lw5pNxt0+1bU5hwHlG1FPrz1P6VgXst3qE7G5mkd+m3J2j6CtPS9Hb5HDKrAjAAy31xSi77I5+V7GwvjHW3eRtPSGwDDAKpudRjoDjAH0FJA8lywfV76/uMfPsU9z3BJwPyrpNE8JzlEYGcMRuYuVAH4Vq6vp8lpbMdQ1CQRKdwaFA4H5jkVvGD6kvQ423ntoLrfY6OkzDkvLPuH15H8q2F1fXpXRbbTdPhLAkLtXkD071bgs7bMTWmoXJV2PzOvy5x3CgYFRXqo80iszs5PCRFsdOcLj6Vai11IWpSI1K5Zd0kSM/JRQwwB24qm9hNtK+YzBlI2iZlB59DV+KaMeVCZZUZMthDyT25IzT5ZhLCX8xWYPtVZGHX/CpZqlcwp7A2isdrgMM7S2Rn6VnXUCxyc5cbT9G+lbV3O88JSXy3PP3ic/Wsp2WM7HULnnAHQZ9axlLsWomfDGqzFFDI57Bs4qZ1ZdwWVieoOMGiUISGRSOM8U8zMVjEjFtqAKcdu1Z3GoleSParMSAx/hxVV/McMQMr35q65wnBYY5571SMpQgc8c+xqWx2IWB4baR2PpTkLLgpzx1PWmyT7mJQY6Hg1LFOuxcLk/TmlcERx712MSMZ4HcetJLAQAXYfMCcA8/Snl0VySDz7UxpIWkY44zkL3NO5LWpUjhwzsrNjkgE802NQ5AZGKqC3HU1aKRF1xleScelQ3kbbiUYuCduQMcfSq6kska0iS0sWjBM7lmfdjHPQe4+tT2LRjUoWlQRBCED5wM5xuOauXd8H1GGSW3jQQoiBEG1Rj+dPmmslkwtqZ2PODwGJ7etWkQttR99HbiwMT3bSwGXzIWOdoI+8BjufWpL64mh1WKWFElCxAwyqT94Y5GfSrr+GtmhI8hVLxpPutJtSNR+pPasUQmW/ezk+03MNupIEWcLk5PHdc1euweZuaDaWVzDdR6yZLWSeMutwQFyepOe49qn0OaK0ljks7+1nQ4VWuYiCnI4yeM03R7W1v9Ou7ee3kS4Unco+Zoxj1PC/SsvXJ1v7ux0zTtzw25HJjCgHjkkU2uXUCTxnrL67qHk2OWTzCVjxnc2Ogz24NTWlkFeaxLOkywhmKuFcjgkqentWvYy2K2t+IrdoltFCm6iVfNUdWJB7kjGPSmahYaXssr2a7SEXOwskzlpWBGd2F+lO3ViZzukWEFxcgX90fs0r+XEu/Gcf3j2GP5Vuf2clp4du7SG3RpJ5MpI8wJAzxgHqKfq8EbabFDYRJG0LDgghgOu48c/nUV7bzB7W71S5jmtogpROrNnkA45/+vSskWjc8JxsdMW1utUtLa6jZ/NiaRC0h6A5YHp0xV/UpLgxLaTwQ3DzxeX5pkURKA3QEAYPc1zs+uWMt8Le08PWSqF4DSuWjPfk9/pU+stClzbwXUlpbxFV5QM4Hcnkk+lKOwH0HbxQ7CW5Q81kXcCq0j26sV7itkQJbz7GJC471YeASKTGA2fSujm6nFY8s8RWP2ywuI+7KRg9K8K8pra8eIqCQxXHbNfTPiHTiAzqu014J4ssDYa1Ku3art5u41NVXjdDpaOxmR5HDqAO1blqkQgUeYzMeu0cfnWNBIrqcDeBwx6YPrWhATHgKevcdMVx7HbB3NVAACTyMdKckUbKMoAD3qrDKUTIc4+lSR3DK2EUjnPJ4NK5skVdasgqLtUtx1Nc2trK5SMkeUmSoboAeSa7O8kja1BkdA5PAHJrOuzJdxxIVQJCmxceme/qeaTWt0VuczPaoXIgG4ddxOAKrssiSBYzz0yp6V0n2LaCgIRcc5qM6YGyY+BjOT3rNxbCxkQNMo5Z+Tg4J/WtGB7njEj+2T0q/b2cYGJDg/wB7t9KnXTieEJbPTbxgUuWRSZRN9cxceaenSlbxBeIoBlJwOMmtOTRVluBbs7I/uP61nX3h14p2RZUdlGSqnJ+lPlkWqmg9fGOpCBITKGjU5CsM4Hp9KiTxVdjLlUZs7gdvSpoPCt1NtKFCrHnB5H19K6B/ClpawRKFjaXH7wyN0P8AhTUJsl1DmLrxfqNwAoAcjgck1n3usateq0U8siREfMqkjIrqzZWhlBMqLGDyIY8Zx6VUuLW2nkO1RGMcb25PuavkkZudzlbKzeWQIkE07gZC4JH6Vp29hfSzLCkSq/Tyx1HNdPY6VbRgLE9zOjDnyjsQfUntXSeH9Ktl/fyCCztj1O4FiP8AePrVxpX3IcjC0XwhePMsH7kzsfmXh9v14r0XRvDtxYbYEuYjN1LRxqCSOwJ6CtzyrGw09X0+MS2r4b9z8xPu7dSPYVkyeKIrS5WOXzLqduqLHs8te2Djp9a6EktiG7lqS11myiVr6FIlmJyUlZ3J9WI4A9hXN+IbtbOEi2F0Ub/Xfumf9SehqbUPE6R28k0Eskly3y/NIMxD6Vgtqx+wSLfagZpGOVizh2PYE+gouLlQ6Vo1003MM11Lc3BAAKqBH6H2HarGmI8wQvcF5VP32wCcDkYFURczCDzntklMgC7DIentmkt9UliQt9i8oclY41yCfUmhzQ1TLWo3a2y+WLUSSDI3cZGe1YerTpnYAyPFx5Y5Az15p+p6tDuQHG6M5C7eWP8A+usORJJ9zbCyHu3OSazlK+xolYddTKw8tD0AwGXgE9Rn0qlcjayqHBUZGD1Iq7ZBwSoWMgZyMZyenSoZEjklIIIfPQrjp71kyiF3iMapghxkZp/kM1thipGPWoZYm35VhtPocnNJNvXaYpGBPQMO9K7Cw2UNGRswfqcg1RuEXfjkHrxwKlnknAUPsyOnOKqS3Mkg2so2g1NyW7EE6EHIXCjjcOhNLFklVJ5Y4HNRuxZsk5FBfIIYHIHFOxmW53Kh02gEdsciqNx+82EjnpkUvnSEEkkHGKW0AMo8wOQFP8WKLXBgw37ok7sDtHWn6bayXV4IIJDlASTnpjt9antxGCApGRksfb61LpbmJri5SIsduPlwACeBVJK+pMr20M/ytkhxKXf1btWhLJK6wpbNI6xLmX5ckE9enX61HFbF0mdpQhbkgDPfv6UW8r2JJkjLptJVcnGe2cfyprcRsW2pXFxaGNYnMJwcYwBj+InqevrTIkkgv9tiGeUpw4Urn0x3HfnNW2aG+t4d4lSMHmKE8Zx39B14FUvEO0TwwzZtrfcS0Ua4KDp368VpcLEu26SCSeSMW8JDBFVyQzd885PPrVvTLG40rTp5rjyzNKBttywVnOeMn9awJ5d9ylqrloVwSX4JHv61vzOTcBLf7JPOiKo2w/KM9SSfSmpJsLDYreVIIbm7uIIPtDYkVMNv9AF9fc0+c2NrqUckqJIfLyCrbyCD8vfgfWpbtV061a6upIbu8K4iAZgMEnG0YwAD6VNpsVkkB/ta5inP35Inc4kb0BA9PWnvsFird3txdIXtoxHZoSyrIMLKw5/4F9OlaS3ml/2XZS3Be5v1kzKsZ52/3FAwAKybiPz55IVuI0QN+4tUDSMw9FPv0qpPNJmS2uIHj8gECNcAIc+3U0n3GkddptobtnvNI8NPCFym+W6KbgO/PU+tY+t2FtBfWs+pWr20shAdTIZgoHTkdM8cVo2/ia4i0zThcwXEcNu7wN5QOCjqec/3h1qprkV9qCW2m2VrcR2tnAMyTR7HdgSd3zH0OO9S2hqOp9GRXKXMeyVssejGrVtG8L4Vsp60qxxGLM0Ix6rS/LGv7tyF962v0RwsoazEqqSwPPc1478SNKN7bSyQhRNECwOOSO4r3JXMyFJ1Upng4rkPFOihCZI0EkZ5wB2q4u+jEz5fTMcpXmPtnqCK2I5/u7CPcE/yqz440pdO1XfChW3lJYcZ2nuKyIMZ+X/HH+fSuWpCzOulK6N2Irg7Tux1xSsC0mQOo65zVK3mIj9T2I/rU0U28MWOCeAB61idSZKByAx7ZxnpTXY7xtztPfHWnx7S3PJ9+tSFSyeXkAE8EnGKEXcR1RVDswcd/UGpYgj9Ny9yf6UxCFKAIWP8Qbjn61MQsKsJJCpTlVC53Z7ZpgS+QnDBTIOpTptp8flrIGZD6jms0NPK7up2jGCQavxNstlRZjLjP3lxg9xQmFrly7ne/ulmZQHUDJLbeBTopVWSSNInSYjI2jdn3zVBpIwihgjf7QPIqu0kjPHtfk8HYaq4rG9590bN0JQKTlhGPmX3rMgRFMm+K5uHBGMuQAPepooYp5MRibzOmWI/xqaK2hKy/bI53PGNvOP1ouwsRRKoj2OYoI3JGN+SK0LSOLG2xeKeVF+ZVgPI+oBrJksWTdJFFcxwA/eKA4NMjnlVSyS3aqRjKZXNUpWFy3OjjOp/Zp/tFvbw23pLJtP0x1NV7nxP5ViLR7ZpVwNybeG9Kyo7G4JDsmwkbg00h6U5TbLKTdTPMDxiI4H0zinzC5F1L6+JtbuYIrY38GnWijAG/bj6kA1n3t7Kv37lZW6eZFIW3e5JFBktQCbKApMc5ZpQwA+hFQqbhQgkvGjRiSPlyCfoOtHMPk7Fiy1GIp5SRyyOTgR/dQn+8TmpJ5WmcCa0wS2S0Ugyf8Pzqk13JYgm3nG6RsM4wGI/HpSLc3BiIlWCNG671G4/40KYuS5bW6g3sCGebOFQHO36HP61PLdrADnekr9guQB6Z71WW5j2FLaMqW6mNgfzJqpIk7vjZPIQPlywPH9KXM2XaxLI6ON8+2UADAztx3496hE43sI0MangDOcU3bdXf3gqovA4Cgfj3qSNjDC8EMaHdwXIDHPtSuNxKM9wy7YUj2gckjt9KjkdY0Hz/OfXsKtPCUcRlMuRke1VvsskmZZioRfmy3GaTYrWI4gSrSOBtz16ZpiN5r7CmAO55qcb5mUMSFU8DHyge9R3GxAqwbstySRwfpUg1coXi75PlA3dBzVdoMAIZCM9OeKugBVYkKT7/wBPeq9zgDCBQfx+UUmybGbKro7bW3KDjNPjjkkBdwCuOSB0q0YVZD5jDHbIz+FMMARdgyFJ654zRcjkK8gLZMkgbHAAFNUDfhyNu3Gcf55qcwlZmf5/LXIBH86I0hAkkZ2CE4H978KZDRULgZVThSTnPOKsQOBbuqMTvPMYPXHrViZFgRoyibymM9dp6mrtgqroqF7dmjLkrI38WP4V9yaa1AxY3Y4Vmdc9lXIHNakMVvI6xQ3Bbyxvw42l29BVhrZkddoj858YA6rk5x+VWoYEklS2thH5jlnknfo2B29AKFcdiCzMVzJ5jqgjRizJzliOvNRXqCWynvCBtkOyNdhwBnqCetS2FpPcziyt2URIrea/HC55/Grmu3sH2aKwibFrGAY8KASc/wBapbBsZOnyva2kmY8zOQJBjnnOP0Fa9nLEIBuBnkmO5tpKEcdD6ge1ZGmnDXN4wLDlVCuVO4+lRWLsCZGZipJ5POPanexKN1fOnltbO0iFznDYMYHHvSyw3cd00s0ewgFGIP3R3NVreaeGJ5YpsEjaNrYIFQXBuADNO7vvGG+Y8enFLm6lNaE9rc2mlLJLblzcysMTSDJQeoFQT3p8zyLMSzxswwzR8v3yR65qGyt7pw1yLKSaAHbkqdo9K1ZNRvLLbcSWDRT7gYpCAoTHI2r/AI1Sd0I2tEuri90+1sYitndwO+4zQF1kz346EcijxPLPe6hHE97An2eEQtNL1c5ySOpx2qpZapdQaZBc6hrV9aNcySOIYYQwY7uW6jvTtZtVuYXuY9TkvXW3EuJIwu6Itg4PqDnik5DTXU+khLMI8SRfL2ZaEO+NuM560wSYIRHA9EzTluV3ESLsYeneujY89Cxs8UeGjLJ24qrqP3lCo5Ddx0FXFnaRcBNqetOhlVNy+ZuH0oTBnmfjbw3DqFpMmdhblWA5BrwO7jk03UZra6zvVyuR/FjvX1t4jtGmsy0YRt3fuK8U+Inhp7mIXFvHi7h54/iFOS5lcqMuVnAIg2hkcAMM8HJp6+gPP14rGW7KOY2Uq4OCDxzWlFcKVBZh0rjlE7ITuaELFHJZsk9jUzHa3ytn8M1REqk/eAzVqKXAA4PPbrUm1yQfNGSZBuzypzTwzbGaMBEzjJIJ5qrI5G7YwcepXBpLTLNgxlieOGpXLNB5RIyoi/dGM4249zVtwREIInU45OHz/OoIJPJGN7ozcNuXIA+tTbkBJJgnZsdflxVIE9SPLbiu3co4LbOn1xTGlWM/L5DEHGfLP86sPEYo9jQXULPyoibcppq3jQoWW6kRjk+XJFmmO42NB98z2gHULzTHnbaVSeIA/gKas2f3rTRMc7drQnmmtIru2Htl6E/uiBSGmupbN/cTxxpNqEZVRgDb2pbgxhQILqaUEdMYxVRXQNg3Vsq93EZ/wpklzhj+/LpkAGMfephdD1aWMYmUsvbcelWba/kgBRZYoo8joN2fwqkxPlsxtbhos/K0nH8sVFKxzlAkCnoobNINGauo3bXZBW6M3G3mEIf0NZ7SKsmImAbgcZJH40gEjw5CNIFGCwxirlnLcx2rReZFFGw+6xwTRuD0K+f3isySRMoxuYgZpVWOTcuQZN3BDb8jHShlVXUSbpOhIDFwafJJG6uBFiTHUtjb+Ap3EtSVJXYAH5FHGT1NNSSNXOFJD9Tnqfc1W3ZBCyKMYwrHcSfYDip3F4saMy7VADYYjp64oHoDebcMFaVVXoNx+UVGJnjkxFzj5fMB4/CkO1yzsVYgc7+MfQUsO2QEYbjoxOFH4UXAeluGcurEux6Z5NIAOQ+Wk6Adh/jSwQwJl5ZZGOCBsOB7daWRyECrH5e7nJ5NAEZiURs/DEHO30HuarMrtGSQVH97p+VTrmWRhEnmEjHzHAH17ChF3McfvXHBP8C+1KwrleWHFupkYKGHC9T+Hp9agWFQqnbx6+taDQqxCgmWU9QoyB+PemCIvNjJkmLYEQGcj3x0oEZ7wh0JZQqjgnH6D1qGS2QsWJwAeFxjmtfa8UmCoknP3VX7sf09TVKaFhKy7TJOST1BH4+pp2JZU8kGIM24lyAsan7319qiFuDKXx5QjGR3yauw5cKsXNycjJ4CD2P9anjtRLMQr4iK5kkYcAew9+1NWIsYV1GfJV2+790epPc0+DdGkBDMDnK5b7uPbtVyZDK6ZUKFbAVeOKgW3DzKm0B89u/1pbE2JbRyF80yDzWO1R6D1qcubZjCpRnfqR6en0p9lZCAtNcKJoxkBW4BNTl0WymbCNczHgBeVA6AU1qNorySC3jKhyXk6k1nXagoqoTuzkjHf61blRRJGrna38Q6mq42gtKzHKjCr70MTHyylNPS324UckdcmsiN2t5cFj+daErFozkfvDzj0HpWddhvlPG6glmlFcLlFXnByc96sTXAVGK7QPbpWNBK6AMMFsYNSXUzCJFIwWosHMatpqN09rJB9pkETfw7uKbFcu5yzkkDaCSTWfGxjh7VKrsIvrzTuyk76naaNPI+mIdVmsfseWSBbiJmY4+9jbzt+tT317DZQSR3f2a6WeNRGsEfloIR0CtnOM9R1yK5y21K2GlxW2o20sqwlvLkgk2MA3JU5HIzTNdmkmNgqW6wW7W4+zoG3EJuPJPqTk0XB6n1HI8gZnYFccAjrSpdBlKO43+p4zUFzO7Nj/WEDqKJLi1MYMyj+ortseeXIp51j4YMucAUr3bxrnZ+lUUMayKYZ8Ads8ZqSW9f/VMgYDqRU2AT7TLIxLHKdduaxddtY7jdJGSD6e9azzozZ2lcj0p0qiWNViVdxGMetWtAZ8/+PfCrSSPd2UWyZcl1A4b3rz63laL5H/ya+qtS0ozRsJ7fn25ryjx14Ggm33OmAR3A+8nZ/wD69RUpqeq3KpzcXZnntvOOrNmraSgEFTj2xXP3EU1tKY5FZXU4w1WreY7c85964pRaOyFS5ux3XOSDg/xHpU6yRsoCspk/2Tg1hfaHONpzj1qxDNyC5ABHpxU2NlI3YruOKT/XTBgMDcAwzUwkErJult5mc8qw2n86xY7iPHyhlweCpqeOfgiRE9dzR5P5ikO9zWkBSXMNuYnHTyp84+lSFpogHcXZJAAYuDj6VnQSW7TjekLA8EEsv41M6o7cLbEcY/fHgfjVFJotS3UrhVC3TxryMyL1qyt9cLFvuWnKYwqiaMf0rKkSMKGBto0z0EjEimDYxyJLdU7HaWzTuwui895EzkiaWFccbwsnPpxUNyJpAjBruZWHURYG6iK4hiRI/tBHJ3BIh/M0991xCwgN7L36cAUtwbITHI+V8qYsBk75Ao/KqzgYy7RRFBwSS2fapXZIoQjWzrJg5dmbJ+opnBtyqCLIyTlBkfiaBXGQTI+7c+SOeBirdvKr/wCpiAZQTmQjP61VkRhJHHcESRjnET46+4p/2QDzMQygYyPmJ5/H2o1E2WDPJIGbzwp2glV7+3tTvMgdhsilkKj5gw3c/h/Wq287I3WO3TaPvE8t9c55py3MkqNM92ysw24QHkDt2ouF2hZTNAq7I3j39PmCgj6daY7FXKySusZHzlMZP60LGrRCR47iVfUcAU3fB/BDiMc4f5s/jTBNjv8ARRbsDMm8jHzbmYfTtUkfkxxKWuFk3jkRggr9Se9UYomuCESNm2kAIi+v0rQS0ubYDdCkBGMNIQG/XtQMcgZVBihCqf8Alqw5P4nv9KeERXIKmZz0TsD7+tRT8uDJeRuc9VyxH06VcgtLhkPlJN5bHlpWEan696LMLkQJc7Z8yMBgRRgcf4frTXmCZWRvLj6+Wo61ZkhhEbCe8VHIIEdqhJYn1aoRZzIgkSDyV7TTHnHsP/rUxXERHZSyssEJ7twT7epoChgwtz5cGcNM/wB5/YAfyqULGGLLDJezEbg75PH+76fWoLgsZle7kXpnbGwyPY9h+FAXG/IZJI4MoOAzseQB6+n0qncyAAxWZJU8MxGS2P5D2q7JA80EbzSR21sclVXl2/4D6n1NU3ceVsj+WPPU9T7k96VhDoUV9sEJ/ePkNKTjd9fQD0pJljCiGFsxLzI/97Hf6elRswkgAiAEYPL9yaVHKjaBtiP5k1VhFe4ZNyy7cDPAFOkIQAKwLyY3H+6PSo5pVyGfg/wqO1QStuIK846n0o0IbL0kik+XETsHUnvUHmqHLEkYHB96gAI+ZcKh796jd2LLlcjstBLkTyABWeRsOegqPI2K+3aAc5FRxBpSW5KjoBzWjpuh31+yiOF3PXJGFH1qo02zN1UtzKaT5mZurdB61UnhmIChTv8ATFejaR4A1O4ZmkWNO2TyR9BXb6J8NIIP3l7M8kg52leK3VC25k699jw6HQ76WHekDEj9apTWNykm2WJwV9R0r6ij8L2sUW6KOTA4AGBUb+HLN9wlgLSLzyAap0Y9yFUn1PmY2twUG5GAPQYqdbVmnt1ljm8osN/lj5gvsDX0fbeHLHziwtxG2OAUFMl8PWdr5tzcJGI0BZmK8gDmj2Ee4/as8SNrowljj8vW8+gRP8KXVbWS9ubWHTLK9ZIIBCPOUAk7ic8fWvYY7Oc+XJHowEUg3oZrhUcr2+XBx9M1qab9mu4pD9jaOSB/LkjkALK2Ae3bBHNL2UR+0kzCOo3SK2HYsTwMYqNNYn8whkJ7c1f+yKGKtIUQ1XmgijkCj5s+h/xroujL0Hf2tmPDBkNWbPWUEuPM3A9yelQXFtHNBjAZicDI5qmlj+6J8jdjjcODmiyFqdVLqaFMCdVGPUc1JDqsbKixHLdQc9K4ho1SVg28duuKkR5EdNgJAPOOaTiug7nosWqNL8pHPRuKrXthHMpEkcbFuxxmuZ+2eUUeJnRT1BpbnVFZlKyGVs5JHFJRYzE8YeA7LUVZUTy5jyrqMnNeMeINA1HQJyl3DmP+GQdDX0fbaopjLSQkgcYz0rO1aKz1GExvbZc93ORUuCmrMalyao+bFky3OcYzjvU24fKCNwruvFHw/eDdPpgbDHJjxkfhXA3lvcWMm26hkjI7MDXJUouJvCqmX4JOVDuSo6DFSsCOgGTxnjmsyFlbhSc4qygZ+p4FY2NlIuCXAOCo9skc1NBOVJVoA25cZPIH0qi8AIJSXLH26UipLsyXT164NCK5jWtrmMvtYRoB0Zoi350vnb3kAWMrjqIRWdFvU/MsZyuOQDmrclx50b74IkOAMJGBn3PNNBdkkLEhirMVXB3cLkfjVqKVS0SbwC56yTBRiq1tBEvzvuCBdpGEB/DNOgi2xKjTqpHdmUcfgOtOwOTZbma228PCJARxvd8/0oS4SMSbDFG+QQBCT+AJqvcbgpQXaNEMEfviQPrxT3Fv5RQCBpFUSFvtL8/7OKdkFy4txElsElmvGBxgKqoKmgks7g7Fto04/wBZcTn88CsIopjVQ9sG3Fs72z9PSpW2tKmGgi+XGzcx59aQcxsLGtujol3podTglYyxx6521Qk1WbBiE0aJnnYoA69eMVFOsISKPzrcKoBeRYyTnPQ5606SUz2wtzNk5/dqluAWp2GpBIbueQxWxuZoBg+g/GlEEygSOYYucBGfLD3wKd9j3qqxw3jOuAPMZVFSxSx7fJFlbRuvWWaQk5/PBosCk0S+RZxwD/TJJJGGQI48L+ZOaaI12MYLJ5lU/fkyR/QU/wA4eYfKvRufqlvbnn+VMNtJ5Ts6XOzs0jrGPxB60WHzFtDOGG5rO0BGRtAJH5DNPeSyKb7u+nuJT0CAAfmaz1jgPKvbYKj92C8rD39M06W1kcK8KtGpP3nCxD/GnYSZZS7IidrSCO1QcCVyS35n+gqo9zGoZvOkuZerBVOzHfJPJ/SlktoGVovMSeY55iBfH4n+dVjaxpCokunWZuCiDH4e5pWDUti8zbtmVbeNjyka8t+A/rTVuVVtsEOzJGZZhlh9PT8KP7Ne0g82WeOFm5WJjmRvfHaqtzbyqvmTZ54y5+b8qQ7Er3ECTNtInk6fMOM+v/66rySyFzuAdlOSo6CoJIiEUhhv/u4xUBLLwH5zyAeKVybmgyutoZ2jO0napPCj6VTaYbOclvX/AAqMvuIVAz9uT0NX7Dw5qepH9zEVXoHkOAK0UHLZGcqiRnSSJu3cn2pB88exQxJPO0Z5r0rQfhd9ojU3lw7SEcoowM13GkeAdK0yVHe1XcozypP41tGj/MYSqvojxXS/DGo320RW8iKenmfKDXX6Z8NbhiJLtyf76jjj0zXqtxDbQLhLY8HCkLSBV38B2Hpg4rVRiiG5PqczpHgnTbUp5kCxknjaN1dENMs7IAxvtGcAECr5O9fkcRqOMKvNVWe2DD9/JJjjLDFO5NtSysMEY3s8hUjCleOakLKzjcXRjwAT+pqn50RJVZJGP8IPTFTYiniCvtXH8S55/EUFNJIlu7iTyQsc0W8dgKqljJEvmEFweQo/rRII8gszBccbk4oYM0gxLsjHcgCgRLAxU5AQD0cUtwhmidHRfJkUqwwMEEc5J6VVdbUTncnmgjlif8KlSJHjdTBHJbsCuzrnP1PNAGd9mnjQWw11URFCosohkZV9A3+NWdN07T7SGTy7tpXkctLL5oYyNxyccDjAxWRYW/g3S2mgvP7PfDkqjRKxiB/hLDOeelb1ja6ULbfo9miW7tuBgjUK59alDuROxjZo42SUZ64AA/AUxjl0DCHI5bI/lUUskYhzdMjqBjaDtB/AU+K6S3iVraIpzgkJ0H41dmQRXkSTMT5O4j+LBA4/Kop7W3EAZ8L32KAM/jU99dqbfesbSZ4y78n8qrpEpgEm2MHqADk0K4Gd9hinYkF1YngNkioJbNYlYLKRk8bvlP4VtNeGKXfhxu4Zs9PyqtK0k4LsFYHp5mcj86rUCjbwsIfN37ypwVKk1WjCsScDy+egwa0IbWYfOASvX92QadNal0EixLjqQQSR+tK9mMp27wKCruMk/wDAq14ViuiojlUHHAGM/rVKONIZ97BPQlcHH51Lc2K+Z5wkjKc/NtAx+vNCZSRYunW2jML53ddrLyR6g1lalZ6drCLFd2cTpjBYrzVqNY3dpZHSYg8Yx0+lMPkjJx5fPTOOKb2Cx57rvwtZ5mOiybA2SFduK4bVvDWuaMjG5s3KA7d6fMK+ghdsypxK0Q7qMmoLie3eVhOpOOmVyDWMqcZDTa2Pmlrt0wHLLjqCKnju9xDbskV7dr/hvRtbYA2oDD+JRhs/WuH1P4a5lP8AZtzInqjjd+orGVB9DRVWjkVuA4dQ3X2qe3nLR4+Ukd8CrF34H1+2LmG3WaNOSUbk/gayTZ6pas2+xuVK9cxnis3TkjRVUzeiZkIfCYxjACtzV2NmnYqivuAwoXYMHvn1rmI9QKr8wYA8EH9RUsd9EANoQnPc5qbNFKSOlhuJFiy6TEpxuVU9PpSql0bp5xFPuPRgiEnj0rFh1BQoBSAgd9nPNXobu13ZcQgD0Qn+tCKui3KTJMNkk+GOWV4U559qSZJ0fYUyWJPMSjj1psWo2XkjMUHBI3eTk8/jTDLZrjEynjGDD1/WqFccqIQdonOBhssqgfjSJGMsszQHy14eS4JH4bartcRrI2HTy8YHygDFAmjPImZgBngKKVx3J7cQOiNNJCW3YAEbOatRQRrct5SXLsecLbBcH2zmqLXKeTmK5kD567gMj3wKa8kJnzJdeaPVnY81SuxXRdvBJG8hRJ492NwecLz9AKIJVxvVbSMjjEu6RifWsu4uLaK4OJBtxkYQ/wBTUaXzh/kZgwGQFABJosyedG499Jkq88ipj5RBHt/XFMS8SOEubWKVxjdJcOWJ+grMt57mcbY7G5myOu1mx7iry6Bq1zeiOwtJmjIG2SVPL/SmoSYe0RK9+Hykk37sDJSFcKKpG8WKNhFtQH+I8tiugsfhprlwuZpYoj/cBJz+IrcsfhPKzR+bd7lz868L+FWqLZPtkeem8j27o87weWY8n6VGs89zMwhillY/xAE5Ne16Z8MbCBfNkiV9p6vJmuhg0qz0/aLKFEjPBynH4GmqCM/at7HiWleD9Xuot5VYIz1DHJ/LtXU6f8NIuDczvJ64ICivSrdY4xIu4ojkj5VNSNbWkRBQh3bLHDHge+K1jCKJcmzG03wrounRKqwqx6gkCtiKK2iytsPLAHJAHP04qUPAFxHaJ0zuzT3vXgVVhEhGR0II/SquTYkVWjwxlfLc/exTJmV4jmWbOcZLcVE9013I0TLJ5h6cE4/OozKkc23zDuAzhloAlJEcaATM7E8EngUxTcq+wlXLHICnoBT7a6kmfy1wBnG4AgD39KDlJixuYWYttG5cGlfUq1h4JIIdRJzyQ2CKhWWH7QqRRuODuww+X069annsUnGIpwpz0Rf6Z5qGGylw4GXIOcsmP0pibJZZ3ijBkkKqDgKGUGmBnmjCJdmPLfdLDmllxFAvmzR9TlVTAJ+tOYuYwsMETowzls5z9aVwI/sKbXD3AkYcFTJnFFtBE/zJJtAG3LDINJDaxtKnmQqhJwHQkc+9OaxdmYxXK+QpIIYEmmSWGnt1iaGXe74ADKQP8Kpz2kk9hcwK81okkbIsrYbkjGfamfZoVmHlwICvzbh/F7nNWb553sZltLUGZom2qMYDY4wPXNJ6DRhWF5f2VqlpBo6usKiL/R5EMbe+SRjPXmtDwxa3MUV6ZEEEl1OZVt4mDJDkAYz6nGTj1rBsrCSPS4L7Q1e3vIx+9iuJCnnkfeRw3fOcMO/tVnwveyXX9rTi3ljka8LbXcBl+RRgjHselJCe5P5sqEhVI5wAwC/0qS4LvIsbRxhtuSc5GfYVXMqISrNJK23ouKYkUJLkxnfniPcW5rbUkt3ErpbCKGFZA38TH+QFVZYpkVUXh8cCOMHA+tOgnkj3qXK5BUoBtH596kdUMZJnJVQMxhioPvxS2AhSJmdBcSlQTnh+R9RV+6gk3bIJS6kZ3K3OfoTVKCRRLthkJT2Of5ipVuJM7BNO6HovGD9OKWoAqXJA8zdwOqYyQPUCk4hXzElAlHU88fUH+lEkLEkSKRkfwnGB+dNlnEULKFRSODuYg/1osNFWe488KQ8eerHqKjjYRwAeWJXP93H5+1aYFqIQ08SyyMRgK2Tk1EUjkcLHbhdo6Ywc/nTsO5RjtHlKtwoJxhTirMVm7XCpCZXboVA/Onlcq/7mTJ6qQTRFcyWwZUSELwAHH9aT7DTC7GYysMkuV429QfY+mKghtyITLIwDL/DtJz+dS3N3cvJuEgkPGDAMfmKdj7SgeUGN9pznOT61NmFx0U8RVYlU5zydv9alwtvMT5e+McnyX5P6VXifYcMNyqMcEDH41EIw8zABoxnO5eKdrBcs74EmLwqfmwcyJwD6H0qzFaW1xhy0W7pjGBn61BBaQLmWK+CMp4EnRv8APuKbC7SOXQIWz/CuOf5UD0H3mhaTcRgXGm7HJJ+aMMnPesK+8H6C0iR3GnwKucK6KMH8RXTiVkYfaHlXOPun5c+hp87RzOFRThgG3jGR/wDWpBY44fDnQJ2PlWrwqeAd55/WopfhVpJcKrXUeeThzg13MRii/wBZMY2U4YNhsj2qS2vbdZMTb2B43rx+lKyA4P8A4VDpJZz9tmVD/Cjg5qBvhLpSZ3X10VHYnGBXorXELsyWXmux9VGPzpF89CgmTJB5G3H4f/XoshnnB+FejuFaOa6Yfw5bAJqynwp0wqCGkRyeu/P4Cu+l8xxkxHBHARsGobaALgzecrdTvYhQaLIDkIfhToqSjIfI6hnbk1dX4daBFG5ksI2K8j5iSa6hmjV8iVWx02seKejgxkLJIQepUEDP40AYlv4I0aOFZBpcJZRn/V5xVqHR7ER+ZHp1vGBwSU6VpMSrfvLpz/dCruH480hVSgZ5WZjztRAd34ZoEVBZxBcxQxxoOMkYqW308zTfvMyIh5WEAHFXpFlliV3tHCKMr+6Gf0pgnWKfgRwuoy29cM1AaEU9s8UrDzJIY14UlQR+NSxlAvEsbsB3XGf1ps1yZjl3DMByFIGR+VVWZ1BHl8dSQ/X26UwLcUr4xFIzE/djxgfiatrJIIXknDBlOAi8j64rPSdXVFxNknKg8gUzfIWYeTIQP4wRz+GetAFmUq8YMEcrsxzg4FI5eB2IV4Txu2ntUUJKrJuUfNzh3AYD8KZIdwBkuTGBwNwBX+VIBHubbJJlcuevO7AqRvJiiDQyTliemabFCjK5t7lmxyT5eQP0prxyxqVeTCMR6qW/KmBPczTbUKzlIzyuFyDVW4Bf5GdMHksBhvwqwI4pgUwQg6okp3AeuDUfkRRxFojL5eeFkj3f04oE2N84JEFidAh4BJMefYVXM8b7fMUKgOM7y3Tv0qxO8kqRYZWIwPL2hfxx2pZUm2FdsjFc7RvUjH0zQK7IJJ7WVkLFVbHGDj+VNDqJMrbKY8/f2kk+/WlLkZedJVxg7QnXHuKb80iAouxW/wBo5x9M0ATReXKCI0hQLyzeWefYZ71cSeaSAolz5aL8uDtBH51mRxyK4UOAD90hSQfyq06TlxLL9nIJwQoOf50WAkEcgRQZy2PZQef50yUtGGiNw1uyDeJGIXP09aNk0hzJI7OFOF8k/L+NMmjdo0lVnkZT8wAGD+dBI2Mq7sXneU7ck+bg/lU8cksEW1vkjOcGRCcj1zioXnfCeTZS7iPmPy44qK/knudPvLcSSpPLCyKvoSPpgU+VjTsRjV/MQPa6bPe2jYHnnALD1UMRkfz7VasZ7C/t4jauYyxKnAKsGHUNkcGuZi1QCx1KDyI3S6Ync1ykaxHaAEkBIK7ccYHatDw0bqSC6m8oSpPIGildmBkCoql+n8RUn9alMLFcRRu2CgAwBxkVNLGLeJVhJRWfBAoorYQ63upFAUBSpYggjNWYpf3kQ8uP94RnjNFFQ9wHXDmK9kROFA6dKzTdSJcMVC8cjIzRRT7ga0TMkbSRnYwXOVAFRTySG3G5ywfO4EAg0UVIxtp88seTzt6gDJ9qlkmaNwqKo3jniiin0DqQ3UeGADvxikB3XKQsAUfk5HOaKKcRkmFAD7V3dOnvTCAJn4/i9TxRRU9QKd7KwgCnBDNggjPFQQuSAh6BgB7ZooqpAOnuDBciLZHIjtg71zUlxi3RvL4AbbjJ6YoopIaLlxJJDHEqSN5ZAOxuRnHvVVrqVdxBXPHaiipKLNrFHdxbplG4HAKkipIYVWNihZTkHIPP50UUAakcrw4jDFkOAQ1XGhW2lKx5KEZKsciiikBXe3he0jk8pQ+4qSM8jFPucR6fCQoJJHJzmiigCNLdDaJJyCx5HanQRb42RpJdq9AHIoooEGoW62sMfks4Ej7WBOcjr3ph3fZjIGKsgLDAH+FFFAMhl1O5ktYmLKC2QcCoJLmZ5AGkJAP59KKKAL9lbhyXMkmS23g9BVTUWMOdpZiDtyzEnHNFFMBsEjAoVYruGTgmrX+ouSU/jQht3OcUUUAVp0jd1JijDYzkLyOabb2yvI+5nO3OBmiigURju0U8OxmH49asNM4CrnI25Oec0UUCYCOM+ZII1Vgdvy8dvaqIuWTygAp3cHOSePxoooA0GnZIWkjCoynA2j6fjSRym5mBmVWPTpRRQgFtZWuLWPcdp3FMoccA1eubGJY3T5mAGRuwT0+lFFAGJaxKzDJOAM4BxVlrSEXSja3JBzvOfzzRRVCLMqfMyGSUpz8pkYj+dV5bWEQSSAOGOOkjDH60UVIiKRAUVDkgrnJOT+ZqIuWiEjBSwYDp2xRRVPcYSQWlz5MtzY2csrHG94FJGOmDUzKxtyBI6gEABcDjFFFStw6n/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bulbous swelling of the distal phalanx of the finger with increased nail curvature is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19570=[""].join("\n");
var outline_f19_7_19570=null;
var title_f19_7_19571="AVP and AVP receptor 2";
var content_f19_7_19571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interaction between AVP and its receptor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 204px; height: 427px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the relation between arginine vasopressin (AVP, antidiuretic hormone) and the AVP receptor 2 (AVPR2). The receptor is depicted as seven coiled red ribbons. AVP is nestled within a pocket formed by the transmembrane domains of AVPR2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bichet DG, Oksche A, Rosenthal E, J Am Soc Nephrol 1997; 8:1951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19571=[""].join("\n");
var outline_f19_7_19571=null;
var title_f19_7_19572="Phenylephrine (nasal): Drug information";
var content_f19_7_19572=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenylephrine (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/52/21316?source=see_link\">",
"    see \"Phenylephrine (nasal): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/10/17572?source=see_link\">",
"    see \"Phenylephrine (nasal): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9504768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      4 Way&reg; Fast Acting [OTC];",
"     </li>",
"     <li>",
"      4 Way&reg; Menthol [OTC];",
"     </li>",
"     <li>",
"      Little Noses&reg; Decongestant [OTC];",
"     </li>",
"     <li>",
"      Neo-Synephrine&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Neo-Synephrine&reg; Mild Formula [OTC];",
"     </li>",
"     <li>",
"      Neo-Synephrine&reg; Regular Strength [OTC];",
"     </li>",
"     <li>",
"      Rhinall&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9504785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neo-Synephrine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9509107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-Adrenergic Agonist;",
"     </li>",
"     <li>",
"      Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9504922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Nasal congestion:",
"     </b>",
"     Intranasal: 0.25% to 1% solution: Instill 2-3 sprays or 2-3 drops in each nostril every 4 hours as needed for &le;3 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9504921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/10/17572?source=see_link\">",
"      see \"Phenylephrine (nasal): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Nasal congestion:",
"     </b>",
"     Intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2-6 years: 0.125% solution: Instill 1 drop in each nostril every 2-4 hours as needed for &le;3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Noses&reg; Decongestant: Instill 2-3 drops in each nostril every 4 hours as needed for &le;3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     6-12 years: 0.25% solution: Instill 2-3 sprays in each nostril every 4 hours as needed for &le;3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;12 years: 0.25% to 0.5% solution: Instill 2-3 sprays or 2-3 drops in each nostril every 4 hours as needed for &le;3 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9504923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9505016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as hydrochloride [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Noses&reg; Decongestant: 0.125% (15 mL) [ethanol free; contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhinall&reg;: 0.25% (30 mL) [contains benzalkonium chloride, sodium bisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as hydrochloride [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 Way&reg; Fast Acting: 1% (15 mL, 30 mL, 37 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 Way&reg; Menthol: 1% (15 mL, 30 mL) [contains benzalkonium chloride, menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neo-Synephrine&reg; Extra Strength: 1% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neo-Synephrine&reg; Mild Formula: 0.25% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neo-Synephrine&reg; Regular Strength: 0.5% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhinall&reg;: 0.25% (40 mL) [contains benzalkonium chloride, sodium bisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9504788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;text-align:justify;display:inline\">",
"     For OTC use as symptomatic relief of nasal and nasopharyngeal mucosal congestion",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F12782775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Neo-Synephrine&reg; (phenylephrine, nasal) may be confused with Neo-Synephrine&reg; (oxymetazoline)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9504829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nasal: Burning, nasal discharge, sneezing, stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9504793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenylephrine or any component of the formulation; hypertension; ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9504794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rebound congestion: May occur when nasal products are discontinued after chronic use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease, including ischemic heart disease: Use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Use with caution in patients with increased intraocular pressure or prostatic hyperplasia. When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 3 days.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9504832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11391445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered intravenously, phenylephrine crosses the placenta. Refer to the Phenylephrine (Systemic) monograph for details. Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy. Short-term use (&lt;3 days) of intranasal phenylephrine may be beneficial to some patients, although its safety during pregnancy has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11391447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if phenylephrine is excreted into breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (4-Way Fast Acting Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (14.8 mL): $3.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (4-Way Menthol Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (14.8 mL): $3.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Afrin Childrens Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (15 mL): $5.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Neo-Synephrine Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (15 mL): $3.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (15 mL): $3.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 mL): $4.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Rhinall Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (30 mL): $2.21",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Denason (BR);",
"     </li>",
"     <li>",
"      Humex Nosni (CZ);",
"     </li>",
"     <li>",
"      Humoxal (FR);",
"     </li>",
"     <li>",
"      Nasalate Nose Cream (AU);",
"     </li>",
"     <li>",
"      Nasenspray (CH);",
"     </li>",
"     <li>",
"      Neo-Sinifrina (PT);",
"     </li>",
"     <li>",
"      Neo-Synephrine (IT);",
"     </li>",
"     <li>",
"      Quranasal (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9504875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent, direct-acting alpha-adrenergic agonist with virtually no beta-adrenergic activity; produces local vasoconstriction resulting in nasal decongestion.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10334904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Intranasal: &le;2 minutes (Chua, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Intranasal: 2.5-4 hours (dose dependent) (Chua, 1989)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chua SS, Benrimoj SI, and Triggs EJ, &ldquo;Pharmacokinetics of Non-Prescription Sympathomimetic Agents,&rdquo;",
"      <i>",
"       Biopharm Drug Dispos",
"      </i>",
"      , 1989, 10(1):1-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/7/19572/abstract-text/2647163/pubmed\" id=\"2647163\" target=\"_blank\">",
"        2647163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9898 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19572=[""].join("\n");
var outline_f19_7_19572=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504768\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504785\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9509107\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504922\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504921\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504923\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505016\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504788\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12782775\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504829\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504793\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504794\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299868\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504832\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391445\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391447\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322409\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962001\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504875\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10334904\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9898\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9898|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/52/21316?source=related_link\">",
"      Phenylephrine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/10/17572?source=related_link\">",
"      Phenylephrine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/7/23668?source=related_link\">",
"      Phenylephrine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/50/37668?source=related_link\">",
"      Phenylephrine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/13/40147?source=related_link\">",
"      Phenylephrine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6903?source=related_link\">",
"      Phenylephrine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33717?source=related_link\">",
"      Phenylephrine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/23/13686?source=related_link\">",
"      Phenylephrine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/53/30547?source=related_link\">",
"      Phenylephrine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/36/20036?source=related_link\">",
"      Phenylephrine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5379?source=related_link\">",
"      Phenylephrine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_7_19573="Plantar anatomy";
var content_f19_7_19573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F61931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F61931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plantar anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 598px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJWAbEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimu6ou52Cr6k4FADqKz5da06JtrXcWf9k7v5Uketac5wt3H+ORU88V1L9nPszRoqOKaKZd0UiOPVTmpKohqwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVV1C/ttPtzNdyiNB0z1J9AO9YfijxZa6MTBEBPe4+4D8qem4/0rzS/1afU52udQuCQuTzwqD2HasalZQ06nRRw0qmr0R2174yuJ5PL06ERLnG9/mb8un86wdQ1GR5T/AGld5f8Auu/T8B0qppVvLPtlnRobdTkIhIeQkcL6gnqemBVtHQSERwW8cec7toI49PU/pXFUrSe53U6cYP3UJBKk6A28scgP3dr1oLGQighx6gjr9KpGwiu1MjW0YY/MNgw31JBptvDcW4IgllVRxk5I/Fec/UVjzvqb8xfUEcAlSOODitG31TULcfLMxUcbWw1ZSziMrLNkxHgyAZC/72OMe/54q2uCAyfcPTFUpNbMpxjNao6Ox8Qq21byPYTx5icr+XUVvI6uoZGDKeQQc5rz3kDn7vr1xVvTdSm02Xj54CcmMH9R6V00sT0kcVbBp60zuaKitbiO6gSaBg0bDIIqWu5O55rVtGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWXrniLRdAWJtd1jTtMWUkRm8ukhDkdcbiM0AalFRWtzBeW0dxaTRT28g3JLE4ZWHqCOCKloAKKgtru2unuEtriGZ7eTyZljcMYn2htrY6HDKcHnBB71PQAUVRtdWsrrVr7TIJt19YpE9xHsYbBJu2HJGDna3QnGOavUAFFFQ3l3bWMHn3txDbw7lTzJXCLuZgqjJ7liAB3JAoAmoqvDdxy3lxbKs4kgCly8Lqh3Zxtcja/TnaTjjOMirFABRRRQAUUUUAFFFFABRRRQAUUUUAFcR468ZRaUsljp0ga/Iw7jkQ/4t7du9TfEbxWPD+nrBasP7RuQfL7+WvdyP0Hv9K8RSYzSklydxOXJySSckmuetV5dEdmFw/O+aRo+fJczFpGJBO4ljlifUn1rZ0vTnu7q3VVD24YPLnozjlUPsB8x/AVj2yguqqu0A8+9d5o0HkwxwxLzIpLN3yeWY/y/AVyU4OpdnfiKipJRXUmFuJ0DuH8gkxoc4zn7zH3P9ae1rGsnm+Wr/LiNCOAvqfb0Her84/cmCIbU4UY7njgfp+dJcDydTkUAMFiBYk9TkDP/wBatvq7e5x+3XQqzQ4jjS2hZR5eSeh3ds/QfhVe5gJEJWQKSrMBkgD5ex/xrZ0tkfzQCpbLoTnof/1VILaJ5EiQ4IVWVT0qJ4Z20KjiFcwTI9vNbvGrMkyEsBzkhsfrVZLmSOXzkZXik+7GMBTz0H91sfhxXR3VpH/ozwgAR5Ur6jcSPxrIvNLGJoIBhmTMZ987h+PWsJ0pwdjaFWMtSzG8cuySJgUddyse4/xqOdjJIHbHPGfWs/R32s8bggyDz1XORknD/rWk6fwseD0zU3utDqj5lvSNQfSLxkmP+iSH5x12n+8P6126sGUFSCDyCO9ebPuwEJyMdTXUeEb7dA1hKf3kIymf4k/+tXZhqv2GcGNoae0XzOiooortPNCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvLV1TR/DfxY8UXfjC6tNPa9t7YaZeXzCONrdY8SRJI3yg+ZuYpkE7gcGvQda13SNCjik1vVbDTY5m2RteXCQh29AWIyfaucv/AB5ax+P7PwtZSaTJcyQJcTNc6ksLhXJ2rFGFYyybVLbcrwVOeaAPN/GusvJq8y6Zqtjo2gf2ZHJozyazNo8ZlZpN8iRpC32hgVT923GCPlO/NS6hPqjweM9bm1zVf7Q0q6037MkF7NHbKWtrRpP3OQpVy7ZVl7ngEmvYda8S6FoTouua1pmms67lF5dRwlhnGRuIyM8VmXHjOwtPFF7pl9Ja2tha6XBqbalNcqkW2WWSMKc4AH7sHdu53Yx6gHlOrvZaOPip9n1i+sPEhvmuLeBdUmRzC8Nt+9SEvtI3bwHCnaAFBAAAm+Kl/aeGWvdHsb3VYNSh0xr6K/1DxZeW5kc7gBDHlxO4KZKbQoyBwDXsEXirw9NpX9qQ69pMmmeZ5P2tbyMw7/7u/OM+2c1lav8AEbwrpdrpF1Nreny2Op3TWkN3FdxNCrKjMzM+4AKNoUkZwzqO9AGN8O7iS88e+KLmcgyzaZpMjkDGWMcxNcX401kxeJ/HUdt4i1GPxPbX1mmh6XFqMih2a3t2KrbhtsiMxbdlSACTxkk+wweLPDlxqiaZb6/pEupOAVtEvI2lYFdwwgbPIIPTpzVfR77wuviLVINK1LTZNavZfOu7eK8WSVniVYSTHuJXaIwpwBgrzzmgDy+bWroeI7rdrWoDxkviZba30f7W4jfT/NAybbOzyzb7pDLtJ3D73aqeraWuofCO+13VtT1u4nGtt5jPqlwIobeLV9pwiuFASNCdxG5cZBAUY9Fl+Iump431DQ2u9Et7XTYw97c3eqpDKpKFiEi2ncF+XczMmN3fGK6CDxV4euNIm1W317SZdLgbbLeJeRtDGeOGcHaDyOp70AeR6trU0Nx4jj0DXb+bw7E2jK95BfyXZgtJJJRcSpKWYj5Ry4JIAzn5chReyX9yLDQvEGq3PhmXxFaW1tfRajJI7q1u7TRJcFi0kYYLzuOCSAflGPWZvFvhyDSodUm8QaRHpkzbYrt72MQufRXLbSfoajfxVpVr9uuNS1bRLXTYDDsuTqKdJE3L5gIATP8AD8zbhzx0oAyvhlJOsfiWwlurq5g07WZbW3a6neeRYvLicKZHJZsGRsEknGBXaVV0vUbLVrKO80u8tr2zkzsntpVkjbBwcMpIPNcdZfEW1X4hXvhHX7GTR77IbTZp5QY9RjPeNsABs8bOT+OQADu6KKKACiiigAooooAKo65qlvoulXOoXrbYYELH1Y9gPcnir1eHfGzxE93rSaLA+LWzAklAON8pHA/4CD+ZqZy5Vc0pQ55WOO1nV7rWtVuL66OZ5iG4PCKOij2FSWkSlPmAPcgdaz7BASWdsHjjritmCNTMqDbvJ27+iqO5/rXmTk5M92lBQRseHbQ3V05HKIoVcH+I/wCAFd1oqDyprrd+5QFIye6jv+JrlPDa+RpdzcIuHmciNQfXha7u0ijt7OC3xmNNob6Dk/y/WvRo0/ZxSPHxNX2tRvoDf6K6ySD/AFPzNn++w4H8vyqjcDz9WuOu1RGc/QHH6mrmru3mQoQCZZVdge/X/wCvVOJg2oTgcjO7PoAP8a3RzsbDEJLzcrbcI4Kjvg4H49a0YGAlYhvu+Ugb3UZpunQgyQAgAJAzHPbIJz+bVa+ygQOpHVWb152cUMRWmm2ziVRiNY4jjr1YmiOdN65zuG11/EDP86j1eHytPuDEPuvFGe3CrVGRSuAM8iMDnpgL/hWUo3NIyK2sI1i0M6qSsE2DjvG3X9D+lX2C5Kg5A6H1pdVge5W/jZs7lwq/3cAdPrmqenP9p0+2k5BMYDE9iOD+orzJx5ZNHrYefNEsHGduOcc1HZs9rcC6UMskRDqM8MvQj8qJCAcqPm96jk3O+FBORgA9jWfwu50uN1Y9HhkWaJJIzlHAYH2NPrD8ITmXSRG3WFygz6dR/OtyvXhLmimfP1I8knHsFFFFUQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwXirTtTtvHdvr9poTa9aNpUunNbxywo8LmQPu/esqlGHytgk8Dg1T+GnhLVvDmsW39pKrww+HLHTzMkgZfOjluGeNQTuwokQAkYIx7gek0UAeZ+Lp7i3+K1o9poEuuTNoM6CCN4V25mQZYyso2n7pxk4P3TzXO6d4Q8a+F7eNtDjimvrfw3p+midXjYGSO5laZI1kYAlY3+UvhTxz1Fe3UUAeK6f4O8QXk+oS6np17LHda/p98Rqb2ZleGJVEjusGI8jbjAGSAOtaWp+Gtctddu9Us9Jku4YfFUerR20E0SvPAdPEDsm91UN5jEkMVJ2k9xn1iigDxzxJpnjjXvEVkbqy1FbC212yvII0exW1jtY5UZmckmczAbwQpC8HBYEA9x8OtFuNF0/WVvbVLee71m/vAQVJkjkuHaNiVJ6oV68jocdK6uigDz3VNO8T2Fz461Dw9bRm/vZLRrAuyHzAkaJJgFgAwAfG8gE4zxzXJQeFvEUz69ealpXiC5kub3T7m2kN1p0V8rwq+ZQEHkEqdg2t1Hc4wPb6KAPHNH0HxTpmu6X4h1LQ21jZDf2zWkZtIbqISyoyTOAywNIyoVco3cYzyKmk0nxjptzrN9oGkHTxfy6cGgs3tnkhgS2KSpAJCsW5H2qN4CkAkA8CvXaKAOH+EukarpGk6wutwXMM91qs91GLl4GlZHCYZvIAjDEhiQoHOevU6XxB8FaT460B9M1iMgg+Zb3MfEttIOjo3Yj9ehrpqKAPIvBXjbVvDHiGLwR8TJoxfuMaVrX3YdTQcBWJ+7N0BHcn1ILeu1g+NvCek+NPD9xo+vWwmtpRlWHDxP2dG7MP8A6xyCRXnHhXxbq3w+1218HfEm7WezmGzSPEL/ACpcgf8ALKYk/LIOBknnjOc5IB7LRRRQAUUUUAVtSvI7DT7m7nO2KCNpGJ9AM18pXl6+parPdXTktPKZJG6nk5r3T41asbLwuLKJgJL19h/3Byf6CvC7KNXkCoFDgc7zwa5q8uh24One8jUgtzED5RypGW78evtWpaQ+ahWJQikFff1P6VQt4zEy7yQp5PvXSWEJS1lc4wqKoP8AtOcn8lFctGPPUR6WIn7Oize8N2ReCyUjEEJMzDucfd/WuuJCW7SMoYscBT39v5VjaYwj0zzEX7zYGfQAD+ZrVZi90kHIjhjDsR3PX/P1r0zwmUNSLC9t3eRsw2+Sc9XZh/IVT0sMkHznc5Tk+pZiT+Qqa/Zmmm2hQ7Mzkn3Hyj8uat2EG3C4yd3QegOAPzq3sJGpYRbHYsCdyNwfcjH8q1JFwuxfvDAz+AzUESiI7VHzIgYn9f51OrZeU+pAH029f50gMrU1VtLmBBw0x/qeaxtQjIibHUFVH/fCf41vaqMwJGo++Q3XHODWLqqeY9rsO1ZJ3lPvgKAP0pMaIru6CXV0xBLBSvHb5gM1FZYUXMIGFimOzjs3zD+Zp9sgnF8T0OcN34NSIAu5gAGdI2/8drz8R/EuejhH7pFKMHpwOtR7yEPTn8SPpUkh3bhu4HU1GQUHzbSMZ47iuSR6S2NrwO7C6vYyeGCuB+ldfXA+FpPK8QRBWyJVZTg+2f6V31ejhJXp+h42Pjy1r9wooorpOMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKyfFPh7TPFWhXWj65apdWNwu10bqD2ZT2YdQR0rWooA8U0HxDqvwm1iz8L+O7s3nhW4PlaR4glGDEe0FyegwOjeg9M7PalYMoZSCpGQR0NUdd0ew1/SLrS9YtY7uwuUMcsMgyGH9COoI5BAIrx7TNU1T4LanaaJ4luZdR8AXL+Vp+ryDMmnMfuwTn+56N/ThQD3CimQTR3EEc0EiSwyKHSRGDKykZBBHUGn0AeD/G6+N14nS2Q5S1hCnH95jk/piuJs4o8gkYIG7OeMVe8a3Tah4n1KdWyHnfH0BwP0FRW8anaygEEDcPeuKu7s9fBRskX7QvNMkRckNwM9q6SFg+mWcIGGupC+P8AZBwD+QNc1D9x2iz5ighfx4GPfJrsLSAS6qUhGY7WMW649cBT+uarCR1bFmMrcsTsNNjimeNU/wBRFGCMjGf8nJ/Cn3tx9jgknChmmlWJQfepbWFfM8qPITPJH91eP8azvE5b7Xp8C8JGTPIewx0rsPLKUxAh88udzjIJ67sFc/p+tbeiANOuTkxorEHs2C3P51zV6fm09kGcuyoh6HBzk+wHPuTW/pbCGO7K5IYgg+u4c02I3o/3krnnaxGf90f/AKjT0Yebt7nCfiR/hUSuESJc8lRn8c1FbyeZc72+UDLge+MD+VIY+6AMcR/uhif++f8A9VZN4A13aryBHDnJ9WOf5Cr2pT7LJFXlnUgDPc9P5VUvVBvLhVPMcKJkf3iP/r0gMmzfbdTQLncIGY+mWbA/xp0bBjcegl8sH2RQo/rVXTJ0W81fUGIaJJnUD/cHT6cU+ydjZxrJuWdVDSowwys3zcj054PevOxD989PBrRDmJzkd6iJ6Z/TtSyHBP8AOoHbntz0FcrPTii3okhXxBYsSQC+38+K9KrzDQhv16yIz8sor0+u/BfAzycz/iL0Ciiiuw80KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq2p2Fpqmn3FjqNvFc2dwhjlhlXcrqeoIqzRQB4ZDNqfwMv4ra8kn1L4aXMu2KdgXm0Z2PCt3aEk9f68P65qesWyeGJ9Ws547i2NuZoZYWDK4I+UqRwQcitK6t4bu2ltrqKOa3mQxyRyKGV1IwQQeCCO1fP3ivRtQ+EsFzDZzXN58Nr+QtLAuXn0ZywO9OcvDnqO2fXlgDlrtt8pYE8nJJ7k9asWrbTtUEgVVu4jHJFJHLFPbzDzIbiJt0cqHoyt3H6g5BwQRUlmWLgHIAH51w1Ue1hLGsH8tYAq/O0ysP+A/N/QV6B4WgMZxtAkHzk+rdB/wCPH9K4jS0SbVrdiPkhjMjD+v8AIV6T4ejcQxyDP7398qkZxkkIPzy1dOHjaFzix1Tmq+h0dn5cUfPRfkye4X/E5rltXmW4eRpASJ8jA67emPx5/Ouj1FTb2LRBvmOIwfX1NcZqUrMr+QSCQ+1h2RVOW/T8zW2yucqV3YnLrJfRRRkFo4GJI6AkHAH4d/etS1ymnNGOWJhQf985Ncz4KnN9pen3IUDNi5xjqSe/5109mdyW6k5V5ic+wwB/WmtY3Q6kXGbi+hrvIGvto4VFGfyqBHKuijq7hfwAqK0m825ll/hZcA598U6HEuodvleTj0AxQSOumEt3ACMp5gX6Y60y5nFuNSuiM+Wskx+owF/WnwOJJYG6KZeT/n6Vla9dR2/hm/csQ8oC7vckkf0/KkwWpy73Bg03T9PbDT3K75gOvzHJ/QfrW7bO12ytMVNwFKoe5X+79K5aBM6xLO7ZlW2UgdwWOD+iit20Lwxb13Hume+OefWvHrS/eu57EI8sI2LcrF1BB5aqUmS4Uffz1z0qcOY5ZY25KEOO+A3OPzzUDkrIZEHIGcmspnoU3dXRqeD4fN8Qwc5WMM/PsMf1r0quH8DwH+1JpGIO2IdPc9K7ivSwkeWmeHmE+asFFFFdRwhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeb/GC9ltRppt32yJ5knTPYDkdxgkEd+a9Irxz4zXA/tmKMn7luBgHnkk1MnZDirtI8mUf2DBc3emW7T+G2lM2oaRCN0mnE/eubTJ5j/vx9semGXoYooZYIbmyuIbrT7hd8N1F/q5F7kehHQg4IPBGazrCaa3mhuIJHilQ7ldOoOaLixuNCivdV8P2v2jSblvM1XQoQAVOPmurQfwuByydMD+7wnPK1T3XuelByw/vpXj+R1/h6zE6xbQN97IvfkRg54+uB+Rr1PRoVGZQMRjlMegGB/n3rifBMljq9umq6Ncx3emNCIraaMfxNwQw6q6jOVPTPpg13+5baAoOAvFdkUkrHnybk7mP4rvPLjaOPJfAgjx3kb/AZNYDQKPtDA5EUDxLzjChCWb88D8Ku6lL9p1MJnAhzux2dhlj+C8fjWN4mvv7M0rXiQFNvp7Hg9C+QAffgn8aiq7RsbYaN5CfDuPyPCelOuCpsiSfrXQ2mEgjOcbMMOenU81k+F4vs3g3T1PH7hI+PfH/160JSArLxs34x9FGf51rBWikY1pc1SUvNmhp6bWizwrMFH0HNSWv7t7p3PzfZ2kx6Ekj+gotiU+zhsfLvJ9sL/wDXptwClrcsMb2hjhGenLZ/oaCCvDI/2eJN3zLG0pIHBYrgfzFZ/igA2mk2Sjia481s9kQAAn6mr0AJt2wCQEVPxJyf0AqrqDifxG6sVVLaOOAFumTyR9ck1MnZXNacXKSijkrR2HinVIXZ8kxQ8LxnZu5/76Ndqlsq6bkclRzj+VcC8jTarrUqjH/ExkMZ7uq4Uhfcba66zvy9pIGK/Ic/I3B7j8a8ST9+Vz15xei7DJnLT3Rc4YOsagDGAF/xNVRw/TOagtbyO4kuljlVpkkZ5EB5XJGPw/rVocvu6Hrz61MldnbTfLTO28CW+yznlI4Zgo98D/69dRWb4dgNvo1qjDDFd7fU81pV69KPLBI+crz56kpBRRRWhiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4F8VLlrjxZfKcERlUH4KK98JABJ4A5Jr5k8U3Talrl5dM3Ek7MuPTPH6YqKjsjSkrzRU09DLKqZ2liF54Ga6uwiFvq7PvYrYICJBwN/Xj8MY+tYuhQxtP5rk+XCjSMSPTgfzruPD2nlkgSRCVZvNcn+I5zj8OBWFCPNNy7HdiJWgodzA1Hw5rng66l8YeC7dbiSZUm1rQFG2O77mWED7swB6Ac5OAclT2uk+K9I8S+G4ta0S5NxaEHeh4kifGTG6/wsOBj3yMjmunP7vanVs5Puf8A9f8AKvLPG/he+0bxDdeLPAccZ1GUBtS0h+INVUMOR/dnzkqR1PuSG7DgtbY2bUlWRZX+eZyrseMRg75mz6cYrhPEWpTa1o80jDnWrlWQAY/cqQEH5Ef99VeuPE9l4l8JAeH5Zy2oSpp8scgxLYg/NMsox8r7VYA9GAJHcDImlF14qto7d82sFx5cQH3cRIWkYe25kX/gNclWTlLlPZwlKMKXtfn939fmemXEiw6HbKqkJlQFHbripcPtTdyxG5vqz9fyFVtSUra2sA6b1/IAD/GtFFxK4xnaVQe+1f8AGu2+p41tC3CS+zjhwxx9ST/LFS6pxbwp2YPK30VcD9TSlNt0AP4R09woH86ZrDlWuAoG6O2Cj2LGkDSIUPkKoba20j8cLz+pNYWmD7Xqd4WZmlW4jMh7HOT/AErUmfEjRg5GGYj2UZx+YFY+g7476UBhul8iQn6q1Y13okduBjeTl5f5f8EydLtZL7w7rQVQ15Z6lNNE3feMkgexXg1HcX39m6bNNCPMBVVhiQfeYjgD8SK0fCMv2bxJ4nt5FYpmK7UD0dAD+ZrA8OW02u+KdNsFz9ms1E8jehzwT9Bkj3xXmxp89RI7cTP2blJ/1csppsmiaVp93Nkz/avLmYfxI/DZ9t3P4V1Njb+deQQkD5pFHP15pvxBi86za1txtZpIo1TPT5lx+QA/EmtDQl83W7Vv+mueldOJgvaRSObC1Zewk33Z6MoCgADAFLRRXYeWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYPjnUv7L8L304OJGTyox6s3H+NfO0mC5BHT9a9V+MepkT2WnIc7VM78984H9a8mnm8oGRhgL2x3PT61hWfQ6cLDmlc3fDsb3OpQQBSYicuR3A5APtnFeuaLaKkzyAbUjULn3H/18/lXFeDrBtNsI3ZTJdTHdyMH2H07/AIV6H/qLBUVSzP8Awjqc/wCP+NbU4ckbDrT55trYEO5prg8Ko49K53UJ1MiuzMBkzMR2VVIH6bj9TW/qIMVqLaP7/HzdmY//AK64bX7w2ttLPAA88sotrRGPDP6n/ZUfMfpTnLljcMPT9rNQXU88v47/AFHWbvxJ4d+zWPiDJtXgkOINZUDLQyjjDgbQJOMtwSCAwm8Eta61f/btOV4YbG3FrPZXR/0mzuHlHmLKMDJJDEPgA+xBArXN2ljpkl6pyzRmCxU9RFk5nb/akYsR7VHoulapqdrp2u6NeC08YQQt5VxMB5N7Bn5Le4z94YXhzyOAeileWlPnklLdHrY2g8PCVSlpF6Nfqj1iUCXU7KIc4bJ+nU/zrTgwb0A427sn37/1rlPAfiW18SvPIYX0/WNPRk1DS7jia1kJweDyyHjDfgeevW2Iwk0hwSqhRn1Peu08PexZgJeZpD6/4n+oqpqDE3UwbJDSIp59Mf1NWLc4eOMEfNJ3+v8A9aqroGVpWJx5pfr16n+opky2KE8qgajJnICCED1JIJP8qyNNuQt2ZFIywswT9VOf51bZNzWkQ588mRuevpXJtcLBNOjNtYeQqntkc/h0rlxLtY9fK4c/N8jSe5Fl4nMxwqXWkHc3vGxAP4Zrc+D9gkGl3eqzJ+9vGyM9fLU4UfQ1wGtSTvZ6I0XVpHsC5OCqyZGf0NeutcWnhnwyXlO21tbcyNjsqrwv6gfjU4WN25EZteEow/rTQ5vU5nvvEe1JAYLTEkpx96U52D8ASx+orovDaltZt8rypPf2rhNJFxb6bY67dKEGoy770e7nCvjsFJC+4r0Twmp/tRQR9xGJ+vSsqqbrK5MOVYZqPS9/U7Wiiiu08sKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKwPE3ie20K5sLMWl5qOp35YW1jZKplcLje+XZVVVyMszAcj1oA36K5zQPGGmaulysnm6ZeWt0tlcWeobYpY5mAKJwxVtwIKlSQ3Ymm+JvHHh/wANm2/tXUrWJZr1bBmM8aiCQp5n7wsw2gKVJ74dTjBoA6Wisg+J9BF7ZWZ1vSxd3qLJawfa499wrDKtGucsCOhGc0618R6Jeao+mWms6bPqSb91pFdI0q7GKvlAc/KwIPHBGKANWisi88T6DY6kunXuuaXb6g7rGtrLdxpKWYAqoQnOSCMDHepJfEGjQ60mjy6vp6atIAyWTXKCdhjORHncenpQBp0VyXij4jeFPDVvM+o65pxnikEbWsd3F527eEPyFgflJyfQA+lX7LxRpt5PNLbapos2lJaC7F1DqCu23e6s7KBtEYKEb9xyQwwNtAG9RWNF4q8PTaV/akOvaTJpnmeT9rW8jMO/+7vzjPtnNXNI1XTtaslvNHv7S/tGJUT2syyoSOo3KSOKALtFFFABRRRQAUjMEUsxAUDJJ7ClrnfH2onTPC17KjbZZF8mM+7cfyzQDPGPFWqHVtev7snMcj4i/wBwcL/n3rI8MWJ1nW1lYE6XYyfO+OJpuoQey9T+AqpqImuJbfT7DP2y9by4/wDZX+Jz7AV6NpOnW2mxWmn6cGa2tF+UD/lox7n3ZsE+2KwiueZ6FOPsaHO93ov1f9dTptCgM97LIyjy4P3YA7t/nNdBGQ04bOSp+X054B/LNVNPiW2hhgByuCWPdvU/ieKsH5InzwCdv1J649gK6jibMzWbny7eWccHB8vP0IB/ma8319Fa6X7ZIfs1vbmJ+o2xnmQ/7zn5B3xmuz124WafEmAi8sueijBx9T8o/OvL/GOrOls7MCzNJ5jKp+/ITtRB6heAPfJrlxMtEj2MppXbm/6/r9TkNdubnVfEC2aAI87qrY/5ZgjCoP8AdXn8q9N0K2+ybowoQbGKj+4qqFX+ea4rwJpBvvFILnetpDvllPO6V+XOfZQQK9MZBc348sBRII48DgZLZ5/z2qcLD3uY1zWt7vIuv5dCr4p8Iyay1vrWi3g0rxVpgWGzvtuVmXbzDOP4oz05BxnuOK0vAHiR/EOm3cGoafNpevadcJDqVjIp2xuQSrRt0ZGCkjk/UjBPRxxb4oEA4kdnP09fyFXpdxgBZjsjHAJ74Ndh4drMzrJt0+7PAVmx6YH/ANenXSqlim7DBlLEeuRUduoEcmQQ3lEn/gRxTdWl2Jar2ZgPqP8AIpoifYxZG/4qSIJ0hkjj6+wH9a831N3hmuEMmXWdcjrwu7NegW751K8YnLrNuH4YB/WuR8V2Bi8V61G8f7tj9oiI6FXQkH881xYpN2Z72TzUZyi+y/D/AIcxry98iwvY1wWikhu4sn+JHBIH4E13ni24XxVqVpoNu7rCYxc3roM7IQwJH+8xwo9c15lefvMQlS08qGNCD94sOP1GPxr2D4X6LJY29zeXvz38kxDlugKEqifRf5k0sI73RWeRUeSa31/QueJ4IbPR/JnQKDA0XlK3CqFzg/Q7fyrf8FbpJxNLjzXgVm+pwTXH+KRJqOvJY7vMW5Xaw/uW6kNJJ9WOFA967nwkmLiZsD7vbtzWlV3qRR49JWoyfc6eiiitjmCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5/xL4oh0S+sNPisL/VNTvVkkhs7FY95jjA3uTI6Iqjco5bJLAAGgDoK4nxVpmqWfjbSPFOj2DaoILObTrqyjlSOXy5HjcSRmRlQkNHggsMg8HisRvGd/4k8Z+HbTw8NXh0W4smvppbWO0DlhMsbJKJiSqIdwcIu/J+UnFdb4m8Vpoer6Zpcek6nql/qMc8sMVisXCxGPfuaSRFH+sXHPY98AgHDXnhzxHfXWp+JZdI8u8n1bT7qLSVuIjN9mtTjl93l+a29zjftAAG6nHRvEcy3urv4fnjn/AOEph1dNP+1QGaS2W0ihOG3+WHyrHaWA+U8kYJ19F8bza34rWTSUurrSpNB+3R2AjjSYzi4aNlJcgBxtKkFwuR171auviRZWVvff2houtWt9Zz2lvJYNHDJOxuX2QsvlyMjAsGHDZ+UjGeKAOP1bwbrV5q+ttNZ+IJLXWr23v/LtptNSOIKkWEmeRWmVo2Q/6ouuMbTkmu/+HWi3Gi6frK3tqlvPd6zf3gIKkyRyXDtGxKk9UK9eR0OOlYet/Ee5gtITpvh/UP7Ri1i30y9sLjyBLGJArAgibYSysu0hyMnnGDW3q3jJ9H+zy6r4c1u2sJGhSS8JtnjgaUqoDhJi/DMFJVSO4JHNAHn/AIp0/UNb174l6FpWhtdz6qtpa/b2khWK1zAvzSbmEh2/eARW5Harl14T10HWNFTSDMNQ16HVY9d8+ILFGrxPlhuEvmqIygAUryPmAyK7vSPFi6vr9/pllo+qtFY3DWtxfusS26SKobAzJvbOQPlU4zziueu/EGu3HxU1HS7S11ltK0mxguDFZCy2XUkgmP7xpn3gHywihNp3BixC4JAKt54S1Q+CPF9rb2Ef9pX2sS38CeYim4QXCyJls4BKrgbsYzziszxt4X1/xRrV/qsGiywRSabp4Flezwgzvb38kz277HdRuTbg5K/MAT1x1dx8R7Gxg1U6vpOrabeactuzWdwsJklWeQxxGNklaMguCuSwwRzgc1NN48SBbOGbw9rqavd3ElvBpbRwieTy1DPIG83yvLAZfm8zGTjrxQByt54W1jXNZvdWuNDaztrzV9MlbT7mWF38u3LeZPJsdkywYDAYnEY+ldn4O0m70zXPGE1zAIba/wBUW6tsMpDp9mgRmwDx86P1weM981U0/wAWm71TVUttO8QXF7b2VrctpMkdtEYxI8i/IWZfn+Ri259uFG3Oedjwt4jh8QJfqtneafeWFx9lurS8CCWJ9iuPuMykFXUghiCDQBuUV5T4j8c694A8XzyeMrdLnwRfSqLTVLOI7tPJwNk6jJK5/i/x2j1GzuYL21iubOaOe3lUPHLGwZXU9CCOCKAJaKKKACvLPi7ey3eq6Zo1oQzt85XPRmOFJ9gATXqTEKCSQAOpNeOaZNHq3iHXfEs6s9tAZEhyeqquDj8AB+JqZPQqEXKSSM3RLOLT2mnEZe7uRlGI5itUOFHs0rZY+30rpvD8RklMjDmRsgnjjv8A1rntPM90vmMf9JvHVzzwo6Rr9AATXX2aLDZO8WQGxDD6kev49aKKtG/c7sbJc/JHZaGrBJlZbgcFiIox6AdfzPFJqEoSTyhgxW0f7wnu7ckVIoFuqKxykEfmNx1Pb8zmsPVJGNi8ZPzOWLknqx6/kP51qcaRzGtXTJZPcyE5lfHH3mznao9yea8waU6lqtyZHCxWCOY2X7vngDOPUKP1NdF441qWOFHgbL7jbWEY6vIThpcegPyj2BrM8G+Hm1i8t9G/eLp9lul1G5U9EJGVB/vuwwPbJ7V5037Seh9PRisNh7y06s6vwRYNpXgtrhoyt5qjvIgzyI84X88AD2BrofDyMLmISEFlDSEgcHAxVbUr4T6i0kahLa3jIiRBwNq4UAf3RxWvo9p5byIMlhEkK/U8n9K7qcORWPn8RVdWTk+r/wCGOgshsKjtFGD+Lf8A1qm1Fh9hCMvLAlufUgU+LCRuwyfMkO3j+FcKKZfLvkjj5ySi/hyx/pVmPUpSgLDfseCVUDPHOOB+tZ2t4/tOxhILDePwHf8AlWtLtDAOMrLdAEew/wD1VzOq3jLrEkxAKRRSScj/AGSKCbXZn6AwkKyyHBmkeTcf9pycGtnX/DS63aY802t9EhjjuCpZShJ+VgOo5OCKy/CSNLplm8g3ybELDuQec12Njjb+4lIGDlScY5qJRUlZm0akqcuaDszgtD8AHTdXt9Q1C+S/kgbdDBBEVTf2Zy3UD0FdnYXcem6TfXF28aRW0jOzFuMkZLE+gGaj1VpQP9Yv3jy8nT8K8/1iC91PX4dFEn/Eswt1cN2kw3CfmMn1xWdo0VdGtSpUxcvfZ0Wh5vxf6mIzHdzbXt/MGNkIJ2xn3bJZvQsPSvQPCBWS2klUcPtI+hGa5CdBHLH5QKiKIuwUdABxn9a7LwXGE0OHjGVUY9PlFctGbnUuwrJRp8qN6iiiu44QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuY8T+GrzUNc0zW9E1KHTtWsYZrYNcWpuYpYZdpZWQOhyGRCCGHQ5BBrp6KAON8JeBo/DmoWF1FfvcG3sJbSQPGA00ks/nySkg8Zfd8uO/XiofGeieIL/xx4a1Hw/cWtmlnZ30M91c2/2hEMpt9i+WJEYk+WxyDgbeevPcUUAeZD4UpDp09rZ63cQGXSW05phEN5ka4ad5iQw4ZnYFBjgnmoNH+EosLm7nW+0u2+0XemXRg03SRawr9jmaXAXzWJL7sFiSQRnngD1SigDhta8CS317q97aaqttd3mo2epQF7bzEhe3RFCsu8F1bYc4KkZ68Vg698J7nXNXutQ1DV9LmuLqW2neaXSDJNbtEEytu7THyY2KZ2gE/Mcsa9XooAxvDeh/2LLrD/aPP/tC/kvsbNvl7lRdvU5xs68delZGueC31O68VzxatNZvrmn29iHhTD25i875w275s+d044Xrzx2FFAHlWl/CmbTv7Yktr/QbeTUbW3tWgt9BVbUiJ3YmSJpWMhcPhiW3cZ3dAJ9L+F8+jvZXujavZ2WrWt3cXCCPTiLFEnSNJIUtxKCifukYYk4bJ74r06igDzXWfhrfaudSnvPEXmXt9BZRSt9j2xSG3lkch0WQFo38zaUDAgD7xrZ+HXgseDl1nE1gw1G6W58mwsBZwQYiRNqRhmwPkz1zzzk5J7GigCG9tbe+tJrW9giuLWZDHLFKgZHU8EEHgg14veaNr3wauZdR8JQ3OteA2YyXmi7i8+n5OWktyeSo6lT7k92Ht1FAGR4U8SaV4r0O31bQLyO7sZhw6dVPdWHVWHcHmtevIvFXgDVfDGuz+LvhYYoL6U79R0NztttRA5yo6JJ1wemT253dd8OvH+k+OdPlex8201O1Pl3um3I2T2rjqGU9Rnow4PscgAE3xI1ZtK8LXPkk/arn/R4QOuW4J/LNYPhrTIoNCXTzgI0Zic+7Agn8zmoPG0/9qeObLT85hsYjK4zxvbp/StXTOCA3Qjb/AMC//VQlcuL5VdHLaDavEZVuFaOeJ2twp7N908ewwB+Ndasai+iQn/R7RMt6Fv8AOKkvNOFxdLeQsEuohjDcJKQPlLehHrWQLp4kFpdK9vLPKfM3jB2Dkn/PrTvbQ0vz6o0riR1sEwD9ovJNyg8EZ6H8BXM+JLxIFK+YEiQlWY9FjUfMx+rYA+laV/rURu5rhDkQJtRRz85+6oHsK5XVPCmqeJ9Mjt5Jv7Ls7hx5s8y5laNecRp6knOWwB71E5PlfKbUYxU06miPPPDb3/jfx48mnQqLe2Vo4JGH7u3QcGRj29u5PSvV1trTQtIGl6VuMQYvJK3355D1dvx6DsBip9LtNN8M6Gmk+Hrf7NaIxLMzbnlf+/I38TfoO1YWpXEkx8m0BY9Wb37VnRpWN8Xi3X0WkUMtHWW7ZCSULpE2O4zub9APzrudEVmkd3P3X3H13GuM0Gw8h3MhL+Xnce2eprvNAiIhjMnDMC7A9uK6VscE90jS2hPssXcD+WT/AFqHiW8Dc4Mxx9FGP8/SrCsA6sx5Cbvpn/6wqkW2SRLkhgjyHHbJ/wAKQkV7/C2dsykglicgdzn/ABrjfE03k6TqMoGHMXlj8QR/Wu11YAQRL/CVX8OlcN46XbpxHVmlUAevzAUPZlwWqNPwwhS1gTO148BT7Y/lXUW5Qtl12vk9PrXN+HuIYlbqGwD6V00DgHa5Ujccbhz1pN6hbQg1JI9jMwwBn5mHSuSnvTa6xDOkEpjeNlBWPcx564/Guw1KSNUY5UkDoBmuYilYaqsj+arMmF+bbkfXGQPpU1IKaswpScXdGDqepXWtXkujWUV3ai5KRTyyoYwEz0HXrzXrHw+uDd+DtMuXI3yRAtjpkfL/AErjdQe3sIb7UHYItjA85Q9Rgcnnkk/dyT3OMV2ngC0+xeCtFh7/AGVHP1Ybj+pNRGlGm7RHOrKpTu+/9fodBRRRWhzhRXI/Fu/1DSfhxr+p6PfS2N/Y2r3MU0aRvyozgh1YEHvxn0IrFvvGetaRM+m2elrrclhokWr3d7d3y2zSKxlBUKkJUv8AuiRgKvPO3HIB6RRXm+rfEa/hl1R9I8PxXthpukwaxcTTX/kN5UqyNsVPLbLgREgEgHnJHGaHiL4zaZpOrXsEa6a9rYeR9p+0aokF0/mKr/uLcqTLtV1Jyy85AyQaAPV6K5Tw94k1XWvEGq2sWj20OladePZSXj3xMjsqBgUiEeMfMAcuMds9KzvEnjbVdO1vXbHSvD8GoQ6NYQ6hcyyah5DMj+b8iL5bZbELEZIB7kcZAO8orza6+J7GHU9T03RxdeHNK8g396915cqiSNJWMcQQhwiSIWy69wM4ql4y8c+JhoPi248P6TZW0WjXDWgvp7/52cbCWSLyWB4f+Ij2z2APVqK841jxrL4e1W+l17SSl/baOLto7HUpJ4XzcGNI1V0jXcSVzIVBGccgZo1f4h6nolrqUOr+HYk1m1WzlitbfUPMiuI7i4EAIlaNcMrE5BXHTBwcgA9Horm/CfiC81W/1fTtW06Gw1HTZI1kSC6NxE6yIHVlcohz1BBXjHU10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5v8Svh2mr3i+J/DN9/YPjCyTMeoxj5JlA5jnX+NSOM4JHHUDFekVyPxS1Y6T4OvDGcXFwPIjA65PX9M0N2BK+iPLfBXiRdV13ULTW4f7N8YyBZZbJmDR3Cgf622fJ3xnBOASQO5AzXptsoC71GUYZIHZvauJvvBOmeJPCmnaZfLJBdafEslte252XFnKcHfG315K9DgdDgin4b8Y6l4Y1iDw38R2ijuZzjT9cUbbXUfQP2jl6ZBwD+Rao6FS7HqRz5aqvzHpkdc05VV1KnDIOAHTPH41G3ysQwKso5PXHrSiVfLGXXLc8g8CmSKEEX/HvFCjE5LBVXn14FZF5OrmWaSQzN0Cp0x7mrc7GXIDbgeOBxVHU8W1ixwsaAck9ce1Sy46s5eOKW8I89tkSk/Kvqf/rVnaxqCWoFvYqBK3APpngVcnuiInS3BLfdz/tHrj+X4VjQWZk1NFY7nB3kdlA4yfxohtc2mtkzptHs2FpHEM5lkw3PYcsfyA/OuwtQfLkK4DSHYo9uAf51j6PEoMki/wCrjQRJzwT1P49BXQWa7ZBuX5Ik/M5yarpYxvd3YM4eaTbnA4/BeB+tUsZMzjkFAB+dOSRvsNxIpyXYoh9+5/P+VPkXbbr9F60hoh1YbpAv8WQBXD+O2Hn2cK7jvukHTr83/wBau2vSPtKjnO4D82FcL4xYnVrQtjYl2nH0Vm/qKC1o0bulxlYoinJyfx5HFdBGCcGNwCGOUcDjmsuxj2hQoB3ZYD+8P8a1JBmFmQjO48N9al7jWwlx5vksT5Kn1wK47U4nudTsI0nJy+XdF3NjHRR0J+vA6108qkx/OsYB+rH8BXH6qZX1jSgrmNHlO8g9FGaHsKKtL+uw/wAWJ5uiXlrbZeSZlhwG3GRywATd3xkD0yTXr+lW/wBk0uztv+eMKR/koFeSW0aal43s7Rf+PawkjZgOgkY5Rceqjcx929q9mqU05MVR+6kFQX97a6favc39zBa2yY3SzSBEXJwMk8DkgVleMvFWkeDdBn1fX7pbe0j4Hd5HPREX+Jj6ficAE15jonhjWfipqlt4j+IVu9l4ahbzdL8Nsfv/AN2a59T6IfXBwMhqMT1Dxl4eh8VeG77RLq8u7S1vEMUz2uwOUPVcurAZHfGfQise98OaNpFrqGo63rM0cU2kx6Rc3l7NDEohVpNrkhVUOTMRnp93j1l+Jus3uieHreTTp0tJbvULWxa8dA4tUllVGlwflyAeN3GSM56HzzxFJquoa3b6Bc+Iry5TTfElmkWoJDbCXL27ybHHleWXjYAghBw65BIzQB39j4N0W60nUTZXtxcWetaPb6YZopUdWt0jkVJI2C4JKzMc8g8YHrFf+ErGxnVrfxLqmiR3zwwyw288EYvJUQIvzPGXDlI1X92y5C9O9SfEq/1LSPDGn/2Xqb2t3NqVhZNePFG7BJbiON2KlduSGPQD2xXC6rqWoS+IrbR77U31eHSvFenxw3sscaSEvA7tE/lqqFlJ6hRwwB5FAHrOiaLb6PJqT2zysb+8e9l8wg7XZVUhcAcYUdc9+a5PWvANxrfi3X7271i8s9I1OwtbKS2sZEVrhUM3mLIWjJVSJAAUZTy2ccVzGk+NdRuPE+lPp2oa5d6Hq8F48EmpwWSRv5cZdXgEQWUAFSP3i4II59cy41bxHP4H0v8AtXxDc348SeE7y9mU2tvGIJVgiceXtjBwRIysG3Z6jb0AB6HqHw30m7urox3eo2mnXrQte6ZA6C2ujEFVd4ZC4+VFUhGXcFGc1o3XgzTbrRPEGlzSXRttbnkuLgiQB0d1UfIQOMbARnPPXPSuFm1C703w94f0uw8SeKLrVZ9ON8n2KDTTtgCRjc7TRpGI0PT5gx3HJPGJfBmv+IPGN74d8zW5tNhuPDttqdylpbwkyzNIytgyI21TjoB9COtAG14j8LeHrazur3xp4hnkiuLH+y5bvUrmC2BUymRTuRI1DhuhGPujgnJq0vw+0+7trl9R1bVdUurs2jG+uJIvM8u3mE0Ua7I1QJvGThcncec4IpfETT59Q8d+BEg1S8sCJ7shrdIWIYW7HcPMjcZxkdOjHvgjnrLxtqL+MdEOnajq9zoWrTX0KTavFZR2x8qGSQNF5QWcKrR7SZBjB65xkA9RsNFt7HW9V1SJ5Tcaj5XmqxG1fLUqu0YyODzkmrc97awXVtbT3MEVzclhBE8gDylRuYKDy2BycdBXh0/jfxPoujTDVdUvY9XntbaTdeW9nJZwrLcpC91BLB1jXfwsvzfdJ756zU9X1Hwz4j0Syu/FkupWMs90148tvbiaGNLNpQreWgHBXeMKCQQDuHUA9Noryr4feKNUvfHUGm3FzrdzpV9oz6nbvrEVkkp2yxqroLbBCMsh4kUHK8d8eq0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeP/ABQvP7V8e6NoQY+TBtllHuef5AfnXsFeCaRcDXPinreog5ggWTyye4yEH6A1MuiNaS1cux6Baoc7kG19x3D1Hapta0jTfEmkz6XrdnFeafOuZIpB6dCD1DDqGHIotgVT5huAGG/xq02BFiNxl2Cjd6VszIzvDOhx6FoFlo8N7fXsVuCiT3kgeUx7iQpYAZABCj2ArZYKoLPJtFV9rAZDKOw561HLGuAJJRlj/DSBkd7fLAisi5DHBZux7cVy2rSz3U371j5Y/eHd6Dpx9f5V010IBCQEySNpdz0rj7mZrqfhywZhk9PlFZz0NqKuytfTx2FqEiGZQpd2PqareGYSLa4v5sl5m8uMH0Hf86paw7XE3lx8tK+B9BXX+H9PR7i1two8mBMMc8HuTWkVaI6r1sb1jALS0t4WyWVTLID3z0/Wr0shgsrlyQHRSSfVuePzNV4naa5aQdGbfj2HAH50+4Uym3tVOfMlG4/TJJoMxlwBBaW8A6ooA47nqfzJ/KrN391cdiD+HFVLjM97Gw+68uV9lUH+tWLokmJB1ZhihlIqXCFtRjK5JEiqQPbJrhvFaY1izXqTPM7H1wuK9EtowbzzST/rGI544GK878QL/wAVBY+Y25UeUn8c0WFF3k/T9DrNJVns4c42BSd5OAv1qS81G3ZFRZ13HPzD7rc0mnWrzaDc20Z/eMcAeo4/nXP3d0IrWNHiIZMggfWspuxvSV2dAUZ0U+Z8uM8CuS8RXEemXNjcIDLLGXZEGPmbHyr+JIH0zXR2k9vMu5vMUiMZA6dK5TxSkcmqaQqAth2bDeuOKU5ctNyHTipVEn/Whv8Awv01hdR+cwafe15cv3eVup+mSePTFdX8RPHeleBtKS41DzLi+uG8qy0+3G6e7lPREUc9cAnoM+pAPn8/jaLwdaeTY2b6t4r1htul6XCP3jrz+8k/uR5ycnqBxwCR0Pw7+HdxY6s/izxzcpq/jK4XHmYzDYJziKAHpjJBbryfUk54dPku92Y15Xnp0M/wb4E1XxFr8PjP4n7JdTT5tN0ZTut9MXOQSOjS+p7fgNvrdFFbmJDeWtve2sttewRXFtKpSSKVA6Op6gg8EVSsPD+jafaQWlhpGnWtrby+fDDDbIiRyc/OqgYDcnkc81p0UAY3ivw5YeKNNisNWVntEuYLpowFKyGKRXCMGBBQlcEdwT0qaz8P6NZWdvaWWkadb2ltL58MMVsiJFJ/fVQMBuTyOea06KAMSy8JeHLG+e9svD+kW145Zmnhso0kYsCGJYLk5BOfXJq9HpOnRLZrFYWiLZxGC2CwqPIjIAKJx8qkKowMDAHpV2igDnv+EI8KeRFB/wAIxofkQytNHH/Z8W1JDjLgbcBjtXJHPA9K1LHSdO08xGwsLS1MUIto/JhVNkQORGMDhQSSF6VdooAhmtLea4gnmt4pJ7csYZGQFoyRglT1GRwcdqy7fwn4cttRfULfQNIiv3Zna5js41lZmDKxLBckkMwJzyGPqa2qKAMbT/C3h/TYLyDTtC0q0gvBtuY4LOONZxzw4Aww5PX1pdO8MaBpiRJpuh6XaJC7SRrb2kcYRmXazDAGCV4JHUcVsUUAY+jeF9A0S4a40XQ9K0+dlZWktLSOJiGIJBKgHBKqT/uj0rYoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzPE9+NM8PajeE4MMDMPrjj9cV4n8IIQbXVrtuklwsKue4Vdzfq1ehfGi9Fr4NeDJDXMqp+A+Y/wAq5b4X2nl+C7IbcPO0l1j1Dsf6AUkrzRpF2py+SO0gDKFx8rdSOo+op87qZPnVCFH060W5+ZVPIPPPYfWggP8ANkMp6AjOSe9aszQzci7AwUMw46kiobqdSxRAdvT5RzV2NfnaQrGMfKC1VLvaysGYvt5wvAFJjW5j6lcu9owjjJlP7ok9M+v5c1hsBCkrud7KuAo6D0rUvJjLNhPkVR8xH+fTNY+pubWyjVRmV2347k44H8qzerOqjaMWynYW7vcvOSPN3LAmRnax54HsMn8RXdaNALeykfnDjIJPRegH+fWsDw9prbEUnmNCu7P3nc/M317D6V1rp+7EanbvIUccKoH9FyfxrV9jB+87klhgRRELh5Pmx7Z4/pSqxQSzryVUpH9ScUsXCzSquFBCRj09B+v60112pFE2NkYDt74/+vSBkMA/0/YDlYIsH/eJA/xqeVgdQgTJyoLn8BUOmruM82cl3XH0HJ/nTEfdql+4PyxxhB9SaTGkWEYpsxySrvivP7359YjDc/vZB9flau/EgF9EgzllkP4BgK88u2Zb9JDwRdODk54wafYmPVna6HJ5SorkjBGGHaq+vWMN5LC6sschJyR0b5jVjTADHkjcMdB1x7Vm3QcXlusbB4y5HH1PUVlUOiju2aJsHto5GkSMqFA3jmvPPHGsf8VHa6H4asYdW8WBS8duwxDYDg+fcN2AHRepyM9QG6jxu/iqSG2sPBscME147JcapNIu3T4wAdwjzl3bJ24GBt98jD8K6HZeD9VtdM08zrHKjz3lzO26a8lyP3kjdzy2F6DJ7kkqo+WDZnBOcrI674QeCbDQrKbW57mXV/EWoM32zVblf3kmCRtQH7iDGAo7AZ6AD0esjwqjJoluWTYHBdV9ATkfzrXpxbaTZlJJNpBRRRVEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4j+0PqWPJtFY4ggeZh/tHp+g/Wuj8O2v2LQ9IjjBAitYl+h2jP9a85+Jjtr3j2WyTLCW8jthj+6CAf5GvXbNArsqDdHknb6DtinBe82U3+7Xm2WSqmJ2wMEYPsahOxQCEUBRwM9zU7BfljGVyctxinlY2kGY8gHJqyUVnfagSMYwMnA6/jVQxgmRnIAzgZOf0q7PKq7mKKMZY7jVC8ufJsSUG5sdfujNS9S1ojCvZAhbyxwxJZ36BRx/jWTDE+oahG2C6q2Tn+JmP+GKNUu90ohhbzJjiNcfdUnqa6XR7BbG3LFTvwBkn+Jv645ppW1LcnsaWmW6xuqDBhhzIx/vHoB+fFSCUSTs7EEJxgdzn+p4+i1HcuLG2jt04d/mYdx2UVFbfK5UnIU8n1I6/l0/OjcnY0o2BuIIM5VG8xz6n1qC8fFpNJg7nwv4HmpLRWIuHY/NJKIxnsAPmx+P8AKo9SO7yowMbssc/59KBdSawULFFnkElvpVDT23y3TYGJJ1U+4B/+xq+jhUTPAETP9B/kVkaLkaeHY5YiSU/kcH8zSZcdixZS7tTRiRlbduT2y2f61xlyPkcEEmO8fk9ea6zTSvmysTz5TqPzH+Fc/exlbu7AHWVXwO+c0PoJdToNNkMOkXM4G6S3QlQe9cxZXc893bTyS+Zuk+YY6V0+gyKilGG+Nhgj+8pH8xXNLpsmnay1upLQFy8L9ivp9aznq0bUmkmdPcsylip3LgnOM8muO1+43a1bB2wwUxhu4Vjg4roIpz5rqzFRvwG6jArmddha41UZcM3lAqFPUhs8+lRiP4T/AK6jw6/eL+uh7pbII7eJB0VQPyFSUi/dGRg+lLWpxhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVHcyrBbyzP92NSx+gGakrlviXqB07wbfupw8qiFT/AL3B/TNAm7I8W8Fp/anxBjuJM7YxLcknsTwv6mvYIYyoO/Kuo257MK80+ElpvfU78jI81LYYH8IBJP5kV6csrxjbIu4DkGqhtcupo1HshUZgZJGfAHA5pjeayH98+T12rmpnlwEjCHAGWyar31/5YVNy7j1xzimxJXZXlhSNR5xkZnP8R7D2Fc74gvBJKkESjGcszHgAfyq5eXheZ5ZGIjjGAT09+awbC2fXNRYH5bQEhiDjIHLH6UkurLb1LnhbT1uLiO8kUu0r7YlI4x649P8A61dfDHGC08hJgQFlGfvnPU/0qHTYoxulA2DZ5cUY4IT1/GquqXf7hIYSN0zZG0YAUcdPyA/Chsa1YyNpbq/kmb5mU+Wh7b+5+g/pVu3ZRNIqDKQHBJPLEDI/xqO3jW1tiwPyRLsXB+8x+8fr2H4UulpvjKn/AJaSHd9M8/y/SmhN9TUjQoFUsPlUk/7zf/WqhfOGu3Y9VG1R+HJ/WtCQllJxxI+R9BwP0BrDnfddRqMfvWBPsC3/ANagS3L2pyiK0vyP+WduEH1IqtZIItLde4hRM+5IqTWBvtrkdRLKq/gAKax22TLxy2fwCk1PU06FLw45k0+2lY8yjGAP9rrVDV1aKR5V+UOiHI553Vd8NkR6TYgg5y5A+immeII8Wqsx4EakgdcYoewL4ixp68MVzhhuwP4W9RViy23N48U4BUqCCPXjms/QZTIu0H94hx1xmrumShr5xIpQqVBYDAz8w5HY0nq0C0iyC6s/LuDnockOD1z61zs6p/wkMESgFpPLUY5zl/8ACutvo2aRlVh8qjgnHOM8V57rF62m+ONIhBAllkh28bgPn5P4VlWV4WXdfmbUPi+TPoKiiitTiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryv49XzRaVp1mh/1krSMM9gMf1r1SvAPjtdm78Vw2cZz5UKxY/wBpz/8AXFJuyuCXNJI3vhnaGz8LWch4+0Fpnx2LNkfpiuzDSFso+5OuM9KztFgFtY28SbVWNAhB4HAxx+VXlEeAx2gk545rW1kkDfNJsZPvJYvx9W4/zmsS+uVjZ5AAxQdW9ataperDGwjUtIe/+elchfyPcOkLMXZjny07n+tFrlR0VxXla8lZCzS7eW29M+ldVYWK2OnrCqqHl+8PXHJz7Dn64qLw/poghQygKqDzJfTd2/75H68+la8kbSMqkYaQB2XHKp/Cv49aNw62InHlafEpch7klyWGCsY6/TPA/H2rP0/N5dzXbDCJ8saAdMd/6AU3XrtppWigbLyHywR0VB1wfw6+xrV0yFbKxR3HAUPjuO4/pU9TRaR9SLUh5SQ2y8FMFz/tsc/oB/KrGmIYgrIAGKhVU9ix/wAKzmVp7hQ2efvZOeSef04/OtzTFVruI4+RVMje3HH6UyWP1ELEsgUn90mPxIrBtkEutRLkfLsXH4EmtbUXItJnJyzSF/6D+dZ2jn9/JJnjft9+ByaARJPmdIhkkNNz7gt/9aorhsrIoH3Uf+Qq3AhXT7Vm5ckDP1ySfyP61VZd0d4cdmGfyFIq5B4fi3WFqvYNIc/XcKdrce+AKAeUK8e2Kk8MnNpHn+/gf+PU7UxuVj3jdT+BGKOgfaOW0m4MEqSfwg7X9jXWWK77mcgbuAR64/r1rirGQRajdQSH5RKVIx0BPH866/ScxSyxv93AKsO3aoW5VTRMivD/AKRKFYnJBIxnHQD+VctBDHN8QLOWSNZXeFbdMjG0GUM3H0H8q6vUXjdn83hj0kUfgM1Q8NWmfGUDlVkbO1WzkBQC2R75AptaCi7L5HqtFFFBgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzZck6/8AFqdgPMjS7eXHUFY//wBQr6G1q+TS9Hvb6UgJbwtIc+wzXgHwft2n1XV9RmUlgmzPozEu2PwAo3aQ47t9j1S2wkbGMkqeMHnk0tzIFiwiMB054FEUi7VO/tkkCsnW9RVVYfMQOpY1t1IRk6tOzM25tsaj7q/p+lT+GdNAxfXChpJOLaP09XNZ+nWsmq3ha6+S0h/ey5HU9h+VdpYQSTSByBGWGMdoox/n8/pSfY0vZFq3gAjBcj7NGckd5nH8lBrN1S7EaFQxVrgmSWTuEHp9egFXr+dWjJXIgjIjjQfxn0/xrlfMW8v52l3SQwvs+U/62Xuo9l/nipCK6st6Vbm5uBPOu1Mbyg/hTsPxwB9AfWtTVrrGVbGQvmP6AnoP6/hT9LiKRF5eCzZY+/oPYDisLX7hpLWWSIfPPJ5cY9exz7AUbFr3nYvwONwKHKEHDE9cAc/ma37BFhhuJD02BM+wHNYECYgGCcKqqOPbJ/Wt6f5LRYV4LKF6d8ZNK45KzsjN1iTy9Nc54yoUf59zVe2OxLsRn/UqVB/vNk5P58fhTtcmWC2kY8iEowA7ndgf+PH9Ki0rK2lyB97zAvPqTQCNuRBFFbJ/cQn8QMf0rOfaltITwCrMfbLf/WrWvQGOAOkeAe/JxWDrzFNIvynUQ4GPcmmyI6j/AAxhIIV9TkfmakmUzSXcX9+EHj1BqLRCFW3YdN4UfTFWAdt3HnPMRH5c0i+rOJ1VFh1+5U8LKqurepxg8V12hyCTY+R8y4YdQaw/F9osN5HcDcFyVOPc/wAuRVrw5JglCcg9v1pLcc9Yl3UMR3LAgquR7jgZ/mao+FAP+E2str4H73gHj7laNw7GXaCGOScHn8P0qh4UTf47sCI1TZbzOwGeSQB0PSiWwo/p+h6pRRRSMQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4D44agbLwBdRowEl3IluOexOT+gNch8Lrc2fheGYAbrmVpTkdVPA/QUftHXbPPoWnx53HzJfYk4Vf61v6XCum2dvaKQBFEsYDDgkCqgtRX0fmaUrxhWYRA5/2uK5jU53uLkRQqrPnoBwOf/1VsanPHBAXlIRAOijk/SqmkxFYvtIQJLIf3Ybk57Z+nWtG7K4RV2aWm2YRI7ZeUhbMr/8APWU9fwH+FbM2Yh9njYiSTDSMP4R2H+e9R2MKWNskmCwXhFPV2P8AieTVLVbtbS0dpX3uw3vjqfp/IVHQv4noZuv3xWWO2sjtuGXy4W7Qp/FIffrjNVfDNt5tqlxACkTsY7UHkhR/Gf1J9yKxtU+0NE8IXN7eMEkIPTP8A9gOPzr0DS7SK1towmPLhjESEd1HLGhFS0skRXx2RLaW/EmAoJ6c1yGqahG/im10eAZEcLSMQf8AVquADj1Zv0FdSsuHmvJPlEaFuexNeafDZzrGsa1rLElZZzEjH+5HwOfckn8KictVFdTooU04zqPp+bPSIYw8kcb/AMXLetahZmuEPXLMf0x/IfrVKE5mmZc7shB78f8A1qsb1ivZpCflgG0fhyT/AEqjC99Tn9bm829+yqcjzEBx3KkMf8+9aenL8qAnObneR75JNczpwefxAsjcx20UkpGfvSsMkn6f0rqdLj/1OMEb2kyf90f4mhahLTQ0rjm5K+gFc5rpd9PmUHbvKxsx6Abuv5V0OCbi4b0ZQK5nVW3W08OcCQxAH6Zz+opsmmTaNKHt5WAwqEFfUAHFa08Y+1WrjgFVH57l/wAKwtAyLW9DAZClFHqeCf51uXAzah+cpGxHvhgaAb3KuvWoukgjYZ8xmiLH+FiOD+dc74eJRivOOh3dVPof8a6jWN5s5TFgsoW4TPqhzgfhXPyD7P4pnaNhsnxMvowcZ4/lilbUu94l7U1DSO6nBEZJB+lR+E5yvi6wEhDboHQHPPQVZu1VmLIQrPGF2t0PPrWdocbReMtJOCFbzAQeo6VNTb+u4qev4/kesUUUUGQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU2WRYo3kc4RQWJ9AKAPC/GwOv8Axogtd3mW2nRqXB7bRuI/76IrrIDNFGPnKqMnLEYH51wngqQ6rq3iDXpwwN9ctHG3ooOT/wCyj8K6bUrmK2tnkuCCAOpOCa2gtLkN6JFO+Y6rqcVlbvvZ3BkfrtXNdhaQrLM7EYt4flUetc14RspEge9kQC6unwNvAVRwOPyFdtPH9khitYgDJgDr3Pf8OTUN8zuav3VYgvp1WLzJyQv3QO+O/wCJ6VzV5P8AaLozTkcHdtPTcBkfgFFX9WYS38cGR5VtHuYg9GPH5gfqa5nV5Va8tLb/AJ6yOWjXqEKfy5qKkuVXOjC0vaSs9t36I0NBtWv722uDk+WMZJ5Z3+Yt78ECux1Fwlu0SHHG3j9f6VleFoPKjDuMbFJIzn5j/wDWwMVevXxLhzjapdj6H1/nVpWRhKXPNyRy3jm/XTvDl1Hv8vch3kcnHQ49+a5z4PQCDwydqFBI+4AnOAeR/OofivI83hjUN527lRE9SzOq8fTdXT+DbIQaQiou0MSQPb7o/lWK96t6I9B2p4P/ABP8jqtNX94r4GMhsn17fyrN1ydjp8yR/wCsnKwgf7LHJ/Ej+daszi3siQBkllUf+Oj+tZGwzvCoyXZJJAO+4/Kn61qzhjqZdk//ABMbvYoWLySQR3JGCfzzXVaTHk2hPJMWfzwP6Vx2jRGXTzNL8wW3aJx06NwPyrsdFJW3tMnlLQkn6E4pQd0mViI8k5RfQlgOYXlyfnmyB7ZrmLuZHuVhRlLiXy8HkZy1dSF8uwtkPG7GfyzXKWmXvN7AMZZwgGOg53H9cfnVGcdCxpoQwiQM3l/8exU92x1/EdfwresU8yOKJv44mXn3GP6VgRZWz2xcqxDxk9yrDOfyNb9q2JkK/dUc/n0/WmiZdSnJIfsls7HLLlHH6GsHxCvl3VmxBzEDCW7HB4/SujuUEV5Mj8JuEhP+yev86z9Wt2uLaTIBkCE49WQ9PxFJ7lRd0Rb/ADrQ7/mITnPU+9ZmlS+T4t0YMTwGHzdvu1NbN5llmNjnbgHuPr/jVWOYN4l0pnCllRmJX6r1qK3wNmlFe9b1/I9jooBzgjpRQYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXL/EzU20nwRqk0R/0iSPyIQByzudoH611Fec/FS7WbV/Dmj5BDyvfSr6rEvy/+PMPyprcUtjl9KsE0bRbKyBUPHGN7E43MeW/HJqjeIbzVrazYArkTSAcjA6A/qfwrTu7tQGDSD5fmBK5IwORUvh6xeJpLy5UvMqAsCfvM33V/I1u9FYS1lc67QYEgW3BVRHCm9h/tEZA/AfzFPnmYebckgyyfJEPc/5/IU8L5UKQM2WwTIQO55b+g/KszWp/s0ay5OUUsIx3xwP1IH4VlsWtXcwfEWox2QvgpACkBmzyccZP4kms7w9CbmZtSu0JmnYx2y+in/7EL+dJPo0uuX1rZsHFvPcCWd89Y05f9Rgf71db5SPqbrCqrbWAEESjpvbrj6DArFe/O/RHoSkqFDkXxS38l2+Zr6dHsiVVGe5P48fmf5VmTzefLO+TsMhQn1VOv+FaV1MLOzLD720lR6nsf8+tY9xGYLIoBmRYlh/4G5y3862ZwROB+KzvLD4fsIyfMuXidl9d0+7n8FFekaPbLGqRqMKg/pmvMfG0n9pfErSbaJd0dpdpEfoin+rCvW7aLZA23G6Q7R+JxWNDWUpHoY9ezp0qXlf7yrfuWliyPljTcOep5x+tZFzdPZ39lMoBh+1RRH2AHGf1P41q3eC9y/bzQkffgDj+Vcl4muzHGYVwWE1rc+pwZCBTrS5Y3M8DS9pUSexd0ePyNO1tXyUjndFJ9N2RXU2gMWlq4xu+yqv/AH0ef51jXUYTR9VKgES3jKvuBgVvY/0KNR3CL/Pirpq0Uc+KnzVJS8x+osUltk7Kuf5f/XrmbdQIfO8xgRKwQ4yOuf64zW/rsm03bLnMcRxj1ArFYQxWlvGpIkMQ2q2TyRkk4qiVsPEUkVsIGX947NsI5BPJ49iOK09MkEsZJI3BFZvYjrWch4t4fMEjHcwJPRvr2+lW/Dh3X11G+MgbeO4NNbmctrk/iIhJbWYthJP3benzDj9aYf3iHPO+MSj2x8rD+tS+IIGm0B+m9FBH1B4/lVaxmWW2tZ1I2FyPqrjOPzoe44bHP+WsEk0SMfk6/wCfSqlqS+v2gblxDjOP8+lX9djFtfyFDgcpkfTINU9IHma3v2r8kePxxWVd2ps2ofGvn+R69ZOJLOBh3Qfyqes7QH36TB6qCp/CtGiLukYyVm0FFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFHegArwbxXrH2/4zyxB8xWdm9sg9GwC36mvdLmZbe3lmf7kaFz9AM18laBqMl343kvJGDPcvKxJ6ndnAprRoErtryZ6TbRf2hdrEQAHYAlR1A5NdtpUaFixH7m3dpWJ/iboB+GDWH4ZtRZafNf3Jwzq7x8dFXj8iQa1ZVaDRrWwVTvucBx3GetaydyUi1ZuZ0EzkgzksgPZc559z/hXOa9eC41GCGM5LzBV+UtuK9BgepBrortykbrCFJQBEx03dAPz/AJVyWmNB/b+p6lcTNFpejwlJJiON7YLEH12gD6tWc3ZWN6EbtyeyNHVLxNKhtrCCRBq2oloo3B4ihBy7/h82PViPStHTFdYoYccsDNt9M8KD9B/KuG0Ge48Ra7d6pMAkNwghgCFXRYgflQEZIwMk+55rvkwkM0yY5by48n09PzqKTUtVsbYqDptRl8XX1fQtSBX2lgSmcKP9kH+vFZuqSeTLCXzlN9yw+hwP1IrTcjzooACAF3MfQDt+JP6Vh+KG3f2jGkgLLZgKfTMi8/qKqo7JmeGhz1Eu5y/h6ykbWopZ/na5me4Y49XJA/JBXp6/JIg6+Wpk/HoP1NctpNqsfiyaJP8AV2MYi+jY5/Surg+aT5v42yT6Koz/ADIpUYcsLF46t7as5LYx9RxGsoGBsHPucHmuFjL6pJp5P7yR0t0P1Wc8H8q6DxfdSw6DqVxb8PwwJHo4A/rUXw8sopL1bmU7YbS2Wds9Ad7kZ+nJrCr701E78Lajh5Vn6f195t6iiJatEi7VW4c4I6kuOa1jlZbaMYxvBx9AKzGDSWNu7nLzSJn/AIESx/mK14Rm9jUkEDex/PArrR40n3M3xFlg8QI/eOqMfRepqnYv52oO33FTIXAycHp9BS+I7kfa4YSMhg8zn0A/ya5vRdZmvfFkdhACIzG8lxIvRSvAX6gEVLko7m8acpxduiua2r3S22pQSRNmNCBLF14PcVp6cqxeIJBFnyygcHPryK4++uheXuolnIezneA4bOdoB59jn9CK67Ryr3FvIp5NsF68cVSd3cynFxikzeuU87Tb6IYyN2MfgRXO6Rn7M8RxwB+GM108uEkuMY/eRK36Y/wrAjhEV46gYBUqf++v/rmhkw6lHxTCZLSWaMAbQsh9wB/+usXw226/u3x93H8hXV3UP2iJIuMyxtF7Zwa5Pw1Eyz3G8lTuZGHfjFc+J0idWE1k/Q9L8KSB7WZc9Hz+YrdrkvCMuy9liP8AEn6iutopO8TKvHlmwooorQyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAwvHdyLTwbrMxO0LauM/UY/rXyf4QjkufE2mxxnDGQAEd6+kPjfcfZ/h1qA3bfNaOM++WHH6V4X8H7VZfFb3MuBHYxNMfw7fypSWiLou0m/I91WyFwwsYRthhKxbif4F5P5mpC/na3PIi4FuCqE/wB4j/DJo0QvDp0lxOQZJiW49P8A65NRxsscLyE/IM4I7nuf6VrfQztqYviHUY9K0S6mXJliXaqjkyTPwFHuAfzauUt7sLcad4YjJaCzbzr6WE4828Y5YD1CZx74FUPG2u3DeJYrKwQA2ILO7DKpM38Z91HQev0rd+GukRfZ7i6ADSIRFGW5x3Zz6nJA+prjqT5p8qPXo0fZUfaS9V69PuOl03SIrPUr6dGikfasjyrCsTucHAbbgMffHetcQM15aWuQfJHmv9eg/X+VM0+MSyysQSJJRtyc4VevP/Af1q1YufM1C8bnaSF/4CMf+hGuqEVFJHmVakqknKX9dBbbDPcSEZVpNgPoF/xOaw7SOOTW7m7uGBsY4TNNu9FfcP0QVtTAW9pGpDLhCd6+vv8ArXI+KpJIPCMVihIu9VKwAj+4zf4bjUzV0a0ZcrVi94JZ7yzuNRk4l1CVpifZjn+VdXcDyNNmlPDeXge2TVHQ7dEso4o1AHEaAdMDj+n61o67u8lY14DNn8h0rTZHO/ekcF42dR4b1IR5JS2GPch1FTXzf2f4KjsIysV5qtxDYrltuVAG7n6Bh+NW9UszqGdNUYac4+oDrkfkDWL4ivLbVvizZ6Sn7yPS4TKqDpuBBdj7jKAfQ1yte838j1Yy/dQp+sn8juJ40WSxVRsQO0u30AHT9KsWq4ZSOixfjknNOddzyZAJjiCc+rHmlgb/AF5H8J2/p0rrR5Mtzj9elH9pXDnGI1EY9yTwP1rl/hPE9vqN5eXQ+aBZw5bucgk/pWh40kU292kblJmleQN7oAR/n3pumxfYPAN9e4zJcpcEcdd7hBXLJ3q+h6tOPJg33k7fd/TOT8L3skmtyfaVIS7ilkcNxubf5g/8davSvCzuVtw+d8LmFs9+uD+WK4TULQwX9jNEpyLho+nVPKCf0rudAIURuh+ZigznI9KeGbd0xZnGK5ZR7fkdezbreKTH8DJn6Y/wqpqEGyZpF6EN+g/+tVpRnTyp4Cuw/nTr4B4AevAb81roZ5kGZM0m0bkOdkok+gIBNcrpbBNZ1JcN8szEbu4OMGulJEkkMeeHhwfqAa5iMFdfuMn70SHGevFYYpe4deC/iW7o6zQpfK1SBjjBbBI9+K7qvMLWQpIjA8ggjNemxtvjVh0YA1lh3o0PGRtJMdRRRXQcYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkv7R1+sPhOyss/vLi5D7R/dUHP6kVwfwh09jZ3JYYa9lWI+0a/M358Ck+MGrv4q8apZWRLW9owtYyozufPzEevPH4V6B4N0qLStNuJY13LGTEmejFfvH86Td5KJVK6Upm3PcMYLhYBkxgRoB/e7fqR+VYfivVo9F0IyI6+aF2Qg/xHoD9OCfwq5BPs01mkJzJcGNW9cDLN+A3fpXlPxA1z+1NdaBOILfgD3xx+Qqa1TlWh1YSh7WeuxmWT4ik5y8rF5HY5LsTkk+9el+HbhrDQoUhimkIUGTaflDu3Q/Qc57V5fauu3AOAeODXrvhHF94btnyqjzmDL1bcD3/Q1w0/i03PXxz/d+R1lknkaeJVPONo+uKktYwmn2tufvSHex/wBkHcf1pLhcafHD0J+99WOB+mTSTyojyu7BYU/d5z0VeT+vH4V6rdj5tXZDrEhlgEcRAluGEEQzzzwTXKX041XxzILcbrLQoPKQg9Z3AGPwX+ZrJ8O6p9svvEnjC8eR7Gzb7Hp6NwJXCnkfTcfxPtXQeC9MFpp9rHMv+k3UxuLlu5bqf1OPwrGMudo7JQ9gnffb5vf7lp8zuNPgEEkEYAxEg/lUWoMZWTAJH3fzNWY3O6Zx1C449c//AF6z7yVrdZrlx+6jiZyR2AFbM5IbmZZ3aW0VxqtwFMVrFLMxPsW2ge5NcP8AC6wuZte1jW7zy5GuSAk46uMlmU+hDkjnnitrXDNZeF9I04ukV5ebZX3gH5Y/3m1gTyCzICPrW14WhaLRJZnt0t5rhtzwqcjceCQe+TzXOtZpdtT0UuTDyl/M0vktfzOhtfngkkP8RL49ugqta5l05HUHEpLD8/8A61Wpf3OnYXqxCj6CpI0+YIuMIMY/SulHmb6nkfiZGutZaOJSV+0p5meyyIePzFa2vEQ+GtI07B23F0iMo5wnmMxP06GrNpYx3mp3srblmn1WNCWbOFUNjA7cU2eVbv4kafaxkCKwgluNnYg/Jj8iTXK42cpdz1PaqoqVJbR1/Uj8f2C6VpcckKfPbwS7m65byyP5mpfDMgNnYtksW8ogMPUgH9RWt8RIw1hApJ2tlPc52is7SolWaLyuEQDleekn/wBetIRtN2OarUc6ST3uzsZQFt5FPALseaJMGOMY+9bqw/CprxFyy99gJ+pIqGLLeQDnIgVT/wB9GtWcqOetnJuYG7rIU49Oa569Aj8USKuMGAAj3ya24pdql/7szH8q5/xHJ5XiWzkAA+0xnbg9Qp/+vWWIX7tnThHatE0YpCJAVPy5r03R38zS7ZvWMV5ZbyK+TtKtnGD3r0rwu/maJbEdgR+tcmGerOvMI7M1aKKK7DzAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK434m+Kx4a0QralTqd0DHbqT9zjlz7D+ddZd3MNnazXNzIscESl3duigdTXzB4p12XxT4kuNSZX8onZboR92IdPz6/jSbtqVCDqPlRPoemT24hntld72cN5TY3MCerY7H+leqwRDz7fSoWLQ2MYM7A8MwGf1OT+Ncl4MtzZ3Wm31xdoYZFbykxh12KWOT3wOp+grctL65HgO/1koi3epymK3RDuBLt5aEfmW/4DWNDrN9TpqqyUEUNfvU03R7eXO+O2tJHJ7mSRic/jgfhXiyOzOzsRuJyR1ru/itfvb3D6TFvFpA6R+aejsiAYz7elecRznOckZPWs6j5mz0MH7kfU14GCng4AOetd74JvrkeVaRMR9tuYo4gB1672/BBXmiPuOc9OvavXfhpYrLqklyFATTbZLaNsfenlG52/BOPxrOnBuokbYyaVFtnpF5IolRwCQpZx36fKv61x3jnVLi1totK0tPO1K+P2WFM5yW6n6A5yfQGutupEj3ysRHHCMgt0BAOCfpkn8q8d1bWDqmo3tzBFJArj7NDI52uIOjbQPul+5PO3jua6cTUSXKebgKDnLmtsdDoWmJdWsUNmTLoWkxmCDst7cE/vLj6b8hT6DNd7pKf6Ygc5MMIDE9yeT/WsTwxNjSNMhxFGssbAKq4wF4UD6AVvWKlLKWXjfK20e46CnhXzJyM8Y/eSNAMRYlz1mkA+gqvf4khhtzx9ql+YeiLy36D9atTxH/RoASAoJJ9+n+Nc5rOtLaT6pcowBtkW2gJ6GWQZ4/3VGTXRJnJFPocB4v8AEM994yv0tbWxv7WyjWA29wMFzklyj9jk4x7V6ho6BdLsY0DBcBtjclMDOM+2QPwryDwjY2z61IZm3Eum7PXPXn8SPzr2qxAl27P4UA59Sf8A61c1B88pSPRxsuSEKK6ItXRHn2MPYAyMPYU0XPkOS5zsi8xs/nSFfOvruT+EbYE/PmsjX5GjhupI/vORCP8AZzxXVc86Ku7GX4Tt2ks/tZcjN6XCn12Dv+Neb+FvEhm+LmsSNxEroRnqYUOxgPwfd+Fd5FqL2vgOW5hP725eT7MvqZX8uMD8FJrzrxxpf/CKa34c1q2j+S2VLe8Hqp4fd+DGuSu3yq3qevlsIupJS6ppfqer/EtWi0yxZjnypXUNnr93BqPS4wkcG4FmIA6+rrj9am8V7LrwtY+Z8671jbH8WAcH8lFP0dMxWStkH5ScD0bP5cVvBa3PNqP3VHtc6W8IMshP95V/mf6VDHyWfHK26KfqCxp82fL3ZG6SY4/I/wCNQSOEW8lB+UKqn2KgmtGZRMCCMSWxI6FZHH1JP+Fc344j2674fYphyjgYPHUf411dnHsijDHO6OMfieT/ADrkviDLjxFoaMRtjkmQkfxfKD/Os8T/AAmb4PXER9RYX23GXJyeoI/WvUfB7btDi/2WYfrXlRdd3OSwOeegFeo+CG3aEuOgkYV5+DfvNHoZivdTN+iiivQPICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyL4/6+9tYWeiQMVN1++nx3RTwv4n+VeTaZGSylTgAgAdq6T48M5+IgUklRax7R6ferndMduMMo6H5uhNY1paaHp5fTumzrdQuUsrDP72K5+yiyt42U5HmNglTjHJIyevSuq8YKunTeHdJEot7PTUSeQBSQSo2r099xrHvr99ZvdAjmURx3V5Ex3EYj2tkqfxXj8K67XZF/trVLyZikUEsUfABaXC5MYz6k1lSajSbJqKTqxj1PGfijdC9m2Wsu+3Xc4Yrgl25dj7k/pivNNJu55XnjeMlIMbpewzwM16j4rtRIkjbdo5+UdBn39uleTzXYtRLaIOZpw8h9QOg/rV0EppplY7mw3JKLOnsimUaQjywct64HJ/SvojwBp503RbG3mXbO++9uf8ArrJzj/gKgD8K8Y+G+ijVfEFh9qQGzj3Xc27kGOPBwR6M20fnXt8V/wCRb6lqF1xEAo5ONzNzj8sD8TV0YpNzZGMqOaUF6/5HK/E7W2R4tMhJUkeZIM+vIB9QBj8a4aAnKlTxu6mo9RvpdR1K7upn3PJIWJ/GpLZWZ1iTlnICAdyTXFOXPJyPVw8FRpqJ6RpDFItKVwd6WrSAZ5yScD9a7jaIzbQjH7sBiPp/9euO0LdL4zFrkmOC3RT6DH/6q66N/MmMn8LPkf7o/wAiu3CK1O54eMd6nyIvEeqR6NYXF/P8+xRHHEv3pJDwFHqSTj8a8vlkbVNc0nRpp1ljnmdrl4zw/V7qXPphRCh9A5rX+I+oG51yCz3KYLBPM2jO6S6f7oHoFTkt23ADk1zPh+Nl1Wdiwe4NhcB5Pu4BCpgeigMcVNWr73KdOHw79m6j7f8ADf15mr4f0qSfTn1c3KWzXF012io38DPgAjH8QwMfSvVdMHkWnmYxhs/98r/iawre2toNIgyqghF2Ln32rxXRypst4YR1YHOPrVYXVXOfGSvLUdEPJtYx1Y5kb6muY8VzGHSJ5RksqMUA67n+SPjvySa6m65fb2VQKwdTiSW8s8Y2+Z55UnsgxH+G4lv+A10S7I5qbs7s4Lx9qp8OTeH7WC2e4s9MZJb0KucKF2jn16tWp4r03/hJ/DMhtmW4SeAzQSKMh/lLKfxGVI9a5zRvFH/FWXi6pbxyaRqsgEbOflGBtCt6AjkH1NdR4Qjm8J+Jb3wsebaRTf6SZDkYP3oc+n+Ncyam322PTadCMek1r69/uDwtejWPhdaS7t7pEm/J53LhSPrjFdHoC7rhvMU4hdgoz69DXH+EYI9MvdW0ONWFst4QisekUh81P03L/wABrudHj/0nbxw7N+Hat6fwo4cRbnduuv3mrPhVs4xwdzOQPTBrNmkLafegAh5ZNqj64X+tbN1sWF29MIrenb/GsnUCI4bc/wAXL49T1/wqzFFUKGnijU/K0pYH0Ve/04Fec+OmluPEOhSO4+d7iT68KM13T3IiimcH5vL8mP3J4J/Ek/lXB+KCJfFFlBHwtnanOexd+n5LWGKf7pnXgI/7RHyv+RZixuA9T3r1rwWmzQISOjMzfrXkcZxgjqefpXtOgQG20WyiPURAn6nn+tcWDWrZ2ZlLRI0KKKK9A8gKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPmv48Bz8RskYUWkeD68tXLaa21QT+leiftHWBTVdG1BQMSRvASOuQc/yNeaWUmOn/wCusK+56+WS92x6B4Zha7v9CZyCq6ojKO+c/wD1jW7r99HNKqmRWle8uZivPy8lVH5Csq0uDYf2JqEKSTWoKSJ5UZZlcDaUx7HJz2qxeXE8NjaxXToyyK8kK9Su5iee/wB44/A1y3tSt3ZrTTnik7HOa+UaykAPbNeUeE/D83ifxXIzArZQP5k0noueAPc4/LJr0TxnfLZ6XIqsTKw2DHcnrVrSdCutL8LWukWKhdS1Qqu7HO+Tqfoq/wBaqnOUYvl3ZeY041JxjLZanWeALVHsbnUEjRI9UuPIt8DGy0hJyfoWyfyqz8Qp2t/B9qEUgXE73TDPRBkJ/MGumttOt7aBrWzwtpbImmW2D0VQN5+pP8jXJfGB0XTNy5XZKlqo9gpYj8OK65rkp8q9DzKT9pWT8zy23cptA5FdL4RiW48QWUbD5RJvbOeijP8ASuVjPHBzXY+BE8ptSvn/AOWMGxc9mY8/oK4pqyPXlK8WeieA7Znv9a1RySWPkx/gMn9SK3JLgWdpNdON4gj4XP3iBnH4nFQeEBHB4OgmJwJw0pJHqf8AACsDx3fm20GK3U4luMlsnBx1P869CP7qin5HhtOtiLd2cK9xJPPLPO2ZZnaRyPVjk89+abHIY9XtyGB82GaI/iAf/ZarKx2qOg/rSorvqOlIvLSXkcQx/tHBP5Zryk9bs+kcFyOJ6VcTvL4k06yUYXzC2B/dUcD8zXdTFW1GNB92JNzVyegWovPF7zuMi3V3zjpzgc10Jl3Jcz8BpWEa+w/zmvSwkbU79z5vFyvOy6CTzZALHb5hLtz0WuD8V6vJHpN3cxu3n6lJ9itFz92MD53HphM/i1dJe3UK295cXEojtVjJkcnAVAOP6mvKNY1g63qH2sJ5VtCghtIT/BF1yf8AabqfwFFepyR03ZrgsP7Wor/Ct/8AIhkigktjbSKGhKhSuOQvb8uK6yzvX1HQNMvm51Lw9KEkcnJeAnbu/D5T+NceCxbG3tnitzwZLt1+W2PMF1auJFzjeowH/wDHW4/3a48NO07dz1cdS5qXP1Wv+Z3V1Yr/AMJeusWrKYbqw8mVR2kR8ofyZhXSaMoWdmP8K5J/z+Fcj4dmjuNEtzEW8x3Ftn1EZIB/Kur0oloJTj/WMIwPavTR8/Jvr6Fu7Ym0hDdXy5HpngVm6xukuEhj6hVj/En/AOtV6R/NvEx0Z2/75Uf41kyy+ZLM3QZJz6buB+Shj+NDCJnM0RuccLAh3tu6BFyc/pn8a86sLiTU9Q1DV3wFvZcw57QqNqfngn8a6PxNfg2FzYrGwkvlaIYP+qh43En3GFH41gwNsjVY1VEUBUVemBwBiuDGT5moI9fLqPLF1X10RvaBZnUNUtbUZYu/zey9Sfyr21VCqFXgAYFee/CzTSftGpSgf88Y+Ondj/IfnXoda4eHLH1OLG1OepbsFFFFbnIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnfxz0dtT8FtPEm6WykE3TovQ/zr55tGzjjPtX2NcwR3MEkE6B4pFKMp7g9a8I8S/CPVrbUJH8PiK6tGJZVeQI6D+6c9frUVI8y0OrB11Rm+bZnOaDrmoabFPFbTbYphhgRnHuPQ+4pbvUI4RLc3c+MDksa04/h54jhtprnUVs9Ns4YzJLNNMG2gDJ4X/wCtXljJda3cgzOTAp+VO341xyotas92jiac5Wp6yNO1Sfxd4lhihHlxu4jhRjwM9WP4V7F4YiZLk6zcTxzSmU6fpjFdoZRw02PwIHrj3rk/AuhBLoSurRw267jIOPmIwoz6kmut0yz83XktbqQvY6bH500g6EgZwMdMDA+pqqNnL8jkzDS6+/8AyOxsIlivrS1ccWkDXMgPZnJCA++Nx/GvHfi/qqm9sNNL5lUSXcwHZnOAD9FFej+G9Xm1a2uLm9hSGW8klc7cgeUvyIT6dT+AzXzt8ThEPFLNYXX+iwv5SXCkncgOSx9e/wBa6ZWm1E82HNSTqNbFuB8jAyT15PavQtItjbeBlCDFxqM4wO5B+Vf0BP415d4aD6vc21taBi9w4RDjk5OK94FtBL428N6PCCbe0D3UoUcAIoVSfUZwPrXNUheSgdsaylHnXqdrdRLZ6bFZpwsFuiHjuRj+Wa8t+JFyZdbit8gLbwBjk92OeK9Wuh9oWaYn5ZJzt9wvH9DXiPjC4SbxNfzkNhWVfbpXTin7ljkwC/e3ZQjkAAY4AJ5HNbXhSMT+JdO3fdgZ7o+wRSR+pFc9GSW3bjgDqvauq8CQbptRumLARxJaqRz8ztuYj/gIA/GvOtqe3Umo03c9O8MoYdPvrggh5HEQ59ssfzP6VJesEtrdB8ofcRx0Hf8ATj8alhh+z6ZBbpkBEPHqWOOf1rI8T6gllDPclv3dtGUB9NvX82IFeukoRsfNa1J37nCfETUJLq4TS0fFtCfNuAD/AKyTsp/2V9O5+lcqgLCPc3zcu31NSF2nnLzthmJc+uTzTWkUMQRlj0/pXlTk6knJn0VKCowUI/0yZXwWBwfTB6VoaPBcGYXFuGAy1uXHGAy5b9MCsreB1xnHOa7vw7aN9hsIJP4iZXGOgPP8hUap+7uXWmlB3N7SbRbK3ijH3kRnPoHfnj6Cuj09vKtQe6jj3Y/5FZES5jlkf70rZ+gJwP0BrYVNiwxEEhf1Y17UFZHzFR3ZHO6weac4EcIj/Pk1jpMW0syhcvJuOO3p+WAB+NS6xK32K4AwHmkKLWL4gvBZaSYlJDInlj/ePb+tRKSV2zSnByaiupyWrXAmvWAYMkYCAg9fX9SaZHEzbUxkufujrVWJflUg59jXYeAdOOq69A0oBigHnPgcZB4H515kV7SXqe7VmqFOy2R6p4asP7N0KztSAHRAX/3jya06KK9FKx8+3d3YUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeS/tFaq9t4XtdNjYgX0v7wA4yi4OD7Zx+VeNaJGNsSL99jjHqT0ArvP2kpS3iHSIT91bctg9yWP+FcJ4WlEWo202cCJ9/PtzisMQ9LHr5VZKUz1COc6Np8VpcwPcIJC++Lg+YR0wfvbR06Vf0aOOTwrK9sjLLrE/2a2ByCUB5c9/7xP4VD4iBuoLeyQE3c7hIgByAwzk/Rckn2rTlgM94yafjytMiFjb4k2AFQDKxbse2faoo6R5jHENzlbvqZ/jkLZWcNraIEEyCIbTg+Ug4/NiT+FfPPxMi8owxx8b2r2nVGF3qTyF3ZSThmYsWx3yfpXlPxCtxLrtrAOiKXIPvUUZWnc7MTQvheXq7fidN8CdLT57lyDMhEUY/uk87vyr1Lwkyf2n4i12RxIQU021z32jfIB+JH5V5r4Skm8PaDe3rQMYpI9qvH/DIOmfqOMdq9DnWTSPBf8AZJVlvI9NluriRQB5c0nzMGz3w2BWsFebmcEo8kPZ/I6cXccmhWlxCG8k2hlQMMHLnA4/OvGvFds1t4jv4Sx2iUnIOeODXp8jG21OG1jHl2lpp8MJjByBtXcc/TIrzPxlcJP4luHQ5xtBPoccj8KmtLmdjTCLklcyY9iKRLnGOCvWvT/Bmlm3s7K2kALs/nyD/bbkD8BiuA8PWIv9URGH7mIebLx1Uc/zwK9h0GFo0aVv9Zt3ZP8Aef8A+t/Koow56i8tTXG1uWFu5r3MohhMo+b58Rj1IHH615n8Rr5YorfTkcF3IkmzycDO38yS35V6BcuHEQYkRIGO704yx/BR+ZrwvW786nrV3d5wJJCV9lHA/SurEytGy6nJgIXnzPoQbn2kE7s8cmhm/vMSuOtRFtqFd2T7Co2Khj0YH8q4OU9bn1NHTYmvL6C3OAHYA47L3J/AV6rpGZ4WlVdqsfLjA6gd/wCn5VwHha1eG0F9IdrXIZIeOiAjcfxPFel6aqx2sKRcbUz/AMCI4/IZNXRipVPQ5MZUvGyNGwVZJgmMqpyR7KKvNIUM0j9IlLE+56f1qj4cG6Nm7MQCfbqf6Veu1UW0MIBBuJC7D0Qf/Wr072R4z1djHmiaW/hiJwkSqSf9puufz/SuL8YXSyXEdrHwq5cgf7R4z+GK7mQ8Sy/xyZk575B/oa8pu7j7ZeXE7EkSN364HSuStPSx6WChefM+g6BMcAgZ7+1e0/DrSTpuhLLIMTXP7w+y/wAI/r+NeX+ENJbVtZt4OCpYM5x0Qdf8K95VQqhVAAHAA7VOHhb3hY6tzPkQtFFFdJwBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgH7TFu41XRbnafLMLx7u2Q2cfrXC+A9j+ILFZQDGZAGB6Eele7/G/QJNb8FySW6b57JvPA77cfNj+f4V836RcS21xFLCxSaJgysByCKxrq8bno5dP4oHs2l6iltc61qk7k3MEjWlsjk8E8uwP4BeOgHvVMzPDBb2kjuyxRgkdjI3zsxHflv0qofFlhfWltLfWjyX8LBgo+6xAwNx9Pp2qhLfy3lw1xMU3ueiDCr7AdhXJUneKilselg8M1VdSoaxAOW+XrnJ715peD+1PE9xMo3xiQIvuB1x+tdPr+tC0szbwNm6mGAP7o7ms/wtpbvPEjZ5YZ4z9f0yaiMrK531o8yu+h22nWseoX+haQ0bCytx/aF7kdY0G8D3y2BW5audS8O3GpXZKy61dpGAeymQAL+QFZNndme11ie3jdbvUpEs7fAyUt0+UN7bmJx9K1PEh+xahoOk2Ss6WEf2uXA4cqCka+xLbm/Cu2jHkp3Z83WblU5Ucr8SdcvbXVtRubObFg8zQSbFzll45/z1rzy1vln/AHiyBlYc85NdT4tu1bSodOjAeGFTLLKf+WkrElm+mTj8K8y+HFt/afjGC1bItri4VZAP7oOT+gpRippyCdR0JRj0Z774H0WSLSYJ5Y2Q3rB2zxiMfdH48mu+nYW9rFvGC2ZD+PA/T+dQ2arPKgicNHIdibeiqOuPYAGl1LM8zgfdMywqO2Nw4/kK2oQ5E33OavUdSSMfx5fNpXhK6cMElnRYF9d0hLN+gArxBXA5yAMevOa9S+Ml8C0Fqv3YpC7A/wB4rwPwGPzrz3w0NPa9vr3WUQ6Tpdsbq4TP+sboifiaxqfvJ2XQ7MPJUaPM+pz2qa3aWCj7RMAzDp3qz4MmtvFGqtDFI4ggXfOcEYT0/GvLtdv59c1q6v5VVXuJC+xRhUHZQPQCvXfg3ax2GgXMkm0TXDgk/wAW0f5FXUpKnDzOSnj6lapZL3Tv1s7i6vopQMQKVjEKrgRxr2/r+Ndomfsu5uGlBJ9s8Y/T9Kg0uOOLT4nI/wBYu76gf/X/AJVcsHj1CW1hXbHLJhzGTyqn/wCsP1qaVFU+urLqVXPpojc0y18rT0XbhpPl/A8n9ABUN/NunvZFHyQILdP97+L9TitDVbpNOtXuDgrAvyj+854VfxOK5e8W9gNrApFwrZmlC4GZMZxn/eOf+A1tVqcqMaUHJ3KXi+8ezsY4oiRPIhYnpgE4OPwGK4CFFXaWxyeM11Pi9xMRJuKsY/LDdyA2AfbgHiues7Yy3KIvOW2j6muHm5m2erSXJTPUfhZpnk2E1/KgDynZGe+0dfzP8q7uqul2a2GnW9qg4iQL+PerVd0VZWPJlLmbkwooopkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACModSrAFSMEHkEV89fEz4b3mjX02paHbvPpjsXMcSlmg9eOpX37V9DUUNXVmOMpQfNF6nx3Ddoo5YDHHJqTUdd+xjyI42NyQCFYYx719P+Jl0PRtMvda1DT7Nvs8ZkZzCu5iOgyR1JwK+U7q7n13XrzV9RKm4upDKQOi+gH0GBXNOikrnr4XGVKsuSxd0Kwnvbrzrr95cSkHnivVNI0RbGx3s6NPIxjOOdgH3sHuegrh/D1rcXV7DFZhDICCPMJA6iuz1jW3tjJBJYz2t23yhfvJuY8FWHBGTXMoczsd+Lr8qUIs1fCVkkV1dXRGyytSVH93djLt+AH6Vh6jqMlx58v8Aq5LwiSXnBVAMRR/goBP1rp9UtDZaNp+hQH55YxLdOD0jJ5B92bj6A1w+pXC3eqXMgwIWlYrtHGOnFb12oJU0cGApOvUlVkji/HV0LbR7pgRvYbQR3JqD4F6JHe3F02WS7VR5Uy9Iv7xI756VV+JbiSe2tFzl/mIHoK6D4eRT2Gi6jPYsRM8awjb1yzBcD361PPanZdRV6PNWcn0PZvBreTon2+VgyxI0UeM4JBOSB26KPxNbL2+2bRrY/wCsaXzZD/uqWP6kVn2tlHaafpGjxusm0KZTngn7zfqP0pNd1iOzk1e8kYFbS1aKNM8mRsE/qYxXcnyx1PLa55+6eRfEjWRqVzO1vEfJFxNIHbgn5gowOwwn6147rWtPc2Umj2mQJ7jzrkj+LaMIv0HJruvFV4LSxYyMG2LgnPU1w3hvTWnmNxIpLuS/TpXPRlZOTOzFUJScaUTc8BeFrW/1eCLUAzWw+eXa+z5QMnn6V6dY+HLJ7wS6FLPZoowA3zrt/HkGuZ8NQiK9aMDhgBnOOvBzntg13umk2jlW+XB5U9T71jPENT1K+qRgrIstDqb2cNt50ZKj78q7cgE4BA46eldR8OVmubS48QXah2uXMNkEXnywQpYZ7MRx7VzN9KdUkj0rT3Jur0/Z969EQ8Oc+oGa9OLWXh/RvNIEdhp8GI1A/hRcD8f6mt6Dc/eZz10oLlW7MPxRqsC69Bp5dSlignlXPLSvwgA74GT+IphvojcLsPmEcKV6Aj/JrnDYQ6jbibVHaPVpJPtbSRNiWF25UD2AAGOnFO05Lmzu4IrxCueky/6uVvr/AAsf7p/Chy5hcnJoSeK7VVuFUgZmjMu7ueQMfh/WovCdgj65YpLhlMgI9sc/0qre6g2qakZUy8UIMEfPDnPzMD3Hb6itDwjvPiWxCnIDknn2Nc6aU7LudevsXc9foooruPMCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA83/aAZl+HNwVzjz4w3uM1832cuAO1fWPxL0iTXfAus2EClp5IC0ajqWX5gPxxivkC0kZeGGGHGCORUVdYnZgJqFRno/wAP79k1+CJIzK0wMe0fw5H3h7jFen6PDFe+IovtmPK06P7RKM5BfHB/AZP415B8PtkutbJGUb0KhWbG/wD2fx/xrudJe6ijlshA0FvIWa7m42eWDllVvUqAMHpmuaikpuTeiOzMG5PlitWJreqCSe7uyHgnvHysW88RAfLkdACDx9Sa5uB1DlmICr3z0plzeSXl3LKwG6Rt3A4A7D8BisLxHqAS2+xWzfv5hhyOy1hK85czPWoQhh6PKjEv3Oq61NcgEx7tid+PWvZdH8Py6f4ST7CB9qeNZg3Hyu2Qp/Ac5rgPBGhSanqFvZwhQ2dxLdAB1Jr1qebULC0jSJRcWaH+6EkjQcD2YDk464rWmuZ+hw418iUer1Zc0KCTTofNumy1jbkud27qM9fXav5tXD63cy3GkFp8faJbktOAc7SPmI/76P8A47XfXFxbnw9am52wR6jIskoPJEKjec49Qq/nXN+O7mwuNOtI9PCSYLGSeNcKx789zz+FdGIdopHn4Bc9W9jwTx3KZrm2tFJIkfLD2FXtFt2UqEU54/KqWtx+b4nwPm8lOD9a3dPUqVPGCOmO9Yc1oo9WlSvUlL5F7TMi6YqCSRhcDOSeBXe2rJJdTW0ZeUNtYMwy3IArI8IWIa5+2yJ8sOWAx/F0X+ZP4V0Ol6dLJfrZwArLON0zD/llF0OP9o9B+faudxdSaSMsTOMG79De8BaRDa3d3qpBZBuigYnJIzhm/FuB9Cas+Kr/APtHVrbR1I8i3AubvHQhTwp+rY/75NdFfS2+iaO8+EitbGMsQOg2jAH0HArgNBDnzrq5H+mXredNu58pf4E9yAc+xJzXfWao01FHkUU69RzfQsGbztRuGXcHYhcFRj1IDDr9O1bVoLaWJ7aULIkw8sp/fPf8qw4mSO4knn2RRsCS00gRVUdNo6n8BWRq/iPzI5rXTkPlyJ5ZnaMphT97ZnnJ6fTmuGnUcTtlS9o7ISRkjvpoo5FcK5RWUjDAeldT4BgMniQP1EcbO3Hrx/WuEto+VcDp0H90e1ep/DK0YW13fPnEjCOM+y9f1NaUVzTJxT5IWO3ooor0DywooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvnb4zfDa6sdSufEGhQGawnbzLiCNfmhbuwA/hPX2r6JpCMjB5Bo8mNNxd0fFNg5UqwYhhzkHBH41051S8vIwlzcuydwT976gV7zrvww8Mavcm4aya1nbq9q/lgn3Xp+lVNM+EvhyznWSb7Xd7TkJNL8n4gYzWMqCb0O+nj2l7y1PLfCOkS65fYTcmn24Mt3cngRIASRnoScdK4S3AvtUnu9mFkdmUei54H5V9H/F+WLRPhre29hDHBHOUtlWJQoUMeeB7A1876adiDaB+NTOmoxsjpweIlWq809kdz4AglF1cMmEHllTJnG3PAx/ntXaRNLd28Om+aC164jMozuCdZGHodoP5iuc0NfseiTCKF2QJulmHOWIwEUf3ucc9BXT6Q72qPeSxiO78oQrCTnyyeT+O0Z+hHrWOHTlU02Q8xrqSbW+yL899A/jFtxQWmnwEKMfKm7HJ99oAArltduTdyNsBECsSuRz9TTFnMdhcXExzcahO0hBGPl9cfgBWddzhQ7ZBUKfbjrRWm5yZvgKCp01N7s8slQyeJb+TsX2j8K6zw7pU2pzrDAoJA3MWOMKO+a5HT38y5mkIOXkJ/WvXPh1FjTN4ZVEkn71h1+UfKPzOfwqZto09ryQckXClvpU8MaMZdigJEDwz9Dn6V1/h+3msoZ7mUeZdtjBAwGlPb6IDXL2Vqw8SRoXV2EeVV5ATuzk5/u8H9M9q6PVtWisp7W3t5FZ/KMyA8A5OAf/Qm+mK6cJBRi5vqeLjKjnNRRnePp3u7q00C2mHlKi3N0xPHlqflDf7zc/hWRPrcdtbSQWSEhiQ87feb1I9Pr+XrUOrNK9vfajODm9mG19v3lHCqPYADH1Nc/I5+Xpk8nnvXLXk6k2+h6GDoxjTXMLcSNK7N/ETksTkmmRISwO0u3TOcn8KCdrdd2OOKfFzglioB+X61HKdU6iSsjR022mmuktYlYzyMFVfc17xpFkmm6Zb2kfSJAM+p7n864f4X6CVj/ti6XBYFbZT2HQv+PQe1eiV3UYcqueFiavtJBRRRWxzhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwHxxspLv4eXjQrk28kc5A/ug4P86+bLOf5gVPWvsy7t4ru1lt7hBJDKpR1PQgjBFfLnxD8B3/g7UZJoo3n0WR8xTgZ8vP8AC3ofepnHmib4at7Kfkzf8P8AiSVdNhtVjiby2Xfu43Lnvn27iuhUvDDMpuY0t3/evcTNwMnLBR6n5efYV5BZ3bIVdGw2OCDWl9ulnUea5KA5I7VypSg7xZ6cqdOtudFe6iLi6AhytvGoSJfRRVDX74Wmkzkn53G1Qe5NVrZ2LKqjc7MAqLyST6Cu58RfC+7u/A/2whv7aj/ffZx02Y+5/vY5/SnSpcz1Hi8WqUOWO54tYfLyD+lek+ArlWjliYgRIVkYMe4zzjuOa8yhLRysrjBBwR0wa2NP1CazmSSFyhHdetXWo3OOjieaNmer6wLZ0S5W7jhuIvmMhOEPHVvXrVkGCVk8qOS8kbbukxkkgdfZec4rg4/E4fHn2oZf4kzwatXHja6WPy9Lt0sQRgup3SH8SOPwrC1S3L0NOVN3Og8bT2llFDbpLuvyoWSPP+rUDgt23H+QrkDcYIwfpWX5ss8zPKxd2OWdjySamjI34J59T2o5LI6oSUY2NOKQkkfjgmuv8C+Fp/EN0JZVMenRn95If4/9lf8AHtSeBPAl5rckd5qCNa6Yecnh5vYDsPf8q9ws7WCyto7e0iWKCMbURRgAVvTpdWcGJxPN7sB8MSQRJFEoSNAFVR0AFPooroOEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApk0Uc8TRTIskbDDI4yCPcU+igDz/WvhL4X1GRpYLaSwmbktbPhc+u08Vl2/wZ02Nv3mq3rp/dwor1SijfcE2tmc74d8GaH4fYSWFmPPH/AC2lO9/zPT8K6KiigDzzxt8K9H8Ryvd2pbTtRbkyxLlHP+0v9RivHfEHw78SaDI/mae13bD/AJeLMGQY91+8Pyr6looeu4orl+E+MDlGIkWRMcYZSpz+NWoVkmISKGWRz0CRkk19gS28EpzLDG5/2lBp0cUcf+rRV/3RipcUzaNaSPmvw74D8Q6wy+XYNawHrNdDYPy6n8BXrfhT4aaToxjnvv8AiYXq4O6UYRT7L/jmu8ooUUiZVJT0bADHSiiiqICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The regional anatomy of the plantar (sole) aspect of the foot is illustrated above. The plantar and medial views of the foot show the origin of the plantar fascia (at the calcaneus) and its insertion onto the plantar aspect of the toes. Also illustrated are the locations of adjacent innervation and the windlass mechanism, or bowstring effect, of the plantar fascia that serves to raise the arch of the foot as the toes are extended during the push-off phase of walking.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clay JH, Pounds DM. Basic Clinical Massage Therapy: Integrating Anatomy and Treatment, 2nd ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19573=[""].join("\n");
var outline_f19_7_19573=null;
var title_f19_7_19574="Principles of teratology";
var content_f19_7_19574=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of teratology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/7/19574/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/7/19574/contributors\">",
"     William Hogge, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/7/19574/contributors\">",
"     Tracy Prosen, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/7/19574/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/7/19574/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/7/19574/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/7/19574/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/7/19574/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teratology refers to the study of malformations, usually in regard to the deleterious effects of environmental agents or external exposures on the developing embryo. Congenital malformations are common: 2 to 3 percent of all liveborn infants and even more stillborn and aborted fetuses have structural anomalies.",
"   </p>",
"   <p>",
"    Congenital anomalies may be divided into malformations, deformations, and disruptions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malformations are alterations in normal development that occur as a result of an intrinsic abnormality in the developmental process.",
"     </li>",
"     <li>",
"      Deformations result from an abnormal mechanical force on an otherwise normal fetus (eg, clubbed foot in the setting of oligohydramnios).",
"     </li>",
"     <li>",
"      Disruptions are due to the disruption of an otherwise normal developmental process (eg, gastroschisis, which is thought to result from a vascular disruption in the fetal anterior abdominal wall).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most discussions of teratogens usually center on drug exposures; however, a broader approach would include any factor that may alter normal intrauterine development of fetal growth, anatomic structures, or",
"    <span class=\"nowrap\">",
"     cognitive/behavioral",
"    </span>",
"    or physical function. This definition encompasses environmental exposures, maternal medical disorders, infectious agents, and genetic conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF MALFORMATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three major etiologies of malformations and their frequencies are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genetic (ie, single gene and chromosomal abnormalities) (20 to 25 percent)",
"     </li>",
"     <li>",
"      Environmental factors (10 percent)",
"     </li>",
"     <li>",
"      Unknown (65 to 75 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The unknown category is likely largely made up of malformations that result from genetic conditions that have not yet been identified, combinations of genetic factors, or a combination of genetic and environmental factors. More of these factors may be identified as additional information accrues about the human genome, thus shifting the categorization of malformations from the unknown to a genetic etiology.",
"   </p>",
"   <p>",
"    It may be possible to categorize potential mechanisms of teratogenesis by looking at common mechanisms that might lead to malformations. The potential pathways include: folate antagonism, neural crest disruption, endocrine disruption, oxidative stress, vascular disruption, and specific receptor- or enzyme-mediated teratogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIRECT GENETIC CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors may be inherited or can represent new mutations. Heritable genetic conditions may follow autosomal dominant, autosomal recessive, X-linked, and non-Mendelian forms of inheritance, such as mitochondrial inheritance. Karyotypic abnormalities are the most readily apparent genetic conditions that may be considered teratogenic. The abnormal presence or the absence of large pieces of genetic material, and consequently the abnormal presence or absence of multiple genes, nearly always results in structural malformations or neurodevelopmental problems. Karyotypic abnormalities may be the result of nondisjunction events, translocations (both inherited and de-novo) that are either balanced or unbalanced, and other inherited or de-novo structural chromosomal abnormalities. Each of these genetic defects is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link\">",
"     \"Genetic and environmental causes of birth defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENETIC SUSCEPTIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic makeup of the fetus determines its relative resistance or susceptibility to teratogenic agents. The degree of genetic susceptibility is separate from any specific genetic conditions that are known direct causes of birth defects. As an example, fetuses with defects in folate metabolism (eg, methylenetetrahydrofolate reductase (MTHFR) gene mutations) appear to be at increased risk for structural malformations such as neural tube defects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/2\">",
"     2",
"    </a>",
"    ], cleft lip and palate, and cardiac malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/3\">",
"     3",
"    </a>",
"    ]. The risk of these malformations may be decreased by maternal supplementation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    in the preconceptional period and in early pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Therefore, a malformation such as an open neural tube defect may result from genetic susceptibility related to a combination of factors consisting of the presence of a fetal MTHFR gene defect and a state of inadequate maternal folate intake. This is probably an extreme oversimplification as there are probably many, as yet unidentified, genes and environmental exposures or conditions that also contribute to developmental defects in the neural tube. Another example is that some fetuses have low or deficient epoxide hydrolase activity that results in increased levels of teratogenic oxidative metabolites when they are exposed to antiepileptic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetic makeup of the mother and her state of health also play a role in teratogenesis. The production of a malformation is dependent upon the ability of a woman to absorb and metabolize a teratogen. Maternal medical disease states can act as teratogens. As an example, hyperglycemia related to maternal diabetes mellitus and high phenylalanine levels due to maternal phenylketonuria are associated with a higher risk of birth defects in offspring due to impaired maternal metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link&amp;anchor=H22#H22\">",
"     \"Genetic and environmental causes of birth defects\", section on 'Maternal illness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, sometimes it is difficult to distinguish whether a malformation is related to the maternal disease state or its treatment. As an example: does maternal hypertension or antihypertensive therapy cause fetal growth restriction? (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental factors associated with birth defects include drugs, maternal conditions or disease states, physical agents and chemicals, and infections. The potential teratogenic effects of environmental agents is altered by several factors including the developmental stage of the fetus at the time of exposure, the amount of exposure, drug-drug interactions, and species specificity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link&amp;anchor=H21#H21\">",
"     \"Genetic and environmental causes of birth defects\", section on 'Teratogens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Developmental stage at time of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The susceptibility of a fetus to teratogenic influences is dependent upon the developmental stage at which the exposure occurs (",
"    <a class=\"graphic graphic_figure graphicRef56642 \" href=\"UTD.htm?22/46/23272\">",
"     figure 1",
"    </a>",
"    ). Exposure to teratogens in early embryogenesis usually results in either embryo-lethality (ie, spontaneous abortion) or no adverse effect. This is referred to as the \"all or none\" period, and in humans it is approximately the first two weeks after conception or a menstrual age of up to four weeks. An insult during this period either causes pregnancy loss due to severe cellular insult and developmental damage or is associated with normal development because the surviving undifferentiated embryonic cells can replace the cells destroyed or damaged by the teratogen.",
"   </p>",
"   <p>",
"    Fetal tissues begin to differentiate during the period of organogenesis (menstrual weeks 5 to 10) and are susceptible to the effects of teratogens. The organ systems that are developing at the time of teratogen exposure are most susceptible to the effects of the teratogen (",
"    <a class=\"graphic graphic_figure graphicRef65816 \" href=\"UTD.htm?32/30/33261\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/7\">",
"     7",
"    </a>",
"    ]. Limb defects have a relatively short period (developmental days 24 to 33) of susceptibility to teratogenic agents, while the fetus is susceptible to microcephaly due to radiation exposure over a period of weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cell growth and differentiation characterize the remainder of pregnancy. Exposure to teratogenic agents at this time may decrease the cell population by cell death, retard cell growth, or inhibit differentiation. As an example, repeated exposure to antenatal corticosteroids in the third trimester may decrease birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/9\">",
"     9",
"    </a>",
"    ] and a single exposure accelerates morphologic development of the type I and type II pneumocytes observed histologically as flattening of pulmonary epithelial cells, thinning of alveolar septa, and increased cytodifferentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dose and duration of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose and duration of the embryo's exposure to a teratogen are also important. Most drugs exhibit threshold effects: there is a dose below which the incidence of embryonic death, malformation, growth restriction, or functional impairment is not greater than for unexposed controls. Such thresholds are usually one to three orders of magnitude below the teratogenic dose of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When no human data are available, a dose teratogenic in animals that is less than 10-fold higher than the maximum human therapeutic dose suggests a high risk that the drug may be teratogenic in humans. A 100-fold difference between the animal teratogenic dose and the maximal human dose indicates a low risk of potential human teratogenicity.",
"   </p>",
"   <p>",
"    One teratogen may be more harmful in a single large dose than in the same dose spread over several days, while another teratogen may be more harmful when an exposure is prolonged at a lower dose than if the same dose were given all at once. As an example, binge drinking of seven alcoholic beverages may be more harmful to the fetus than daily intake of only one drink for a week. Conversely, an occasional very high maternal blood glucose in an otherwise well-controlled diabetic mother is probably less harmful than a persistently moderately elevated blood glucose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=see_link\">",
"     \"Alcohol intake and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug-drug interactions can also be important. Two drugs administered together may have synergistic effects, the drugs may act completely independently, or one drug may protect against the teratogenic effects of the other. As an example, the vitamin",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    may protect against the increased risk of open neural tube defects when taken by women who are taking antiepileptic drugs, such as valproic acid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/12\">",
"     12",
"    </a>",
"    ]. However, valproic acid should not be used in pregnancy, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=see_link\">",
"     \"Management of epilepsy and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Species specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teratogenic agents may have different effects in different species. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    is not teratogenic in rabbits, but has devastating effects in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, many drugs produce malformations in animals when given at 10 to 1000 times the normal dose administered to humans; extrapolating teratogenic risk in such cases is problematic. As an example, high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"     meclizine",
"    </a>",
"    given to mice cause cleft palate due to appetite suppression; force feeding the mice prevents the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolite of a drug may be more harmful than the drug itself, pregnancy may alter drug distribution and metabolism, and fat soluble substances (eg, etretinate) can have very long half-lives and thus may cause fetal malformation beyond the time of last ingestion of the drug.",
"   </p>",
"   <p>",
"    Fetal physiologic development may affect the drug kinetics and susceptibility to teratogens at various stages of gestation. Placental transport is also a factor. Most",
"    <span class=\"nowrap\">",
"     drugs/chemicals",
"    </span>",
"    cross the placenta and enter the fetal circulation, although the degree of placental transport can vary across pregnancy and depends upon placental blood flow, placental drug metabolism, and the pH gradient between maternal and fetal tissues. Compounds that readily cross the placenta have low molecular weight (less than 1000 daltons) and are lipid soluble, nonpolar, and nonprotein-bound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41256?source=see_link&amp;anchor=H15#H15\">",
"     \"Placental development and physiology\", section on 'Placental transfer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SCOPE OF THE PROBLEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women take an average of four drugs, excluding nutritional supplements, during pregnancy and 40 percent of these drugs are taken in the first trimester, when the risk of teratogenesis is highest [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/16\">",
"     16",
"    </a>",
"    ]. Approximately 60 percent of all pregnant women take a prescription medication sometime during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/17\">",
"     17",
"    </a>",
"    ]. A study of a rural US population revealed that 97 percent of the women took an over-the-counter medication, and 60 percent used herbal medications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who have a child with a birth defect may have more incentive to remember prenatal drug exposure than those who bear offspring without congenital anomalies, thereby confounding epidemiologic survey data. This recall bias is compounded by multiple study design biases, including sample size, indication bias, retrospective design, bias against the null hypothesis, and citation bias [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/19\">",
"     19",
"    </a>",
"    ]. Therefore, proving a particular drug caused a malformation is very difficult.",
"   </p>",
"   <p>",
"    Studies of drugs approved by the US Food and Drug Administration (FDA) from 2000-2010 found that the teratogenic risk in human pregnancy was &ldquo;undetermined&rdquo; for 98 percent of the drugs approved for human use. More concerning is that of the 640 prescription drug treatments approved by the FDA since 1980, the teratogenic risk has been determined for only 9 percent, and of those only approximately 30 are deemed &ldquo;safe&rdquo; in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/20\">",
"     20",
"    </a>",
"    ]. At present, the options for improvement of these circumstances are limited, but two promising approaches to providing somewhat better information are prospectively collected exposure data from teratogen information agencies and large-scale birth defects registries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Proof of teratogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;To prove that an agent is a teratogen one might show [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is more often associated with individuals having a specific defect than with appropriately matched controls.",
"     </li>",
"     <li>",
"      A specific malformation or group of malformations is consistently associated with exposure to the teratogen.",
"     </li>",
"     <li>",
"      Biologic plausibility; the agent was present at the time in organogenesis when the anomaly would have to occur. As an example, it is unlikely that exposure to drug X in the third trimester would cause a cleft palate because the palate closes in the first trimester.",
"     </li>",
"     <li>",
"      The anomaly was less common before the presumptive teratogen was introduced. Phocomelia, as an example, was almost nonexistent before the introduction of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Experimental animals will develop the anomaly if given the presumed teratogen at the appropriate stage of organogenesis.",
"     </li>",
"     <li>",
"      As the dose of the teratogen is increased, the frequency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severity of the anomaly or anomalies increase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6169608\">",
"    <span class=\"h1\">",
"     KEY MANAGEMENT PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key principles in management of pregnant women exposed to medication vary depending on whether there has been inadvertent exposure versus planned initiation or continuation of a medication during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19574/abstract/24\">",
"     24",
"    </a>",
"    ]. In general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain accurate details of exposure and gestational age.",
"     </li>",
"     <li>",
"      Check for confounding family or personal medical history.",
"     </li>",
"     <li>",
"      Emphasize background risk of birth defects.",
"     </li>",
"     <li>",
"      Try to avoid first trimester use of a medication.",
"     </li>",
"     <li>",
"      Use drugs that have been used extensively in pregnancy, if possible.",
"     </li>",
"     <li>",
"      Use the minimum dose recommended.",
"     </li>",
"     <li>",
"      Absence of information does not imply safety.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several resources are available for current information on possible teratogenic exposure. These include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     National Library of Medicine",
"    </span>",
"   </p>",
"   <p>",
"    Bethesda, MD",
"   </p>",
"   <p>",
"    800-638-8480",
"   </p>",
"   <p>",
"    (",
"    <a class=\"external\" href=\"file://sis.nlm.nih.gov/\">",
"     sis.nlm.nih.gov/",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Reproductive Toxicology Center",
"    </span>",
"   </p>",
"   <p>",
"    REPROTOX",
"   </p>",
"   <p>",
"    Columbia Hospital for Women Medical Center",
"   </p>",
"   <p>",
"    Washington, DC",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     file://www.reprotox.org/",
"    </span>",
"   </p>",
"   <p>",
"    202-293-5137",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Teratogen Information System",
"    </span>",
"   </p>",
"   <p>",
"    TERIS and Shepard's Catalog of Teratogenic Agents",
"   </p>",
"   <p>",
"    Seattle, WA",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     file://depts.washington.edu/terisweb/teris/",
"    </span>",
"   </p>",
"   <p>",
"    206-543-2465",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pregnancy Exposure Registries",
"    </span>",
"   </p>",
"   <p>",
"    A list is available at",
"    <a class=\"external\" href=\"file://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm134848.htm\">",
"     file://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm134848.htm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Organization of Teratology Information Specialists (OTIS)",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.otispregnancy.org/\">",
"     www.OTISPregnancy.org",
"    </a>",
"   </p>",
"   <p>",
"    877-311-8972",
"   </p>",
"   <p>",
"    <strong>",
"     Motherisk",
"    </strong>",
"   </p>",
"   <p>",
"    The Hospital for Sick Children",
"   </p>",
"   <p>",
"    Toronto, Canada",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.motherisk.org/women/drugs.jsp\">",
"     file://www.motherisk.org/women/drugs.jsp",
"    </a>",
"   </p>",
"   <p>",
"    877-439-2744",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Teratogenesis is the study of malformations.",
"     </li>",
"     <li>",
"      Any factor that alters normal intrauterine development can be considered a teratogen. This includes drugs and environmental exposures, maternal medical conditions, infectious agents, and genetic factors.",
"     </li>",
"     <li>",
"      The developmental stage of pregnancy at exposure is critical in determining risk.",
"     </li>",
"     <li>",
"      Dose of a teratogen (ie, amount and duration of exposure) are important.",
"     </li>",
"     <li>",
"      Some teratogens have species specificity.",
"     </li>",
"     <li>",
"      Maternal and fetal genes may alter an individual pregnancy's susceptibility to a specific teratogen.",
"     </li>",
"     <li>",
"      Exposure to potential teratogens is common.",
"     </li>",
"     <li>",
"      Because of the complex interactions involved, teratogenicity of an agent is very difficult to prove.",
"     </li>",
"     <li>",
"      When prescribing drugs in pregnancy, try to use drugs or drug classes known to be of low teratogenic potential, avoid critical periods of toxicity (eg, during organogenesis for all drugs, near delivery for some drugs), and consult one of the resources described above, as needed.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/1\">",
"      van Gelder MM, van Rooij IA, Miller RK, et al. Teratogenic mechanisms of medical drugs. Hum Reprod Update 2010; 16:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/2\">",
"      Wenstrom KD, Johanning GL, Owen J, et al. Role of amniotic fluid homocysteine level and of fetal 5, 10-methylenetetrahydrafolate reductase genotype in the etiology of neural tube defects. Am J Med Genet 2000; 90:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/3\">",
"      Wenstrom KD, Johanning GL, Johnston KE, DuBard M. Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations. Am J Obstet Gynecol 2001; 184:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/4\">",
"      Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 1991; 338:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/5\">",
"      Czeizel AE, Dud&aacute;s I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/6\">",
"      Finnell RH, Buehler BA, Kerr BM, et al. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 1992; 42:25.",
"     </a>",
"    </li>",
"    <li>",
"     Simpson, JL, Golbus, MS. Principles of Teratology. In: Genetics in Obstetrics and Gynecology, Simpson, JL Golbus, MS (Eds), W.B. Saunders Company, Philadelphia 1992. p. 241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/8\">",
"      Brent RL. The effects of embryonic and fetal exposure to x-ray, microwaves, and ultrasound. Clin Perinatol 1986; 13:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/9\">",
"      French NP, Hagan R, Evans SF, et al. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol 1999; 180:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/10\">",
"      Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 1995; 173:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/11\">",
"      Beckman DA, Brent RL. Mechanism of known environmental teratogens: drugs and chemicals. Clin Perinatol 1986; 13:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/12\">",
"      Hern&aacute;ndez-D&iacute;az S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/13\">",
"      Harden CL, Meador KJ, Pennell PB, et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/14\">",
"      LENZ W, KNAPP K. [Thalidomide embryopathy]. Dtsch Med Wochenschr 1962; 87:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/15\">",
"      Brent RL. The complexities of solving the problem of human malformations. Clin Perinatol 1986; 13:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/16\">",
"      Forfar JO, Nelson MM. Epidemiology of drugs taken by pregnant women: drugs that may affect the fetus adversely. Clin Pharmacol Ther 1973; 14:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/17\">",
"      Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/18\">",
"      Glover DD, Rybeck BF, Tracy TS. Medication use in a rural gynecologic population: prescription, over-the-counter, and herbal medicines. Am J Obstet Gynecol 2004; 190:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/19\">",
"      Koren G, Nickel S. Sources of bias in signals of pharmaceutical safety in pregnancy. Clin Invest Med 2010; 33:E349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/20\">",
"      Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011; 157:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/21\">",
"      Lisi A, Botto LD, Robert-Gnansia E, et al. Surveillance of adverse fetal effects of medications (SAFE-Med): findings from the international Clearinghouse of birth defects surveillance and research. Reprod Toxicol 2010; 29:433.",
"     </a>",
"    </li>",
"    <li>",
"     Simpson, JL, Golbus, MS, Martin, AO, Sarto, GE. Principles of human embryology and teratogenesis. In: Genetics in Obstetrics and Gynecology. Grune and Stratton, New York 1982, p. 210.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/23\">",
"      Koren G, Graham K, Shear H, Einarson T. Bias against the null hypothesis: the reproductive hazards of cocaine. Lancet 1989; 2:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19574/abstract/24\">",
"      Henderson E, Mackillop L. Prescribing in pregnancy and during breast feeding: using principles in clinical practice. Postgrad Med J 2011; 87:349.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6744 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19574=[""].join("\n");
var outline_f19_7_19574=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY OF MALFORMATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIRECT GENETIC CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENETIC SUSCEPTIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ENVIRONMENTAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Developmental stage at time of exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dose and duration of exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Species specificity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SCOPE OF THE PROBLEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Proof of teratogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6169608\">",
"      KEY MANAGEMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      National Library of Medicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Reproductive Toxicology Center",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Teratogen Information System",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pregnancy Exposure Registries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Organization of Teratology Information Specialists (OTIS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6744\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6744|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/46/23272\" title=\"figure 1\">",
"      The developing fetus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/30/33261\" title=\"figure 2\">",
"      Risk wk for fetal abnormalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=related_link\">",
"      Alcohol intake and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=related_link\">",
"      Management of epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41256?source=related_link\">",
"      Placental development and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_7_19575="Valsartan and hydrochlorothiazide: Drug information";
var content_f19_7_19575=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Valsartan and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/24/29061?source=see_link\">",
"    see \"Valsartan and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diovan HCT&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diovan HCT&reg;;",
"     </li>",
"     <li>",
"      Sandoz Valsartan HCT;",
"     </li>",
"     <li>",
"      Teva-Valsartan HCTZ;",
"     </li>",
"     <li>",
"      Valsartan-HCTZ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F233279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F233264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose is individualized; combination product may be used as initial therapy or substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monotherapy (using one of the agents or an agent within same antihypertensive class).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial therapy: Valsartan 160 mg and hydrochlorothiazide 12.5 mg once daily; dose may be titrated after 1-2 weeks of therapy. Maximum recommended daily doses: Valsartan 320 mg; hydrochlorothiazide 25 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Add-on/replacement therapy: Valsartan 80-320 mg and hydrochlorothiazide 12.5-25 mg once daily; dose may be titrated after 3-4 weeks of therapy. Maximum recommended daily dose: Valsartan 320 mg; hydrochlorothiazide 25 mg.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F233265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F233266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling; safety and efficacy has not been established. Use is contraindicated in patients with anuria.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F233267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment necessary; use with caution. Patients with mild-to-moderate chronic disease have twice the exposure of valsartan as healthy volunteers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral: 80 mg/12.5 mg: Valsartan 80 mg and hydrochlorothiazide 12.5 mg; 160 mg/12.5 mg: Valsartan 160 mg and hydrochlorothiazide 12.5 mg; 160 mg/25 mg: Valsartan 160 mg and hydrochlorothiazide 25 mg; 320 mg/12.5 mg: Valsartan 320 mg and hydrochlorothiazide 12.5 mg; 320 mg/25 mg: Valsartan 320 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diovan HCT&reg; 80 mg/12.5 mg: Valsartan 80 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diovan HCT&reg; 160 mg/12.5 mg: Valsartan 160 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diovan HCT&reg; 160 mg/25 mg: Valsartan 160 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diovan HCT&reg; 320 mg/12.5 mg: Valsartan 320 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diovan HCT&reg; 320 mg/25 mg: Valsartan 320 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6713095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F233251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F233285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Diovan&reg; may be confused with Zyban&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F233277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported with combination product; other reactions have been reported (see individual agents for additional information)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Renal: BUN increased (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (6%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, appetite increased, bronchospasm, constipation, dehydration, depression, dysuria, epistaxis, flushing, gout, hematocrit/hemoglobin decreased, hyperkalemia, libido decreased, neutropenia, orthostatic hypotension, photosensitivity, pruritus, syncope, transaminases increased, vasculitis, vision abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rhabdomyolysis has been reported (rarely) with angiotensin-receptor antagonists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined, but occurred at &gt;0.2% incidence (limited to important or life-threatening): Abdominal pain, anxiety, arthralgia, chest pain, cough, diarrhea, dyspepsia, dyspnea, fatigue, fever, flatulence, hyperhidrosis, infection, insomnia, myalgia, nausea, palpitation, paresthesia, peripheral edema, pollakiuria, postural dizziness, rash, somnolence, tachycardia, tinnitus, vertigo, vomiting, weakness, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F233254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to valsartan, hydrochlorothiazide, sulfonamide-derived drugs, or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F233241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with angiotensin II receptor antagonists; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: During initiation of therapy, hypotension may occur, particularly in patients with heart failure or who are post-MI. Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with valsartan/hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use valsartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use valsartan with caution with pre-existing renal insufficiency, and severe renal impairment. Avoid hydrochlorothiazide in severe renal disease (ineffective); may precipitate azotemia; discontinue or consider withholding if renal impairment occurs. Contraindicated in patients with anuria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F233273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrochlorothiazide: May enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F233269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F233257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion of valsartan in breast milk is not known and use during nursing is not recommended; hydrochlorothiazide is excreted in breast milk",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6713068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid salt substitutes which contain potassium. May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F233255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Diovan HCT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80-12.5 mg (90): $433.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160-12.5 mg (30): $157.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160-25 mg (30): $178.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     320-12.5 mg (30): $199.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     320-25 mg (30): $226.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Valsartan-Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80-12.5 mg (90): $353.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160-12.5 mg (90): $384.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160-25 mg (90): $436.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     320-12.5 mg (90): $487.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     320-25 mg (90): $552.87",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F233258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Co-Diopass (KP);",
"     </li>",
"     <li>",
"      Co-Diovan (AT, AU, BG, CH, CL, CZ, EE, GR, HK, ID, IL, MY, NL, NZ, PH, PK, PL, PT, RU, SG, TH, TR, TW);",
"     </li>",
"     <li>",
"      Co-Diovane (BE);",
"     </li>",
"     <li>",
"      CoDiovan (DE, GB, IE, KP, MX);",
"     </li>",
"     <li>",
"      Cotareg (FR, IT, KP, TW);",
"     </li>",
"     <li>",
"      Diovan Comp (DK, NO, SE);",
"     </li>",
"     <li>",
"      Diovan D (AR, PY, UY);",
"     </li>",
"     <li>",
"      Diovan HCT (BR, CO, EC, HN, PE, VE);",
"     </li>",
"     <li>",
"      Duotan (KP);",
"     </li>",
"     <li>",
"      Duovan (KP);",
"     </li>",
"     <li>",
"      Maxdioplus (KP);",
"     </li>",
"     <li>",
"      Nisisco (FR);",
"     </li>",
"     <li>",
"      Simultan D (EC);",
"     </li>",
"     <li>",
"      Tareg D (CN);",
"     </li>",
"     <li>",
"      V-Van Plus (KP);",
"     </li>",
"     <li>",
"      Valent-H (IN);",
"     </li>",
"     <li>",
"      Valsaprex-H (CO);",
"     </li>",
"     <li>",
"      Valtan H (PE);",
"     </li>",
"     <li>",
"      Valtan Plus (KP);",
"     </li>",
"     <li>",
"      Valtens H (GT);",
"     </li>",
"     <li>",
"      Vector Plus (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6712943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Valsartan produces direct antagonism of the angiotensin II (AT2) receptors, unlike the ACE inhibitors. It displaces angiotensin II from the AT1 receptor and produces its blood pressure-lowering effects by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. This action results in more efficient blockade of the cardiovascular effects of angiotensin II and fewer side effects than the ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hydrochlorothiazide inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F233253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/7/19575/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/7/19575/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K and Kjekshus J, &ldquo;Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/7/19575/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, &ldquo;Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/7/19575/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/7/19575/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/7/19575/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(2):203.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, &ldquo;Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      ,  2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/7/19575/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/7/19575/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10107 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19575=[""].join("\n");
var outline_f19_7_19575=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708861\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233260\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233261\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233279\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233264\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233265\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233266\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233267\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233249\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233238\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6713095\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233251\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233285\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233277\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233254\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233241\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233273\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233245\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233246\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233256\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233269\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233257\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6713068\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233255\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233258\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6712943\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233253\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10107\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10107|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/24/29061?source=related_link\">",
"      Valsartan and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_7_19576="Hyperleukocytosis and leukostasis";
var content_f19_7_19576=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyperleukocytosis and leukostasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/7/19576/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/7/19576/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/7/19576/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/7/19576/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/7/19576/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/7/19576/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/7/19576/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperleukocytosis refers to a laboratory abnormality that has been variably defined as a total leukemia blood cell count greater than 50 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (50,000/microL)",
"    </span>",
"    or 100 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (100,000/microL).",
"    </span>",
"    In contrast, leukostasis (also called symptomatic hyperleukocytosis) is a medical emergency most commonly seen in patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) in blast crisis. It is characterized by an extremely elevated blast cell count and symptoms of decreased tissue perfusion.",
"   </p>",
"   <p>",
"    Leukostasis is a pathologic diagnosis in which white cell plugs are seen in the microvasculature. Clinically, leukostasis is typically diagnosed empirically when a patient with leukemia and hyperleukocytosis presents with respiratory or neurological distress. Prompt treatment is indicated since, if left untreated, the one-week mortality rate is approximately 20 to 40 percent.",
"   </p>",
"   <p>",
"    The epidemiology, clinical presentation, diagnosis, and management of hyperleukocytosis and leukostasis will be reviewed here. Other complications of leukemia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link\">",
"     \"Overview of the complications of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of hyperleukocytosis and leukostasis vary by leukemia type and patient population. In general, symptoms of leukostasis are more common in leukemias with large, poorly deformable blasts, such as acute myeloid leukemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute myeloid leukemia &mdash; Hyperleukocytosis is present in 10 to 20 percent of patients with newly diagnosed acute myeloid leukemia (AML). It is more common in patients with myelomonocytic (FAB-M4) leukemia, monocytic (FAB-M5) leukemia, or the microgranular variant of acute promyelocytic leukemia (FAB-M3) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/1\">",
"       1",
"      </a>",
"      ]. Symptoms of leukostasis occur less frequently and typically affect patients with white blood cell (WBC) counts over 100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (100,000/microL).",
"      </span>",
"     </li>",
"     <li>",
"      Acute lymphoblastic leukemia &mdash; Hyperleukocytosis is seen in 10 to 30 percent of patients with newly diagnosed acute lymphoblastic leukemia (ALL) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/2\">",
"       2",
"      </a>",
"      ]. The incidence appears to be highest in infants, patients between the ages of 10 and 20 years, males, and those with a T cell phenotype [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. Symptoms of leukostasis are rarely seen in patients with ALL and hyperleukocytosis. Tumor lysis syndrome and disseminated intravascular coagulation are more common complications related to the elevated WBC count.",
"     </li>",
"     <li>",
"      Chronic lymphocytic leukemia &mdash; A significant proportion of patients with chronic lymphocytic leukemia (CLL) present with hyperleukocytosis. Symptoms of leukostasis are rare unless the WBC count exceeds 400 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (400,000/microL).",
"      </span>",
"     </li>",
"     <li>",
"      Chronic myeloid leukemia &mdash; Patients with chronic myeloid leukemia (CML) typically present with leukocytosis and a median WBC count of approximately 100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (100,000/microL).",
"      </span>",
"      Most often, these are segmented neutrophils, metamyelocytes, and myelocytes. Symptoms of leukostasis are very uncommon in patients in chronic phase but can be seen occasionally in patients with myeloid blast crisis and very elevated blast counts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF LEUKOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of leukostasis is not well understood. There are two main theories, which are not mutually exclusive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukostasis may be due to increased blood viscosity as a direct complication of a large population of leukemic blasts that are considerably less deformable than mature leukocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. With increasing blast counts, plugs of these more rigid cells can develop in the microcirculation, thereby impeding blood flow (leukostasis)&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/1,6\">",
"       1,6",
"      </a>",
"      ]. This situation can be worsened by red blood cell transfusions or the use of diuretics, both of which can increase whole blood viscosity.",
"     </li>",
"     <li>",
"      Local hypoxemia may be exacerbated by the high metabolic activity of the dividing blasts and the associated production of various cytokines [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. These cytokines can result in endothelial damage and subsequent hemorrhage that add to the hypoxic damage already present from reduced blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Leukemic blasts can migrate into the surrounding tissues, causing additional damage [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/9\">",
"       9",
"      </a>",
"      ]. Thus, the lower incidence of clinically significant leukostasis and vascular injury in patients with CLL and ALL may be related to the lower metabolic and mitotic rate in the former and the lack of catabolic enzymes and cytokines in both.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is likely that both of these mechanisms, and additional yet unidentified mechanisms, are involved in the development of leukostasis. In vitro studies have demonstrated a dramatic rise in viscosity when leukocyte suspensions exceed a fractional volume of leukocytes (ie, leukocrit) of 12 to 15",
"    <span class=\"nowrap\">",
"     mL/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/10\">",
"     10",
"    </a>",
"    ]. Attainment of such a high leukocrit requires an AML blast count of approximately 300 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (300,000/microL)",
"    </span>",
"    or an ALL blast count of approximately 600 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (600,000/microL).",
"    </span>",
"    This observation is consistent with the increased incidence of leukostasis in AML compared with ALL. It also suggests that factors other than white blood cell count are important in the pathogenesis of leukostasis, since symptoms of leukostasis commonly occur at blast concentrations below these predicted thresholds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SIGNS AND SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pathologic evidence of leukostasis can be found in most organs in patients with extremely high white blood cell (WBC) counts, the main clinical symptoms of leukostasis and causes of early death are related to involvement of the central nervous system (approximately 40 percent) and lungs (approximately 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary signs and symptoms include dyspnea and hypoxia with or without diffuse interstitial or alveolar infiltrates on imaging studies. Measurement of the arterial pO2 can be falsely decreased in patients with hyperleukocytosis, since the WBCs in the test tube utilize oxygen. Pulse oximetry provides a more accurate assessment of O2 saturation in this setting. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Laboratory abnormalities'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Neurological signs and symptoms include visual changes, headache, dizziness, tinnitus, gait instability, confusion, somnolence, and, occasionally, coma.",
"     </li>",
"     <li>",
"      Approximately 80 percent of patients with leukostasis are febrile, which may be due to inflammation associated with leukostasis or concurrent infection. Since an infectious cause cannot be easily excluded, we treat empirically for infection in all such patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"       \"Overview of neutropenic fever syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"       \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Less common signs or symptoms of leukostasis include electrocardiographic signs of myocardial ischemia or right ventricular overload, worsening renal insufficiency, priapism, acute limb ischemia, or bowel infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasionally, patients develop dyspnea and worsening hypoxemia following the initiation of chemotherapy due to the lysis of leukemic cells trapped in the lungs (eg, acute lysis pneumopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperleukocytosis may result in laboratory abnormalities, which can be due to interference with laboratory assays or may be a consequence of the high number of circulating blasts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial pO2 can be falsely decreased because of the enhanced metabolic activity of the malignant cells, even when the specimen is appropriately placed on ice during transport to the laboratory. Pulse oximetry provides a more accurate assessment of O2 saturation.",
"     </li>",
"     <li>",
"      The platelet count may be overestimated by automated blood cell counters because fragments of blasts on blood smear can be mistakenly counted as platelets. A manual platelet count and careful review of the peripheral smear is appropriate in such settings. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=see_link&amp;anchor=H10#H10\">",
"       \"Approach to the patient with thrombocytosis\", section on 'Spurious thrombocytosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum potassium can be spuriously elevated due to its release from leukemic blasts during the in vitro clotting process. Potassium levels measured from heparinized plasma samples, rather than serum, can circumvent this effect. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link&amp;anchor=H4#H4\">",
"       \"Causes and evaluation of hyperkalemia in adults\", section on 'Pseudohyperkalemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation (DIC) occurs in up to 40 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/2\">",
"       2",
"      </a>",
"      ]. DIC presents with various degrees of thrombin generation (eg, decreased fibrinogen) and increased fibrinolysis (eg, elevated fibrin degradation products and D-dimer). DIC may develop or worsen following chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spontaneous tumor lysis syndrome (TLS) is present in up to 10 percent of patients with leukostasis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/2\">",
"       2",
"      </a>",
"      ]. Laboratory evidence of tumor lysis syndrome includes increased elevated serum concentrations of uric acid, potassium, and phosphate, often accompanied by hypocalcemia. TLS may develop or worsen following chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukostasis (symptomatic hyperleukocytosis) is diagnosed empirically when a patient with leukemia and a white blood cell (WBC) count over 100 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (100,000/microL)",
"    </span>",
"    presents with symptoms thought to be due to tissue hypoxia, most commonly respiratory or neurological distress. The diagnosis requires a high degree of suspicion, and some patients have pathologically proven leukostasis at WBC counts below this level.",
"   </p>",
"   <p>",
"    Pathologically, leukostasis is diagnosed when a biopsy of involved tissue demonstrates white cell plugs in the microvasculature&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. A pathologic diagnosis of leukostasis is rarely obtained because of the risks associated with biopsy of affected tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukostasis (symptomatic hyperleukocytosis) constitutes a medical emergency, and efforts should be made to rapidly stabilize the patient and lower the white blood cell count. In most cases, rapid cytoreduction can be achieved with induction chemotherapy, which should be administered in conjunction with prophylaxis for tumor lysis syndrome. Adequate fluid resuscitation to prevent dehydration and ensure good urine flow is important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some clinicians also advocate therapy of asymptomatic hyperleukocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cytoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty to 40 percent of patients with symptomatic hyperleukocytosis die within the first week of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/15-21\">",
"     15-21",
"    </a>",
"    ]. The mortality rate appears to be unrelated to the level of the white blood cell count, but patients with symptoms (eg, respiratory distress or neurological compromise) have a significantly worse prognosis when compared with patients who have hyperleukocytosis alone.",
"   </p>",
"   <p>",
"    Cytoreduction can be achieved through the use of chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    or remission induction chemotherapy) or leukapheresis. While both modalities rapidly decrease the circulating white blood cell count, chemotherapy also destroys leukemia cells in the bone marrow and is the only treatment proven to improve survival. There have been no prospective trials or large observational studies comparing these two options for the treatment of hyperleukocytosis and leukostasis.",
"   </p>",
"   <p>",
"    In general, we propose the following approach to patients with hyperleukocytosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with symptomatic or asymptomatic hyperleukocytosis, we suggest initial treatment with induction chemotherapy rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      or leukapheresis. This should be accompanied by tumor lysis syndrome prophylaxis with aggressive hydration and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Induction chemotherapy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"       \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Our preference for induction chemotherapy is primarily based upon the knowledge that such therapy is also a necessary step toward the successful treatment of patients with leukemia. There is little evidence to confirm that decreasing the white blood cell (WBC) count alone will reduce the early mortality rate. In addition, clinical deterioration may occur after the WBC count has been significantly reduced.",
"      <br/>",
"      <br/>",
"      An exception to this approach may occur in patients who cannot start induction chemotherapy immediately. Such patients include those who have poor venous access, renal insufficiency, or other severe metabolic disturbances, and those with delays in initiating prophylaxis for tumor lysis syndrome (TLS). If induction chemotherapy must be delayed, our approach to hyperleukocytosis depends upon whether or not the patient is having symptoms of hyperleukocytosis (ie, leukostasis):",
"     </li>",
"     <li>",
"      For patients without symptoms of leukostasis who must have induction chemotherapy delayed, we suggest cytoreduction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      rather than leukapheresis. Cytoreduction with hydroxyurea can precipitate or exacerbate hyperuricemia and occasionally precipitate TLS, therefore such patients also need intravenous hydration and TLS prophylaxis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hydroxyurea'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with symptoms of leukostasis who must have induction chemotherapy delayed, we suggest initial cytoreduction with leukapheresis in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      to lower or stabilize the WBC count. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Leukapheresis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of these three approaches to cytoreduction is presented in more detail in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Induction chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction chemotherapy is an essential component of the successful treatment of patients with leukemia. In the setting of hyperleukocytosis, induction chemotherapy serves to both rapidly decrease the circulating WBC count and target the leukemia cells in the bone marrow. Induction therapy typically substantially reduces the WBC count within 24 hours. Details regarding the administration of induction therapy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with hyperleukocytosis are at higher risk of developing tumor lysis syndrome with induction chemotherapy. This syndrome is best prevented via appropriate treatment with intravenous hydration to ensure adequate urine flow,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    to reduce serum uric acid levels, and correction of any electrolyte disturbances or causes of reversible renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically reserve",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    for patients with asymptomatic hyperleukocytosis who are unable to receive immediate induction chemotherapy. Hydroxyurea, given at a total dose of 50 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally, reduces the WBC count by 50 to 80 percent within 24 to 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/22\">",
"     22",
"    </a>",
"    ]. The usual hydroxyurea dose is 2 to 4 grams orally every 12 hours, which is continued until the WBC count is below 50 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (50,000/microL).",
"    </span>",
"   </p>",
"   <p>",
"    Side",
"    effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    are usually minimal and are typically limited to patients who are exposed to hydroxyurea for a prolonged period. Rare complications include fever and abnormal liver function tests. Hydroxyurea should NOT be used in pregnancy or in women who are breastfeeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Leukapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of leukapheresis as an adjunct to the treatment of all patients with hyperleukocytosis is controversial. It is not clear whether survival is improved in patients treated with leukapheresis when compared with patients who receive cytoreductive chemotherapy promptly.",
"   </p>",
"   <p>",
"    Although intensive leukapheresis, with procedure times often lasting many hours, has been reported to produce improvement in pulmonary and central nervous system symptoms, there are theoretical and practical limitations to its benefits. It is precisely the patient in whom leukostasis is most likely to occur, that is, the patient with a high and rapidly rising blast count, in whom the technical limitations of leukapheresis are relevant. It is often difficult, even with highly efficient cell separators, to reduce the rapidly rising count. Cycle-specific chemotherapeutic agents (eg, induction chemotherapy) are more likely to be the most rapidly effective.",
"   </p>",
"   <p>",
"    Although some clinicians advocate its use for patients with asymptomatic hyperleukocytosis, we typically reserve leukapheresis for patients with symptomatic hyperleukocytosis who must have induction chemotherapy postponed. Our preference to reserve leukapheresis for this selected patient population is primarily based upon the known risks associated with leukapheresis described below and an unclear benefit. Anecdotal reports have claimed dramatic responses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/23-27\">",
"     23-27",
"    </a>",
"    ], but larger retrospective analyses have demonstrated conflicting effects on early mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/18,21,28\">",
"     18,21,28",
"    </a>",
"    ]. Given the paucity of data concerning the efficacy of leukapheresis in reducing early mortality",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    improving overall survival, leukapheresis cannot be recommended for routine therapy as a form of tumor \"debulking\" in patients with high blast counts.",
"   </p>",
"   <p>",
"    However, patients with symptomatic leukocytosis have an extremely high mortality rate without immediate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/15-21\">",
"     15-21",
"    </a>",
"    ]. When both respiratory failure and neurologic compromise are present, the death rate at one week reaches 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/21\">",
"     21",
"    </a>",
"    ]. Therefore, if facilities are available, we suggest leukapheresis for patients with leukemic blast counts greater than 50 to 100 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    (50 to",
"    <span class=\"nowrap\">",
"     100,000/microL)",
"    </span>",
"    <strong>",
"     and",
"    </strong>",
"    associated symptoms as a temporizing measure until chemotherapy can be initiated. It is difficult to predict the percent leukocyte count reduction in individual patients, but sessions are usually planned for four- to five-hour collections with repeat sessions as needed.",
"   </p>",
"   <p>",
"    It is generally agreed that leukapheresis should NOT be used for patients with acute promyelocytic leukemia because it may worsen the intrinsic coagulopathy associated with this subtype of leukemia. Placement of large intravenous leukapheresis catheters in these patients has been associated with venous thrombosis or hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\", section on 'Disseminated intravascular coagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional considerations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukapheresis usually requires the placement of a large bore, central venous catheter, is only available at select medical centers, and lacks standardization. The procedure can also be done using antecubital veins if they are adequate for placement of large bore needles bilaterally.",
"     </li>",
"     <li>",
"      A small number of platelets are inevitably removed with the leukemic blasts, resulting in worsening thrombocytopenia.",
"     </li>",
"     <li>",
"      Some patients require multiple sessions to control their white blood cell (WBC) count, while many others, presumably those with the most rapidly proliferating AML, do not respond to multiple sessions of leukapheresis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The effect is generally transient with WBC counts typically rebounding after leukapheresis is discontinued unless chemotherapy is begun.",
"     </li>",
"     <li>",
"      It is unclear whether leukapheresis can reverse vascular damage already sustained from leukostasis. In addition, symptomatic leukostasis can still develop after the WBC count has been lowered by leukapheresis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following supportive care measures should be considered for all patients with hyperleukocytosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic leukostasis can be precipitated by increases in whole blood viscosity following red blood cell transfusions. Such transfusions should be withheld, if possible, until the blast count is reduced. If a transfusion is necessary, it should be given slowly, administering a single unit of red blood cells over a few hours, or during the leukapheresis procedure. Hydration is encouraged and diuretics are discouraged.",
"     </li>",
"     <li>",
"      Patients with hyperleukocytosis are at risk of tumor lysis syndrome (TLS), although this syndrome is less common in patients with AML than in those with ALL or Burkitt",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma.",
"      </span>",
"      TLS is best prevented with intravenous hydration to ensure adequate urine flow,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      to reduce serum uric acid levels, and the correction of any electrolyte disturbances or causes of reversible renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"       \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coagulation abnormalities, including disseminated intravascular coagulation (DIC), further increase the risk of local hemorrhage. Specific treatment aimed at the DIC should be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link&amp;anchor=H18#H18\">",
"       \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Control of coagulopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients should also receive prophylactic platelet transfusions to maintain a count of greater than 20 to",
"      <span class=\"nowrap\">",
"       30,000/microL",
"      </span>",
"      until the WBC count has been reduced and the clinical situation has been stabilized. The risk of intracranial hemorrhage is greatest after the WBC count has been markedly reduced, suggesting that a reperfusion injury may occur when the circulation is restored to previously hypoxemic or ischemic capillary beds. Thus, aggressive platelet support and correction of coagulopathy should continue for several weeks during the remission induction period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients with leukostasis often require specialized, symptom-directed supportive care including mechanical ventilation for respiratory failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Is there a role for cranial irradiation?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some centers advocate low dose cranial irradiation (eg, 400 cGy in a single fraction), including treatment of the retina, in order to prevent further proliferation of leukemic cells in central nervous system sites where drug delivery may theoretically be compromised. However, there are no comparative studies to determine whether the results with cranial irradiation are superior to those with chemotherapy alone, and we do not advocate the routine use of cranial irradiation in this setting. Nevertheless, it could be considered for patients with serious central nervous system symptoms related to leukostasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic impact of hyperleukocytosis and leukostasis (symptomatic hyperleukocytosis) depends upon the type of leukemia (acute myeloid leukemia or acute lymphoblastic leukemia) and the presence of symptoms.",
"   </p>",
"   <p>",
"    The initial mortality rate for patients with acute myeloid leukemia (AML) and leukostasis has been estimated at 20 to 40 percent and appears to be unrelated to the severity of the hyperleukocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/15-18,21\">",
"     15-18,21",
"    </a>",
"    ]. If patients survive the initial period, they tend to have somewhat lower remission rates. Remission durations are also shorter, possibly because of a larger initial tumor mass, but more likely related to the biology and intrinsic chemotherapy resistance of the leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for mortality in patients with AML and hyperleukocytosis were identified in a retrospective analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/21\">",
"     21",
"    </a>",
"    ]. When compared with patients who lived more than one week after presentation, patients who died within the first week of presentation had significantly higher rates of coagulopathy (64 versus 18 percent), respiratory distress (100 versus 15 percent), renal failure (43 versus 29 percent), and neurologic symptoms (64 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with acute lymphoblastic leukemia (ALL), hyperleukocytosis is rarely complicated by leukostasis and the early death rate is less than 5 percent in childhood ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/3\">",
"     3",
"    </a>",
"    ]. The challenge of leukostasis management in ALL involves preventing tumor lysis syndrome, disseminated intravascular coagulation, and the higher risk of relapse (approximately 50 percent by four years) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19576/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37753?source=see_link\">",
"     \"Risk group stratification and prognosis for acute lymphoblastic leukemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperleukocytosis is a laboratory abnormality that has been variably defined as a total white blood cell (WBC) count greater than 50 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (50,000/microL)",
"      </span>",
"      or 100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (100,000/microL).",
"      </span>",
"      In contrast, leukostasis (also called symptomatic hyperleukocytosis) is a medical emergency that is most commonly seen in patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) in blast crisis and is characterized by an extremely elevated WBC count and symptoms of decreased tissue perfusion.",
"     </li>",
"     <li>",
"      The main clinical symptoms of leukostasis and causes of early death are related to involvement of the central nervous system and lungs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinically, leukostasis is diagnosed empirically when a patient with leukemia and a blast cell count over 50 to 100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (100,000/microL)",
"      </span>",
"      presents with respiratory or neurological distress. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial management of a patient with hyperleukocytosis is directed at rapid lowering of the WBC count. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with symptomatic or asymptomatic hyperleukocytosis, we suggest initial cytoreduction with induction chemotherapy rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      or leukapheresis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"       \"Treatment of acute myeloid leukemia in older adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link\">",
"       \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with asymptomatic hyperleukocytosis who must have induction chemotherapy delayed, we suggest cytoreduction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      rather than leukapheresis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with symptoms of leukostasis who must have induction chemotherapy delayed, we suggest initial leukapheresis in addition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      (if possible) to lower or stabilize the WBC count (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following supportive care measures should be considered for all patients with hyperleukocytosis (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Supportive care'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Red blood cell transfusions should be withheld, if possible, until the blast count is reduced. If a transfusion is necessary, it should be administered slowly.",
"     </li>",
"     <li>",
"      Most patients with hyperleukocytosis are candidates for tumor lysis syndrome prophylaxis with aggressive intravenous hydration and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      to decrease serum uric acid levels. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"       \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coagulation abnormalities require aggressive treatment with platelet transfusions and coagulation factors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link&amp;anchor=H18#H18\">",
"       \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Control of coagulopathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/1\">",
"      Cuttner J, Conjalka MS, Reilly M, et al. Association of monocytic leukemia in patients with extreme leukocytosis. Am J Med 1980; 69:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/2\">",
"      Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/3\">",
"      Eguiguren JM, Schell MJ, Crist WM, et al. Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis. Blood 1992; 79:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/4\">",
"      Lichtman MA, Weed RI. Peripheral cytoplasmic characteristics of leukocytes in monocytic leukemia: relationship to clinical manifestations. Blood 1972; 40:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/5\">",
"      Lichtman MA, Rowe JM. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 1982; 60:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/6\">",
"      Lester TJ, Johnson JW, Cuttner J. Pulmonary leukostasis as the single worst prognostic factor in patients with acute myelocytic leukemia and hyperleukocytosis. Am J Med 1985; 79:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/7\">",
"      Stucki A, Rivier AS, Gikic M, et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001; 97:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/8\">",
"      Azoulay E, Fieux F, Moreau D, et al. Acute monocytic leukemia presenting as acute respiratory failure. Am J Respir Crit Care Med 2003; 167:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/9\">",
"      Schiffer CA, Wiernik PH. Functional evaluation of circulating leukemic cells in acute non-lymphocytic leukemia. Leuk Res 1977; 1:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/10\">",
"      Lightman MA. Rheology of leukocytes, leukocyte suspensions, and blood in leukemia. Possible relationship to clinical manifestations. J Clin Invest 1973; 52:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/11\">",
"      Myers TJ, Cole SR, Klatsky AU, Hild DH. Respiratory failure due to pulmonary leukostasis following chemotherapy of acute nonlymphocytic leukemia. Cancer 1983; 51:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/12\">",
"      Dombret H, Hunault M, Faucher C, et al. Acute lysis pneumopathy after chemotherapy for acute myelomonocytic leukemia with abnormal marrow eosinophils. Cancer 1992; 69:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/13\">",
"      Tryka AF, Godleski JJ, Fanta CH. Leukemic cell lysis pneumonopathy. A complication of treated myeloblastic leukemia. Cancer 1982; 50:2763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/14\">",
"      W&uuml;rthner JU, K&ouml;hler G, Behringer D, et al. Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis: a clinicopathologic report of four cases. Cancer 1999; 85:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/15\">",
"      Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol 1987; 5:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/16\">",
"      van Buchem MA, te Velde J, Willemze R, Spaander PJ. Leucostasis, an underestimated cause of death in leukaemia. Blut 1988; 56:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/17\">",
"      Vaughan WP, Kimball AW, Karp JE, et al. Factors affecting survival of patients with acute myelocytic leukemia presenting with high wbc counts. Cancer Treat Rep 1981; 65:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/18\">",
"      Bug G, Anargyrou K, Tonn T, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion 2007; 47:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/19\">",
"      Kasner MT, Laury A, Kasner SE, et al. Increased cerebral blood flow after leukapheresis for acute myelogenous leukemia. Am J Hematol 2007; 82:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/20\">",
"      Porcu P, Farag S, Marcucci G, et al. Leukocytoreduction for acute leukemia. Ther Apher 2002; 6:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/21\">",
"      Porcu P, Danielson CF, Orazi A, et al. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol 1997; 98:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/22\">",
"      Grund FM, Armitage JO, Burns P. Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. Arch Intern Med 1977; 137:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/23\">",
"      Eisenstaedt RS, Berkman EM. Rapid cytoreduction in acute leukemia. Management of cerebral leukostasis by cell pheresis. Transfusion 1978; 18:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/24\">",
"      Bloom R, Taveira Da Silva AM, Bracey A. Reversible respiratory failure due to intravascular leukostasis in chronic myelogenous leukemia. Relationship of oxygen transfer to leukocyte count. Am J Med 1979; 67:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/25\">",
"      Karp DD, Beck JR, Cornell CJ Jr. Chronic granulocyte leukemia with respiratory distress. Efficacy of emergency leukapheresis. Arch Intern Med 1981; 141:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/26\">",
"      Lane TA. Continuous-flow leukapheresis for rapid cytoreduction in leukemia. Transfusion 1980; 20:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/27\">",
"      Mehta AB, Goldman JM, Kohner E. Hyperleucocytic retinopathy in chronic granulocytic leukaemia: the role of intensive leucapheresis. Br J Haematol 1984; 56:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/28\">",
"      Giles FJ, Shen Y, Kantarjian HM, et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma 2001; 42:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19576/abstract/29\">",
"      Thi&eacute;baut A, Thomas X, Belhabri A, et al. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol 2000; 79:501.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4522 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19576=[""].join("\n");
var outline_f19_7_19576=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY OF LEUKOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SIGNS AND SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cytoreduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Induction chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Leukapheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Is there a role for cranial irradiation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=related_link\">",
"      Approach to the patient with thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37753?source=related_link\">",
"      Risk group stratification and prognosis for acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_7_19577="Nephrology pattern 9";
var content_f19_7_19577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 9",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19577=[""].join("\n");
var outline_f19_7_19577=null;
var title_f19_7_19578="Vagus nerve stimulation therapy for the treatment of epilepsy";
var content_f19_7_19578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vagus nerve stimulation therapy for the treatment of epilepsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/7/19578/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/7/19578/contributors\">",
"     Steven Karceski, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/7/19578/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/7/19578/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/7/19578/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/7/19578/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/7/19578/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiepileptic drugs (AEDs) are the primary treatment modality for patients with epilepsy. However, approximately one-third of patients with epilepsy continue to have seizures on medication [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/1\">",
"     1",
"    </a>",
"    ]. In the one-third of patients whose seizures are incompletely controlled by medications, their seizures are referred to as refractory or drug-resistant. In patients with refractory epilepsy, a combination of antiseizure medications may be tried. A combination may help to reduce the total number of seizures. However, polypharmacy often leads to an increased number of side effects. When medications are not enough to control seizures, physicians often turn to nonpharmacologic options: epilepsy surgery, ketogenic diet, and vagus nerve stimulator (VNS) therapy.",
"   </p>",
"   <p>",
"    In 1997, the VNS Therapy System&trade; (Cyberonics, Inc) was approved by the Food and Drug Administration (FDA) as adjunctive therapy for adults and adolescents over 12 years of age whose partial-onset seizures were refractory to antiepileptic drugs. This topic reviews the relevant anatomy, possible mechanisms of action, and clinical results of VNS in patients with epilepsy. Other aspects of epilepsy treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2890?source=see_link\">",
"     \"Evaluation and management of drug-resistant epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND THERAPEUTIC MECHANISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vagus nerve is comprised of approximately 20 percent efferent (nerve cells that send signals that leave the brain) and 80 percent afferent (nerve cells that send signal towards the brain) fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/2\">",
"     2",
"    </a>",
"    ]. If an electrical stimulus is placed on the vagus nerve, 80 percent of the applied stimulation travels back to the brainstem where the vagus nerve originates. The electrical stimulus is applied to the axons of the neurons of the vagus nerve (cranial nerve 10), which have their cell bodies in the nodose and jugular ganglia and synapse bilaterally on the nucleus of the solitary tract (NTS) in the brainstem. From the NTS, vagal afferent pathways project to many regions in the brain, including pontine and midbrain nuclei, the cerebellum, thalamus, and cortex. In short, electrical impulses, which are applied to one of the vagus nerves, travel to both sides of the brain, and to many disparate regions.",
"   </p>",
"   <p>",
"    One vagal pathway, perhaps of particular relevance to epilepsy therapy, ascends to the forebrain via the pontine parabrachial nucleus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/3\">",
"     3",
"    </a>",
"    ]. This pathway transmits sensations of visceral origin to the ventroposterior parvocellular nucleus of the thalamus, which then projects to the insular cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/4\">",
"     4",
"    </a>",
"    ]. The parabrachial nucleus also projects to other thalamic nuclei, the amygdala, and the basal forebrain. These vagal projections travel to sites that are often found to generate seizures. One way VNS may work is through connections with the seizure generating region.",
"   </p>",
"   <p>",
"    Another way in which VNS may operate is through the locus coeruleus. The locus coeruleus is another pontine nucleus that receives afferents from the NTS. While receiving less dense vagal input than the parabrachial nucleus, the locus coeruleus may be essential to the antiepileptic effect of VNS, as suggested by animal studies using ablative and immunolabeling procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vagal efferent fibers originate in the dorsal motor nucleus of the vagus and the nucleus ambiguous. These innervate the heart, vocal cords, and other laryngeal and pharyngeal muscles, and also provide parasympathetic input to the gastrointestinal viscera [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/2\">",
"     2",
"    </a>",
"    ]. Because the right vagus nerve provides more innervation to the cardiac atria than the left vagus nerve, electrical stimulation of the left vagus nerve is generally used in clinical practice to avoid adverse cardiac effects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/7\">",
"     7",
"    </a>",
"    ]. However, right-sided VNS has been reported safe in at least one case series, and in animal studies it appears equally effective against seizures as left-sided stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vagus nerve stimulator (VNS) is a battery-powered device similar to a cardiac pacemaker. Stimulating leads are surgically placed around the left vagus nerve in the carotid sheath and are connected to an infraclavicular subcutaneous programmable pacemaker (",
"    <a class=\"graphic graphic_figure graphicRef69707 \" href=\"UTD.htm?12/10/12452\">",
"     figure 1",
"    </a>",
"    ). A noninvasive, transcutaneous vagal nerve stimulator that targets the auricular branch of the vagus nerve of the left tragus has been developed and appears promising in a pilot study [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 1960s, studies in animals showed that repetitive vagus nerve stimulation (VNS) would either synchronize or desynchronize cortical electrical activity. The effect of stimulation on brain activity depended on the stimulus frequency and the strength of the electrical current [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Because epileptic seizures are characterized by hypersynchronized cortical activity, the observation that VNS can desynchronize cortical rhythms suggested a potential antiepileptic effect of VNS.",
"   </p>",
"   <p>",
"    VNS studies in a variety of animal models were then undertaken and have demonstrated that VNS has multiple antiepileptic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/14-21\">",
"     14-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VNS can abort an ongoing seizure after seizure onset",
"     </li>",
"     <li>",
"      VNS is effective in acute seizure prophylaxis; ie, seizure-inducing insults (eg, strychnine administration) are less effective in inducing a seizure in the presence of VNS",
"     </li>",
"     <li>",
"      VNS is effective in chronic seizure prophylaxis, reducing seizure frequency in animal models of epilepsy",
"     </li>",
"     <li>",
"      VNS can inhibit epileptogenesis in animal models of seizure kindling",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    How VNS exerts its antiseizure properties remains unclear. Studies in animal models and in patients with epilepsy suggest some possible facets of underlying mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-intensity trains of VNS hyperpolarize (inhibit) pyramidal neurons in the rat parietal association cortex [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/22\">",
"       22",
"      </a>",
"      ]. Low-intensity stimulation, which predominantly activates myelinated fibers, was more effective in this model in inducing long-lasting inhibitory effects than higher stimulus intensities, which also entrains nonmyelinated vagus fibers. Other studies also suggest that the unmyelinated C fibers are not activated in therapeutic VNS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/15,23\">",
"       15,23",
"      </a>",
"      ]. This may explain why efferent vagal symptoms do not more commonly complicate VNS.",
"     </li>",
"     <li>",
"      The cortical inhibition that is associated with VNS may be secondary to the release of inhibitory neurotransmitters, such as glycine and gamma-aminobutyric acid (GABA). A study using transcranial magnetic stimulation in five patients with VNS showed that effective vagus nerve stimulation was associated with a pronounced increase in cortical inhibition without an observed effect on cortical excitability [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/24\">",
"       24",
"      </a>",
"      ]. This finding is consistent with enhanced GABA-A cortical activity. In another small case series, a therapeutic response to VNS was associated with normalized, ie, increased, GABA receptor density [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/25\">",
"       25",
"      </a>",
"      ]. GABA-mediated neuronal inhibition is a therapeutic mechanism that also underlies several antiepileptic drugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H13#H13\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Drugs that affect GABA activity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The electrophysiological effects of VNS are not well characterized. Studies of interictal electroencephalogram (EEG) background rhythms in patients with VNS have had mixed results in regard to whether VNS is associated with a reduction in interictal epileptiform discharges in epileptic patients, and whether this change is associated with a therapeutic response to VNS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/26-29\">",
"       26-29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of neuroimaging studies have attempted to define which central structures are integral to VNS effect. Positron-emission tomography (PET) and single photon emission computed tomography (SPECT) studies have variably demonstrated regional areas of increased blood flow in the thalamus and temporal cortex with VNS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/30-36\">",
"       30-36",
"      </a>",
"      ]. Correlations between the extent of these changes in blood flow, particularly in the thalamus, and reductions in seizure frequency are also reported, although not consistently [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/32,34,35\">",
"       32,34,35",
"      </a>",
"      ]. Functional magnetic resonance imaging (fMRI) is a more sensitive test than SPECT and PET for evaluating neural activity. Diffuse activation in multiple cortical and limbic regions, as well as the thalamus, have been seen in patients treated with VNS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/36-40\">",
"       36-40",
"      </a>",
"      ]. Regional activation varies with the pulse width of VNS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/37\">",
"       37",
"      </a>",
"      ]. In one study, thalamic activation appeared important to the antiepileptic effect of VNS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first case series of patients treated with vagus nerve stimulation (VNS) was reported in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/41\">",
"     41",
"    </a>",
"    ]. This was followed by two large pivotal trials of VNS in patients with partial epilepsy, the E03 study [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/42-45\">",
"     42-45",
"    </a>",
"    ] and the E05 study [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Partial-onset seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The E03 and E05 studies were multicenter, blinded, randomized trials that compared two different VNS stimulation protocols for partial-onset seizures: active treatment or high stimulation (30 Hz, 30 seconds on, five minutes off, 500 microseconds pulse width) and an active control, low stimulation (1 Hz, 30 seconds on, 90 to 180 minutes off, 130 microseconds pulse width) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. Enrolled patients were at least 12 years of age with at least six seizures per month. Patients were treated with a mean of 2.1 antiepileptic drugs (AEDs) at study entry; these were not adjusted during the study period. The primary efficacy measure was the percentage change in seizure frequency during VNS treatment (measured over 12 weeks, two weeks after implantation) compared with a 12-week preimplantation baseline.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the E03 study, 114 patients with predominantly partial seizures were enrolled [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/45\">",
"       45",
"      </a>",
"      ]. The high-stimulation group experienced a greater mean reduction in seizure frequency compared with the low-stimulation group (24.5 versus 6.1 percent). More patients in the high-stimulation group experienced a greater than 50 percent reduction in seizures (31 versus 13 percent).",
"     </li>",
"     <li>",
"      In the E05 study, 199 patients with complex partial or secondarily generalized seizures were enrolled [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/46\">",
"       46",
"      </a>",
"      ]. The mean reduction in seizure frequency was greater in the high-stimulation group (28 versus 15 percent). A greater than 75 percent reduction in seizures was achieved in more patients in the high-stimulation group (11 versus 2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients in both studies, as well as 124 other patients who received VNS on a compassionate-use basis, were followed for an additional 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. All patients received high-stimulation VNS. Median seizure reductions compared with baseline appeared even greater than in the controlled portion of the study: 34 percent at three months and 45 percent at 12 months. At 12 months, 20 percent of patients achieved seizure reduction of greater than 75 percent. These and other open-label studies suggest that the efficacy of VNS may improve over time [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/50-56\">",
"     50-56",
"    </a>",
"    ]. However, these results should be interpreted with some caution; there were no control groups in these studies, and AED adjustments, permitted during in at least some of these observational studies, may have contributed to improved seizure control.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In addition to these randomized controlled clinical trials, multiple large case series have reported responder rates (&gt;50 percent reduction of seizures) of 50 to 64 percent in patients implanted with VNS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/53,57-60\">",
"       53,57-60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other seizure types and patient populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two large randomized studies were conducted in patients over 12 years in age, leading to the FDA approval in this age group. Although there are limited randomized studies in other age groups or seizure types, there are many published open case reports and uncontrolled studies that suggest that the benefits of VNS may extend to a broad range of patients in regard to age, neurologic comorbidity, epilepsy syndrome, and seizure type [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children - One randomized study and multiple observational studies have studied the efficacy and tolerability of VNS in children.",
"      <br/>",
"      <br/>",
"      In the only randomized study to date, 41 patients (mean age 11 years, range 3 to 17 years), most with intractable localization-related epilepsy, were randomized to high-output stimulation versus low-output (control) stimulation and followed for 20 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/61\">",
"       61",
"      </a>",
"      ]. At the end of the blinded randomized treatment phase, there was no difference in the number of patients achieving 50 percent or greater reduction in seizure frequency (16 percent in the high-stimulation group versus 21 percent in the low-stimulation group). After a 19-week unblinded add-on phase during which 34 children all received high-output stimulation, 26 percent of patients achieved a 50 percent or greater reduction in seizure frequency and 94 percent of parents or guardians reported positive qualitative effects of treatment.",
"      <br/>",
"      <br/>",
"      These results contrast with many prior observational studies that suggested that VNS was similarly effective in children compared with adolescents and adults [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/57,62-66\">",
"       57,62-66",
"      </a>",
"      ]. There are several possible explanations for this discrepancy. Some have suggested that the randomized study was under-powered or too short to see the full impact of VNS, since data in adults suggest that improvement may only be seen after a year or longer of stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/67\">",
"       67",
"      </a>",
"      ]. Alternatively, differences in electrophysiology and incomplete maturation of the vagus nerve in children compared to adults could impact the effectiveness of stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/29\">",
"       29",
"      </a>",
"      ]. In other reports, VNS has been used with success in children as young as 11 months.",
"     </li>",
"     <li>",
"      Elderly &mdash; Experience with VNS in elderly patients with epilepsy is limited. The subset of 45 patients in the EO3 and EO5 studies who were 50 years of age or older experienced a benefit similar to the population as a whole [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/68\">",
"       68",
"      </a>",
"      ]. However, only eight of these patients were older than 60 years, and it is doubtful that this can be considered an elderly population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17512?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment of seizures and epilepsy in the elderly patient\", section on 'Vagal nerve stimulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epilepsy syndromes &mdash; Case series suggest that VNS is also effective in generalized epilepsy syndromes [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/54,57,58,64,65,69\">",
"       54,57,58,64,65,69",
"      </a>",
"      ]. While some studies found that symptomatic generalized epilepsy is more responsive to VNS than idiopathic syndromes, others have reported the opposite or found no difference [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/54,69-71\">",
"       54,69-71",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A relatively large accumulation of clinical experience with VNS in the Lennox Gastaut syndrome is due in part to the fact that seizures are often medically intractable, and surgical treatment options are limited [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/64,70-80\">",
"       64,70-80",
"      </a>",
"      ]. VNS appears to be particularly effective in this patient group, leading to a greater than 50 percent reduction in seizure frequency, shortened seizure duration, and reduced number of AEDs prescribed [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/80\">",
"       80",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other refractory epilepsies with onset in childhood also appear to respond to VNS in uncontrolled case series; these include epileptic encephalopathies (eg, Landau Kleffner syndrome, severe myoclonic epilepsy of infancy, Dravet syndrome), tuberous sclerosis complex, and typical absence epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/54,63,64,69-76,81-85\">",
"       54,63,64,69-76,81-85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Previous epilepsy surgery &mdash; VNS treatment has been reported to be successful in patients with previous epilepsy surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/53,63,64,70,86,87\">",
"       53,63,64,70,86,87",
"      </a>",
"      ]. The cumulative experience in this group, as documented in the VNS registry, was reported in 2004 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/88\">",
"       88",
"      </a>",
"      ]. The response was favorable but somewhat less so in the 591 surgical patients compared with the 2382 nonsurgical patients; median reduction in seizure frequencies at 3 and 12 months were 42.5 versus 47 percent and 46 versus 60 percent. While some case series have suggested that the outcomes with VNS may be more favorable in the post-callosotomy group, the VNS registry data suggest that at 12 months, response rates are similar in these two groups.",
"     </li>",
"     <li>",
"      On-demand stimulation &mdash; On-demand stimulation with the supplied magnet can be an effective adjunct to chronic stimulation for attenuating or interrupting seizures in some patients who experience auras [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/62\">",
"       62",
"      </a>",
"      ]. In the E03 study, patients receiving high-stimulation (active) treatment also received an active magnet, while patients in the control group received an inactive magnet. Use of the active magnet terminated more seizures than the inactive magnet (21.3 versus 11.9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/89\">",
"       89",
"      </a>",
"      ]. Similar efficacy was seen in the E04 study. The effect of the magnet on reducing seizure severity or duration was similar in both groups. One case series in children reported that 19 of the 27 patients were able to abort or attenuate at least some of their seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/65\">",
"       65",
"      </a>",
"      ]. A similar percentage of patients in the E04 study reported that they were able to terminate seizures with the magnet [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Status epilepticus &mdash; In at least two cases, one adult and one child, VNS apparently terminated prolonged, medically-refractory status epilepticus [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/90,91\">",
"       90,91",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nonseizure outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality of life measures improve in most studies of VNS in both children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/63-65,79,92-96\">",
"     63-65,79,92-96",
"    </a>",
"    ]. While this effect is greatest in those who achieve the highest reduction in seizures, there appears to be an effect that is independent of reduction in seizure frequency, and may relate to independent effects of VNS on mood, alertness, and other factors. As with seizure reduction, improvement in quality of life measures also appear to increase over time.",
"   </p>",
"   <p>",
"    Evidence indicating that VNS may improve mood and other depressive symptoms in patients with epilepsy is inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. In some but not all studies, a positive effect of VNS on mood appeared to correlate with reduction in seizures. VNS is under investigation as a treatment for major depression in nonepileptic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of resistant depression in adults\", section on 'Vagus nerve stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VNS may improve daytime alertness and vigilance and reduce daytime sleepiness despite its potential to exacerbate sleep apnea (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Other adverse effects'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/75,93,100,101\">",
"     75,93,100,101",
"    </a>",
"    ]. In one series, this was documented by longer mean sleep latency times and improved scores on a daytime sleepiness scale. Improved alertness occurred even in patients without significant reduction in seizure frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/101\">",
"     101",
"    </a>",
"    ]. Vagal stimulation of brainstem centers known to promote alertness (eg, parabrachial nucleus, locus ceruleus) may mediate this effect. There appears to be a differential effect of high versus low-intensity stimulus on sleep and alertness. Low-intensity stimulation (&lt;1.5 mA) more consistently improves daytime alertness than higher intensity stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/93,101\">",
"     93,101",
"    </a>",
"    ]. In one study, higher intensity stimulation was associated with reduced REM sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with autism and mental retardation have demonstrated improved behavioral outcomes with VNS treatment of their epilepsy. Benefits included improved alertness, mental age, and performance on functional measures and some cognitive tests, as well as reduced autistic behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/63,71,77,81,83,92,102\">",
"     63,71,77,81,83,92,102",
"    </a>",
"    ]. In some cases, these improvements appeared to be independent of seizure control. In adult patients, cognition does not appear to be positively or negatively affected by VNS treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduction of AEDs can be of primary benefit to patients and may also impact the quality of life outcomes discussed above. In most cases, patients with VNS continue to require medical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/105\">",
"     105",
"    </a>",
"    ]. However, some patients are able to reduce one or more drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    doses, and a few patients are seizure free with VNS and no AED treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/69,106\">",
"     69,106",
"    </a>",
"    ]. There is limited information regarding the frequency of this outcome. Larger series indicate that most patients remain on the same number of AEDs after VNS, but don't specifically discuss dose alterations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/55,63,105\">",
"     55,63,105",
"    </a>",
"    ]. Smaller case series report higher percentages of AED dose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drug reductions, perhaps reflecting a more aggressive effort of the clinicians involved in achieving this goal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SAFETY AND TOLERABILITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Common side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the E03 study, side effects that occurred in at least 5 percent of patients receiving high-stimulation vagus nerve stimulation (VNS) were [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hoarseness (37 percent)",
"     </li>",
"     <li>",
"      Throat pain (11 percent)",
"     </li>",
"     <li>",
"      Coughing (7 percent)",
"     </li>",
"     <li>",
"      Shortness of breath (6 percent)",
"     </li>",
"     <li>",
"      Tingling (6 percent)",
"     </li>",
"     <li>",
"      Muscle pain (6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hoarseness was the only side effect that occurred significantly more often with high stimulation than with low stimulation. In the E05 study, shortness of breath and pharyngitis, as well as voice alteration, occurred significantly more often in the high-stimulation group than in the low-stimulation group [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/46\">",
"     46",
"    </a>",
"    ]. Lowering the pulse width of stimulation can alleviate symptoms and allow for higher stimulation intensities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/107\">",
"     107",
"    </a>",
"    ]. Lowering the frequency can also attenuate side effects related to VNS stimulation.",
"   </p>",
"   <p>",
"    Long-term studies of vagus nerve stimulation (VNS) generally show improved tolerability over time [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/55\">",
"     55",
"    </a>",
"    ]. Among 444 patients who continued VNS after participating in a clinical study, the most commonly reported side effects at the end of the first year post-implantation were voice alteration (29 percent), tingling (12 percent), dyspnea (8 percent), and cough (8 percent); at the end of two years, the prevalence of these complaints was 19, 4, 3, and 6 percent, and at three years, each of these was present in less than 3 percent. High retention rates (&gt;70 percent) may be an indicator of how well VNS is tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cardiac events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic studies have generally found no clinically relevant effects of chronic VNS on cardiorespiratory function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/108-110\">",
"     108-110",
"    </a>",
"    ]. However, bradycardia followed by transient asystole lasting up to 45 seconds has been reported in association with the lead test conducted during VNS implantation (the initial lead test, which is performed in the operating room when the VNS is being implanted for the first time) in approximately 0.1 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/111-113\">",
"     111-113",
"    </a>",
"    ]. Complete heart block due to atrioventricular nodal block was documented in three patients with no reported adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/114\">",
"     114",
"    </a>",
"    ]. In some cases, a rechallenge stimulus is uneventful, and the VNS has been implanted successfully without adverse consequences. More often, the procedure is aborted. In general, baseline cardiac conduction disorders are considered a contraindication to VNS.",
"   </p>",
"   <p>",
"    Two case reports describe VNS-induced episodes of bradycardia and asystole occurring 2 and 9 years after device implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/115,116\">",
"     115,116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither sudden death nor overall mortality rates appear to be increased in patients receiving VNS. Rates of sudden unexplained death in epilepsy (SUDEP) were similar among a cohort of 1819 individuals with VNS to that of other cohorts of patients with medically refractory epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of any implanted pacemaker is widely regarded as a contraindication to magnetic resonance imaging (MRI). Potential problems include considerable heating at the lead tip, which has been documented in animal experiments, and programming changes of pacing parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/118\">",
"     118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=see_link&amp;anchor=H19#H19\">",
"     \"Principles of magnetic resonance imaging\", section on 'Precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The VNS manufacturer's (Cyberonics, Inc) guidelines state that brain MRI operating at &lt;2 Tesla and a specific absorption rate of &lt;1.3",
"    <span class=\"nowrap\">",
"     W/kg,",
"    </span>",
"    conducted with a send and receive head coil, with the VNS turned off is safe [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/119,120\">",
"     119,120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In October 2011, new guidelines regarding the use of VNS when operating a 3 Tesla (T) MRI were published. These guidelines are helpful not only for brain (head) MRI, but also provide help when a body or extremity MRI might be needed. For",
"    <span class=\"nowrap\">",
"     head/brain",
"    </span>",
"    MRIs, all cylindrical MRI scanners (not just General Electric) with magnetic field strengths of 3.0 and 1.5- Tesla are safe with VNS. When performing the",
"    <span class=\"nowrap\">",
"     head/brain",
"    </span>",
"    MRI, the head coil must be transmit and receive type. When an extremity MRI is needed,",
"    <span class=\"nowrap\">",
"     transmit/receive",
"    </span>",
"    RF coils must also be used. The area of the body which cannot be imaged with MRI is between C7 and T8; this is the region where the VNS generator is placed subcutaneously in most individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An ex vivo study of temperature changes associated with different MRI conditions found no clinically significant temperature changes under the guidelines outlined by the manufacturer [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/120\">",
"       120",
"      </a>",
"      ]. Excessive heating was observed with the use of body coil during imaging of the neck and shoulder but not of the lumbar spine; however, the number of experiments in the latter case was limited. VNS device function was not affected by the MRI procedure.",
"     </li>",
"     <li>",
"      A survey reviewing the experience of 27 MRI scans in 25 patients with VNS revealed no significant complications [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/119\">",
"       119",
"      </a>",
"      ]. Most, not all, were conducted under guidelines; one body coil was used; three were conducted with the stimulator on. The investigators concluded that the guidelines as written by the manufacturer are associated with safe performance of MRI.",
"     </li>",
"     <li>",
"      A functional magnetic resonance imaging (fMRI) study at 1.5T in four patients showed that Echo-planar MRI (EPI) scanning could be performed safely in epilepsy patients with an implanted vagus nerve stimulator [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the paucity of safety data, use of MRI outside the limits outlined by the manufacturer cannot be considered safe and is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     End of battery life",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the VNS generator battery is expended, seizure frequency may increase in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. Others may note decreased or irregular perception of stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/123\">",
"     123",
"    </a>",
"    ]. Fortunately, the end of battery service can be predicted with the current VNS model, allowing for elective generator replacement before the battery is fully depleted. A reason for re-implanting a new battery before the old one is depleted is that a small number of patients who initially responded to VNS reportedly did not regain seizure control with VNS re-implant after a period of seizure-worsening associated with an expended battery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/122\">",
"     122",
"    </a>",
"    ]. As a result of these cases, it is generally agreed that patients who experience efficacy with VNS should have the generator battery replaced before it is expended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical complications associated with VNS are infrequent. Early reports of electrode failure and lead fracture appear to be largely resolved with improvements in the device and enhancements in surgical techniques and postoperative care [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/124-127\">",
"     124-127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection of the subcutaneous pocket that holds the VNS generator, usually with Staphylococcus aureus, complicates surgery in 3 to 7 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/57,128-130\">",
"       57,128-130",
"      </a>",
"      ]. Systemic antibiotics along with explantation of the device",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      open wound debridement is usually required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=see_link\">",
"       \"Infections involving cardiac implantable electronic devices\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are some reports that children with severe mental and motor retardation on assisted feeding may aspirate. This seems to occur if the child is fed during the time that the VNS is delivering its programmed stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/64,126,131,132\">",
"       64,126,131,132",
"      </a>",
"      ]. However, the association between aspiration and VNS has been disputed [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/131\">",
"       131",
"      </a>",
"      ]. Saying this, there are reports that using the magnet to inactivate the VNS during meal time controls this problem.",
"     </li>",
"     <li>",
"      Sleep apnea is a relative contraindication for VNS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/133-135\">",
"       133-135",
"      </a>",
"      ]. VNS is associated with more frequent apnea and hypopnea episodes in sleep, but this appears clinically relevant only in those with preexisting sleep apnea. Lowering stimulus frequency can ameliorate VNS-related apnea and hypopnea [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/134\">",
"       134",
"      </a>",
"      ]. Continuous positive airway pressure (CPAP) may be required for some cases [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/135\">",
"       135",
"      </a>",
"      ]. Botulinum toxin was reported to be helpful in one case of VNS-induced laryngospasm [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Unilateral vocal cord paralysis occurs in about 1 percent of cases, and is attributed to intraoperative manipulation of the recurrent laryngeal nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/45,57,58\">",
"       45,57,58",
"      </a>",
"      ]. Most of these recover. Two cases of delayed permanent vocal cord paralysis occurring several weeks after implantation appeared to be self-inflicted by patients who manipulated the device externally, presumably placing traction on the recurrent laryngeal nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/137\">",
"       137",
"      </a>",
"      ]. This phenomenon appears analogous to the \"twiddler's syndrome\" described in individuals with cardiac pacemakers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link&amp;anchor=H14#H14\">",
"       \"Implantable cardioverter-defibrillators: Complications\", section on 'Twiddler's syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other cranial nerve palsies that can complicate VNS implant include Horner's syndrome and facial paralysis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/138\">",
"       138",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pneumothorax has been described in at least one patient [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients experience uncomfortable spasm of the left chest wall, which has been demonstrated to be due to collateral spread of stimulation to phrenic nerve, causing contraction of the left hemidiaphragm [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/139\">",
"       139",
"      </a>",
"      ]. Contraction of the left anterior sternocleidomastoid muscle may also occur as a result of current stimulating adjacent structures [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/140\">",
"       140",
"      </a>",
"      ]. These symptoms are often precipitated by assumption of certain postures or movement and are relieved by changing position.",
"     </li>",
"     <li>",
"      While gastrointestinal side effects might be expected with VNS, reports of this are infrequent. One patient experienced chronic diarrhea after VNS implant, but this is exceptional [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/141\">",
"       141",
"      </a>",
"      ]. One case series documented clinically significant weight loss in 17 of 27 patients who had received VNS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/142\">",
"       142",
"      </a>",
"      ]. This observation requires further confirmation.",
"     </li>",
"     <li>",
"      Forced normalization refers to a phenomenon of psychiatric disturbances that emerge in some patients with long-standing, high-frequency seizures when their seizures are dramatically reduced. This has been described with VNS, usually with reduction in seizure frequency of greater than 75 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/143,144\">",
"       143,144",
"      </a>",
"      ]. Some, but not all, of these patients exhibited psychiatric symptoms, including psychosis prior to VNS implantation. Psychosis in these cases usually responds to psychotropic medication; in some cases lowering the potency of antiepileptic treatment is required.",
"     </li>",
"     <li>",
"      Patients are cautioned by the manufacturer not to undergo short-wave, microwave, or therapeutic ultrasound diathermy, which in theory could cause the VNS generator or lead to heat up and cause thermal tissue damage. There are no documented cases of this complication in VNS-treated patients.",
"     </li>",
"     <li>",
"      There are reports that programmable shunt valves can be affected by use of the magnet [",
"      <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/145\">",
"       145",
"      </a>",
"      ]. VNS stimulation using the magnet should probably be avoided in individuals with programmable shunts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Food and Drug Administration (FDA) has approved vagus nerve stimulator (VNS) therapy as adjunctive treatment for adults and adolescents over 12 years of age whose partial-onset seizures were refractory to antiepileptic drugs. Since the approval of VNS therapy for epilepsy, clinicians have actively debated its role [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/146-149\">",
"     146-149",
"    </a>",
"    ]. While further controlled studies are needed to more fully understand the safety, tolerability, and efficacy profile of VNS in children and in patients with generalized seizures, VNS is often used in these cases as well.",
"   </p>",
"   <p>",
"    In general, VNS is considered a valid treatment option for patients with well-documented medically-refractory seizures, who are either opposed to intracranial surgery, are not candidates, or whose medically-refractory seizures were not substantially improved by prior intracranial epilepsy surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/52,87,88\">",
"     52,87,88",
"    </a>",
"    ]. Resective surgery for appropriate candidates is preferred over VNS because of the substantially greater potential for complete seizure remission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=see_link\">",
"     \"Surgical therapy of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2890?source=see_link\">",
"     \"Evaluation and management of drug-resistant epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial cost of VNS implantation is high ($15,000 to $25,000), however, economic analyses suggest that VNS reduces doctors visits, hospitalizations, and other epilepsy-related direct medical care costs when these are averaged over the lifespan of the generator [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/147,150-152\">",
"     147,150-152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identification of factors that accurately predict a clinical response to VNS has been elusive [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/53,57,153,154\">",
"     53,57,153,154",
"    </a>",
"    ]. While some studies have suggested that VNS may be more efficacious in individuals who have had refractory seizures for a shorter duration, other studies find rather that seizures with an onset later in age (greater than one year) have a better response to VNS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/63,65,69\">",
"     63,65,69",
"    </a>",
"    ]. Earlier age of epilepsy onset is also a predictor of medical intractability [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/155\">",
"     155",
"    </a>",
"    ]. Further studies are needed to identify predictive factors associated with a response to VNS.",
"   </p>",
"   <p>",
"    Typical initiation stimulation parameters are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef59936 \" href=\"UTD.htm?4/38/4716\">",
"     table 1",
"    </a>",
"    ). These are then adjusted over outpatient follow-up to maximize efficacy and minimize side effects. More research is needed to determine whether any initiation stimulation settings provide more benefit than standard initial settings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/7/19578/abstract/27,156\">",
"     27,156",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the role of vagus nerve stimulation (VNS) in the management of epilepsy is debated, it is a valid treatment option for patients with medically refractory epilepsy who are not candidates for, or whose seizures persist after, resective epilepsy surgery. VNS is effective, safe, and well-tolerated in patients with long-standing, refractory partial-onset seizures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical evaluation is recommended for patients with refractory partial-onset seizures (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Eligible patients with medically refractory epilepsy are more likely to achieve seizure remission with epilepsy surgery than with other treatment modalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2890?source=see_link&amp;anchor=H15#H15\">",
"       \"Evaluation and management of drug-resistant epilepsy\", section on 'Treatment options'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Controlled trials in individuals greater than 12 years of age with partial-onset epilepsy indicate that 30 to 40 percent achieve a greater than 50 percent reduction in seizure frequency. Open-label studies suggest that these benefits may increase over time and adjustment of parameter settings. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Partial-onset seizures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are conflicting data on the efficacy of VNS in children. A small randomized study found no benefit of VNS compared with low-stimulation control in patients 3 to 17 years in age. Other open-label studies suggest that younger children and individuals with other seizure types and epilepsy syndromes might benefit from VNS. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Other seizure types and patient populations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Side effects that occur during stimulation in a minority of patients are usually mild to moderate in severity and diminish with time or reduction in stimulation intensity. These include voice alteration and tingling. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Common side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious adverse events are rare and include infections, cardiac arrhythmias, and aspiration. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cardiac events'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Other adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) in patients with VNS is limited to brain MRI under specific conditions outlined by the manufacturer. Diathermy is also contraindicated in patients with VNS. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Other adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/1\">",
"      Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/2\">",
"      Henry TR. Therapeutic mechanisms of vagus nerve stimulation. Neurology 2002; 59:S3.",
"     </a>",
"    </li>",
"    <li>",
"     Saper, CB. The central autonomic system. In: The Rat Nervous System, 2nd ed, Paxinos, G (Ed), Academic Press, San Diego 1995. p.107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/4\">",
"      Cechetto DF, Saper CB. Evidence for a viscerotopic sensory representation in the cortex and thalamus in the rat. J Comp Neurol 1987; 262:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/5\">",
"      Naritoku DK, Terry WJ, Helfert RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. Epilepsy Res 1995; 22:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/6\">",
"      Krahl SE, Clark KB, Smith DC, Browning RA. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia 1998; 39:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/7\">",
"      Saper CB, Kibbe MR, Hurley KM, et al. Brain natriuretic peptide-like immunoreactive innervation of the cardiovascular and cerebrovascular systems in the rat. Circ Res 1990; 67:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/8\">",
"      McGregor A, Wheless J, Baumgartner J, Bettis D. Right-sided vagus nerve stimulation as a treatment for refractory epilepsy in humans. Epilepsia 2005; 46:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/9\">",
"      Krahl SE, Senanayake SS, Handforth A. Right-sided vagus nerve stimulation reduces generalized seizure severity in rats as effectively as left-sided. Epilepsy Res 2003; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/10\">",
"      Stefan H, Kreiselmeyer G, Kerling F, et al. Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: a proof of concept trial. Epilepsia 2012; 53:e115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/11\">",
"      Chase MH, Sterman MB, Clemente CD. Cortical and subcortical patterns of response to afferent vagal stimulation. Exp Neurol 1966; 16:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/12\">",
"      Chase MH, Nakamura Y, Clemente CD, Sterman MB. Afferent vagal stimulation: neurographic correlates of induced EEG synchronization and desynchronization. Brain Res 1967; 5:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/13\">",
"      Chase, MH, Nakamura, Y, Clemente, CD, Sterman, MB. Cortical and subcortical EEG patterns of response to afferent abdominal vagal stimulation: neurographic correlates. Physiol Behav 1968; 3:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/14\">",
"      McLachlan RS. Suppression of interictal spikes and seizures by stimulation of the vagus nerve. Epilepsia 1993; 34:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/15\">",
"      Woodbury DM, Woodbury JW. Effects of vagal stimulation on experimentally induced seizures in rats. Epilepsia 1990; 31 Suppl 2:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/16\">",
"      Woodbury JW, Woodbury DM. Vagal stimulation reduces the severity of maximal electroshock seizures in intact rats: use of a cuff electrode for stimulating and recording. Pacing Clin Electrophysiol 1991; 14:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/17\">",
"      Zabara J. Inhibition of experimental seizures in canines by repetitive vagal stimulation. Epilepsia 1992; 33:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/18\">",
"      Lockard JS, Congdon WC, DuCharme LL. Feasibility and safety of vagal stimulation in monkey model. Epilepsia 1990; 31 Suppl 2:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/19\">",
"      Takaya M, Terry WJ, Naritoku DK. Vagus nerve stimulation induces a sustained anticonvulsant effect. Epilepsia 1996; 37:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/20\">",
"      Fern&aacute;ndez-Guardiola A, Mart&iacute;nez A, Vald&eacute;s-Cruz A, et al. Vagus nerve prolonged stimulation in cats: effects on epileptogenesis (amygdala electrical kindling): behavioral and electrographic changes. Epilepsia 1999; 40:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/21\">",
"      Magdaleno-Madrigal VM, Vald&eacute;s-Cruz A, Mart&iacute;nez-Vargas D, et al. Effect of electrical stimulation of the nucleus of the solitary tract on the development of electrical amygdaloid kindling in the cat. Epilepsia 2002; 43:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/22\">",
"      Zagon A, Kemeny AA. Slow hyperpolarization in cortical neurons: a possible mechanism behind vagus nerve simulation therapy for refractory epilepsy? Epilepsia 2000; 41:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/23\">",
"      Krahl SE, Senanayake SS, Handforth A. Destruction of peripheral C-fibers does not alter subsequent vagus nerve stimulation-induced seizure suppression in rats. Epilepsia 2001; 42:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/24\">",
"      Di Lazzaro V, Oliviero A, Pilato F, et al. Effects of vagus nerve stimulation on cortical excitability in epileptic patients. Neurology 2004; 62:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/25\">",
"      Marrosu F, Serra A, Maleci A, et al. Correlation between GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy. Epilepsy Res 2003; 55:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/26\">",
"      Ebus SC, Majoie HJ, Arends JB, Boon PJ. Can spikes predict seizure frequency? Results of a pilot study in severe childhood epilepsies treated with vagus nerve stimulation. Seizure 2004; 13:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/27\">",
"      Kuba R, Guzaninov&aacute; M, Br&aacute;zdil M, et al. Effect of vagal nerve stimulation on interictal epileptiform discharges: a scalp EEG study. Epilepsia 2002; 43:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/28\">",
"      Olejniczak PW, Fisch BJ, Carey M, et al. The effect of vagus nerve stimulation on epileptiform activity recorded from hippocampal depth electrodes. Epilepsia 2001; 42:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/29\">",
"      Koo B. EEG changes with vagus nerve stimulation. J Clin Neurophysiol 2001; 18:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/30\">",
"      Garnett ES, Nahmias C, Scheffel A, et al. Regional cerebral blood flow in man manipulated by direct vagal stimulation. Pacing Clin Electrophysiol 1992; 15:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/31\">",
"      Ko D, Heck C, Grafton S, et al. Vagus nerve stimulation activates central nervous system structures in epileptic patients during PET H2(15)O blood flow imaging. Neurosurgery 1996; 39:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/32\">",
"      Henry TR, Votaw JR, Pennell PB, et al. Acute blood flow changes and efficacy of vagus nerve stimulation in partial epilepsy. Neurology 1999; 52:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/33\">",
"      Ring HA, White S, Costa DC, et al. A SPECT study of the effect of vagal nerve stimulation on thalamic activity in patients with epilepsy. Seizure 2000; 9:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/34\">",
"      Van Laere K, Vonck K, Boon P, et al. Perfusion SPECT changes after acute and chronic vagus nerve stimulation in relation to prestimulus condition and long-term clinical efficacy. J Nucl Med 2002; 43:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/35\">",
"      Vonck K, Boon P, Van Laere K, et al. Acute single photon emission computed tomographic study of vagus nerve stimulation in refractory epilepsy. Epilepsia 2000; 41:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/36\">",
"      Bohning DE, Lomarev MP, Denslow S, et al. Feasibility of vagus nerve stimulation-synchronized blood oxygenation level-dependent functional MRI. Invest Radiol 2001; 36:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/37\">",
"      Mu Q, Bohning DE, Nahas Z, et al. Acute vagus nerve stimulation using different pulse widths produces varying brain effects. Biol Psychiatry 2004; 55:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/38\">",
"      Sucholeiki R, Alsaadi TM, Morris GL 3rd, et al. fMRI in patients implanted with a vagal nerve stimulator. Seizure 2002; 11:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/39\">",
"      Narayanan JT, Watts R, Haddad N, et al. Cerebral activation during vagus nerve stimulation: a functional MR study. Epilepsia 2002; 43:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/40\">",
"      Liu WC, Mosier K, Kalnin AJ, Marks D. BOLD fMRI activation induced by vagus nerve stimulation in seizure patients. J Neurol Neurosurg Psychiatry 2003; 74:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/41\">",
"      Penry JK, Dean JC. Prevention of intractable partial seizures by intermittent vagal stimulation in humans: preliminary results. Epilepsia 1990; 31 Suppl 2:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/42\">",
"      Ben-Menachem E, Ma&ntilde;on-Espaillat R, Ristanovic R, et al. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group. Epilepsia 1994; 35:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/43\">",
"      Ramsay RE, Uthman BM, Augustinsson LE, et al. Vagus nerve stimulation for treatment of partial seizures: 2. Safety, side effects, and tolerability. First International Vagus Nerve Stimulation Study Group. Epilepsia 1994; 35:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/44\">",
"      George R, Salinsky M, Kuzniecky R, et al. Vagus nerve stimulation for treatment of partial seizures: 3. Long-term follow-up on first 67 patients exiting a controlled study. First International Vagus Nerve Stimulation Study Group. Epilepsia 1994; 35:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/45\">",
"      A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group. Neurology 1995; 45:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/46\">",
"      Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 1998; 51:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/47\">",
"      Michael JE, Wegener K, Barnes DW. Vagus nerve stimulation for intractable seizures: one year follow-up. J Neurosci Nurs 1993; 25:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/48\">",
"      Salinsky MC, Uthman BM, Ristanovic RK, et al. Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial. Vagus Nerve Stimulation Study Group. Arch Neurol 1996; 53:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/49\">",
"      DeGiorgio CM, Schachter SC, Handforth A, et al. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia 2000; 41:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/50\">",
"      Uthman BM, Reichl AM, Dean JC, et al. Effectiveness of vagus nerve stimulation in epilepsy patients: a 12-year observation. Neurology 2004; 63:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/51\">",
"      Spanaki MV, Allen LS, Mueller WM, Morris GL 3rd. Vagus nerve stimulation therapy: 5-year or greater outcome at a university-based epilepsy center. Seizure 2004; 13:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/52\">",
"      Kuba R, Br&aacute;zdil M, Nov&aacute;k Z, et al. Effect of vagal nerve stimulation on patients with bitemporal epilepsy. Eur J Neurol 2003; 10:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/53\">",
"      Labar D. Vagus nerve stimulation for 1 year in 269 patients on unchanged antiepileptic drugs. Seizure 2004; 13:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/54\">",
"      Murphy JV. Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group. J Pediatr 1999; 134:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/55\">",
"      Morris GL 3rd, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 1999; 53:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/56\">",
"      Siddiqui F, Herial NA, Ali II. Cumulative effect of vagus nerve stimulators on intractable seizures observed over a period of 3years. Epilepsy Behav 2010; 18:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/57\">",
"      Elliott RE, Morsi A, Kalhorn SP, et al. Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: long-term outcomes and predictors of response. Epilepsy Behav 2011; 20:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/58\">",
"      Vonck K, Thadani V, Gilbert K, et al. Vagus nerve stimulation for refractory epilepsy: a transatlantic experience. J Clin Neurophysiol 2004; 21:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/59\">",
"      Renfroe JB, Wheless JW. Earlier use of adjunctive vagus nerve stimulation therapy for refractory epilepsy. Neurology 2002; 59:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/60\">",
"      De Herdt V, Boon P, Ceulemans B, et al. Vagus nerve stimulation for refractory epilepsy: a Belgian multicenter study. Eur J Paediatr Neurol 2007; 11:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/61\">",
"      Klinkenberg S, Aalbers MW, Vles JS, et al. Vagus nerve stimulation in children with intractable epilepsy: a randomized controlled trial. Dev Med Child Neurol 2012; 54:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/62\">",
"      Boon P, Vonck K, Van Walleghem P, et al. Programmed and magnet-induced vagus nerve stimulation for refractory epilepsy. J Clin Neurophysiol 2001; 18:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/63\">",
"      Murphy JV, Torkelson R, Dowler I, et al. Vagal nerve stimulation in refractory epilepsy: the first 100 patients receiving vagal nerve stimulation at a pediatric epilepsy center. Arch Pediatr Adolesc Med 2003; 157:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/64\">",
"      Lundgren J, Amark P, Blennow G, et al. Vagus nerve stimulation in 16 children with refractory epilepsy. Epilepsia 1998; 39:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/65\">",
"      Patwardhan RV, Stong B, Bebin EM, et al. Efficacy of vagal nerve stimulation in children with medically refractory epilepsy. Neurosurgery 2000; 47:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/66\">",
"      Coykendall DS, Gauderer MW, Blouin RR, Morales A. Vagus nerve stimulation for the management of seizures in children: an 8-year experience. J Pediatr Surg 2010; 45:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/67\">",
"      Pressler RM. Vagus nerve stimulation in children with intractable epilepsy. Dev Med Child Neurol 2012; 54:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/68\">",
"      Sirven JI, Sperling M, Naritoku D, et al. Vagus nerve stimulation therapy for epilepsy in older adults. Neurology 2000; 54:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/69\">",
"      Labar D, Murphy J, Tecoma E. Vagus nerve stimulation for medication-resistant generalized epilepsy. E04 VNS Study Group. Neurology 1999; 52:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/70\">",
"      Ben-Menachem E, Hellstr&ouml;m K, Waldton C, Augustinsson LE. Evaluation of refractory epilepsy treated with vagus nerve stimulation for up to 5 years. Neurology 1999; 52:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/71\">",
"      Parker AP, Polkey CE, Binnie CD, et al. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics 1999; 103:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/72\">",
"      Buoni S, Zannolli R, Macucci F, et al. Delayed response of seizures with vagus nerve stimulation in Lennox-Gastaut syndrome. Neurology 2004; 63:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/73\">",
"      Helmers, SL, Al-Jayyousi, M, Madsen, J. Adjunctive treatment in Lennox-Gastaut syndrome using vagal nerve stimulation. Epilepsia 1998; 39 (Suppl 6):169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/74\">",
"      Murphy, JV, Hornig, G. Chronic intermittent stimulation of the left vagal nerve in nine children with Lennox-Gastaut syndrome. Epilepsia 1998; 39 (Suppl 6):169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/75\">",
"      Frost M, Gates J, Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia 2001; 42:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/76\">",
"      Hosain S, Nikalov B, Harden C, et al. Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. J Child Neurol 2000; 15:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/77\">",
"      Aldenkamp AP, Van de Veerdonk SH, Majoie HJ, et al. Effects of 6 months of treatment with vagus nerve stimulation on behavior in children with lennox-gastaut syndrome in an open clinical and nonrandomized study. Epilepsy Behav 2001; 2:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/78\">",
"      Parain D, Penniello MJ, Berquen P, et al. Vagal nerve stimulation in tuberous sclerosis complex patients. Pediatr Neurol 2001; 25:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/79\">",
"      Shahwan A, Bailey C, Maxiner W, Harvey AS. Vagus nerve stimulation for refractory epilepsy in children: More to VNS than seizure frequency reduction. Epilepsia 2009; 50:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/80\">",
"      Kostov K, Kostov H, Taub&oslash;ll E. Long-term vagus nerve stimulation in the treatment of Lennox-Gastaut syndrome. Epilepsy Behav 2009; 16:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/81\">",
"      Majoie HJ, Berfelo MW, Aldenkamp AP, et al. Vagus nerve stimulation in patients with catastrophic childhood epilepsy, a 2-year follow-up study. Seizure 2005; 14:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/82\">",
"      Andriola MR, Vitale SA. Vagus Nerve Stimulation in the Developmentally Disabled. Epilepsy Behav 2001; 2:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/83\">",
"      Murphy JV, Wheless JW, Schmoll CM. Left vagal nerve stimulation in six patients with hypothalamic hamartomas. Pediatr Neurol 2000; 23:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/84\">",
"      Major P, Thiele EA. Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex. Epilepsy Behav 2008; 13:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/85\">",
"      Elliott RE, Carlson C, Kalhorn SP, et al. Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery. Epilepsy Behav 2009; 16:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/86\">",
"      Hornig GW, Murphy JV, Schallert G, Tilton C. Left vagus nerve stimulation in children with refractory epilepsy: an update. South Med J 1997; 90:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/87\">",
"      Koutroumanidis M, Binnie CD, Hennessy MJ, et al. VNS in patients with previous unsuccessful resective epilepsy surgery: antiepileptic and psychotropic effects. Acta Neurol Scand 2003; 107:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/88\">",
"      Amar AP, Apuzzo ML, Liu CY. Vagus nerve stimulation therapy after failed cranial surgery for intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry. Neurosurgery 2004; 55:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/89\">",
"      Morris GL 3rd. A retrospective analysis of the effects of magnet-activated stimulation in conjunction with vagus nerve stimulation therapy. Epilepsy Behav 2003; 4:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/90\">",
"      Patwardhan RV, Dellabadia J Jr, Rashidi M, et al. Control of refractory status epilepticus precipitated by anticonvulsant withdrawal using left vagal nerve stimulation: a case report. Surg Neurol 2005; 64:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/91\">",
"      Winston KR, Levisohn P, Miller BR, Freeman J. Vagal nerve stimulation for status epilepticus. Pediatr Neurosurg 2001; 34:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/92\">",
"      Gates J, Huf R, Frost M. Vagus Nerve Stimulation for Patients in Residential Treatment Facilities. Epilepsy Behav 2001; 2:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/93\">",
"      Galli R, Bonanni E, Pizzanelli C, et al. Daytime vigilance and quality of life in epileptic patients treated with vagus nerve stimulation. Epilepsy Behav 2003; 4:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/94\">",
"      Cramer JA. Exploration of Changes in Health-Related Quality of Life after 3 Months of Vagus Nerve Stimulation. Epilepsy Behav 2001; 2:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/95\">",
"      Morrow JI, Bingham E, Craig JJ, Gray WJ. Vagal nerve stimulation in patients with refractory epilepsy. Effect on seizure frequency, severity and quality of life. Seizure 2000; 9:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/96\">",
"      Helmers SL, Wheless JW, Frost M, et al. Vagus nerve stimulation therapy in pediatric patients with refractory epilepsy: retrospective study. J Child Neurol 2001; 16:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/97\">",
"      Elger G, Hoppe C, Falkai P, et al. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res 2000; 42:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/98\">",
"      Harden CL, Pulver MC, Ravdin LD, et al. A Pilot Study of Mood in Epilepsy Patients Treated with Vagus Nerve Stimulation. Epilepsy Behav 2000; 1:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/99\">",
"      Hoppe C, Helmstaedter C, Scherrmann J, Elger CE. Self-Reported Mood Changes following 6 Months of Vagus Nerve Stimulation in Epilepsy Patients. Epilepsy Behav 2001; 2:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/100\">",
"      Rizzo P, Beelke M, De Carli F, et al. Chronic vagus nerve stimulation improves alertness and reduces rapid eye movement sleep in patients affected by refractory epilepsy. Sleep 2003; 26:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/101\">",
"      Malow BA, Edwards J, Marzec M, et al. Vagus nerve stimulation reduces daytime sleepiness in epilepsy patients. Neurology 2001; 57:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/102\">",
"      Huf RL, Mamelak A, Kneedy-Cayem K. Vagus nerve stimulation therapy: 2-year prospective open-label study of 40 subjects with refractory epilepsy and low IQ who are living in long-term care facilities. Epilepsy Behav 2005; 6:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/103\">",
"      Dodrill CB, Morris GL. Effects of Vagal Nerve Stimulation on Cognition and Quality of Life in Epilepsy. Epilepsy Behav 2001; 2:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/104\">",
"      Schachter SC. Vagus nerve stimulation: mood and cognitive effects. Epilepsy Behav 2004; 5 Suppl 1:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/105\">",
"      Labar DR. Antiepileptic drug use during the first 12 months of vagus nerve stimulation therapy: a registry study. Neurology 2002; 59:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/106\">",
"      Tatum WO, Johnson KD, Goff S, et al. Vagus nerve stimulation and drug reduction. Neurology 2001; 56:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/107\">",
"      Liporace J, Hucko D, Morrow R, et al. Vagal nerve stimulation: adjustments to reduce painful side effects. Neurology 2001; 57:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/108\">",
"      Frei MG, Osorio I. Left vagus nerve stimulation with the neurocybernetic prosthesis has complex effects on heart rate and on its variability in humans. Epilepsia 2001; 42:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/109\">",
"      Binks AP, Paydarfar D, Schachter SC, et al. High strength stimulation of the vagus nerve in awake humans: a lack of cardiorespiratory effects. Respir Physiol 2001; 127:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/110\">",
"      Galli R, Limbruno U, Pizzanelli C, et al. Analysis of RR variability in drug-resistant epilepsy patients chronically treated with vagus nerve stimulation. Auton Neurosci 2003; 107:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/111\">",
"      Asconap&eacute; JJ, Moore DD, Zipes DP, et al. Bradycardia and asystole with the use of vagus nerve stimulation for the treatment of epilepsy: a rare complication of intraoperative device testing. Epilepsia 1999; 40:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/112\">",
"      Tatum WO 4th, Moore DB, Stecker MM, et al. Ventricular asystole during vagus nerve stimulation for epilepsy in humans. Neurology 1999; 52:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/113\">",
"      Andriola, MR, Rosenzweig, T, Vlay, S. Vagus nerve stimulator (VNS): induction of asystole during implantation with subsequent successful stimulation. Epilepsia 2000; 41 (Suppl 7):223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/114\">",
"      Ali II, Pirzada NA, Kanjwal Y, et al. Complete heart block with ventricular asystole during left vagus nerve stimulation for epilepsy. Epilepsy Behav 2004; 5:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/115\">",
"      Amark P, St&ouml;dberg T, Wallstedt L. Late onset bradyarrhythmia during vagus nerve stimulation. Epilepsia 2007; 48:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/116\">",
"      Iriarte J, Urrestarazu E, Alegre M, et al. Late-onset periodic asystolia during vagus nerve stimulation. Epilepsia 2009; 50:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/117\">",
"      Annegers JF, Coan SP, Hauser WA, Leestma J. Epilepsy, vagal nerve stimulation by the NCP system, all-cause mortality, and sudden, unexpected, unexplained death. Epilepsia 2000; 41:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/118\">",
"      Luechinger R, Zeijlemaker VA, Pedersen EM, et al. In vivo heating of pacemaker leads during magnetic resonance imaging. Eur Heart J 2005; 26:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/119\">",
"      Benbadis SR, Nyhenhuis J, Tatum WO 4th, et al. MRI of the brain is safe in patients implanted with the vagus nerve stimulator. Seizure 2001; 10:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/120\">",
"      Shellock, FG, Begnaud, J, Inman, DM. Vagus Nerve Stimulation therapy system: in vitro evaluation of magnetic resonance imaging-related heating and function at 1.5 and 3 Tesla. Neuromodulation 2006; 9:204.",
"     </a>",
"    </li>",
"    <li>",
"     MRI with the VNS Therapy System, Cyberonics, 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/122\">",
"      Tatum WO 4th, Ferreira JA, Benbadis SR, et al. Vagus nerve stimulation for pharmacoresistant epilepsy: clinical symptoms with end of service. Epilepsy Behav 2004; 5:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/123\">",
"      Vonck K, Dedeurwaerdere S, De Groote L, et al. Generator replacement in epilepsy patients treated with vagus nerve stimulation. Seizure 2005; 14:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/124\">",
"      Patil A, Chand A, Andrews R. Single incision for implanting a vagal nerve stimulator system (VNSS): technical note. Surg Neurol 2001; 55:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/125\">",
"      Vaughn BV, Bernard E, Lannon S, et al. Intraoperative methods for confirmation of correct placement of the vagus nerve stimulator. Epileptic Disord 2001; 3:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/126\">",
"      Murphy JV, Hornig GW, Schallert GS, Tilton CL. Adverse events in children receiving intermittent left vagal nerve stimulation. Pediatr Neurol 1998; 19:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/127\">",
"      Schachter SC. Vagus nerve stimulation therapy summary: five years after FDA approval. Neurology 2002; 59:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/128\">",
"      Smyth MD, Tubbs RS, Bebin EM, et al. Complications of chronic vagus nerve stimulation for epilepsy in children. J Neurosurg 2003; 99:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/129\">",
"      Patel NC, Edwards MS. Vagal nerve stimulator pocket infections. Pediatr Infect Dis J 2004; 23:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/130\">",
"      Ortler M, Luef G, Kofler A, et al. Deep wound infection after vagus nerve stimulator implantation: treatment without removal of the device. Epilepsia 2001; 42:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/131\">",
"      Schallert G, Foster J, Lindquist N, Murphy JV. Chronic stimulation of the left vagal nerve in children: effect on swallowing. Epilepsia 1998; 39:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/132\">",
"      Lundgren J, Ekberg O, Olsson R. Aspiration: a potential complication to vagus nerve stimulation. Epilepsia 1998; 39:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/133\">",
"      Holmes MD, Chang M, Kapur V. Sleep apnea and excessive daytime somnolence induced by vagal nerve stimulation. Neurology 2003; 61:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/134\">",
"      Malow BA, Edwards J, Marzec M, et al. Effects of vagus nerve stimulation on respiration during sleep: a pilot study. Neurology 2000; 55:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/135\">",
"      Marzec M, Edwards J, Sagher O, et al. Effects of vagus nerve stimulation on sleep-related breathing in epilepsy patients. Epilepsia 2003; 44:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/136\">",
"      Kumar S, Sharafkhaneh A, Edmonds J, et al. Treatment of vns-induced laryngospasm with botulinum toxin. Neurology 2009; 73:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/137\">",
"      Kalkanis JG, Krishna P, Espinosa JA, Naritoku DK. Self-inflicted vocal cord paralysis in patients with vagus nerve stimulators. Report of two cases. J Neurosurg 2002; 96:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/138\">",
"      Kim W, Clancy RR, Liu GT. Horner syndrome associated with implantation of a vagus nerve stimulator. Am J Ophthalmol 2001; 131:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/139\">",
"      Leijten FS, Van Rijen PC. Stimulation of the phrenic nerve as a complication of vagus nerve pacing in a patient with epilepsy. Neurology 1998; 51:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/140\">",
"      Iriarte J, Artieda J, Alegre M, et al. Spasm of the sternocleidomastoid muscle induced by vagal nerve stimulation. Neurology 2001; 57:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/141\">",
"      Sanossian N, Haut S. Chronic diarrhea associated with vagal nerve stimulation. Neurology 2002; 58:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/142\">",
"      Burneo JG, Faught E, Knowlton R, et al. Weight loss associated with vagus nerve stimulation. Neurology 2002; 59:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/143\">",
"      Blumer D, Davies K, Alexander A, Morgan S. Major Psychiatric Disorders Subsequent to Treating Epilepsy by Vagus Nerve Stimulation. Epilepsy Behav 2001; 2:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/144\">",
"      Prater JF. Recurrent depression with vagus nerve stimulation. Am J Psychiatry 2001; 158:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/145\">",
"      Tatum WO 4th, Helmers SL. Vagus nerve stimulation and magnet use: optimizing benefits. Epilepsy Behav 2009; 15:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/146\">",
"      McLachlan RS. Vagus nerve stimulation for treatment of seizures? Arch Neurol 1998; 55:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/147\">",
"      Boon P, Vonck K, D'Have M, et al. Cost-benefit of vagus nerve stimulation for refractory epilepsy. Acta Neurol Belg 1999; 99:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/148\">",
"      Ben-Menachem E. Vagus nerve stimulation for treatment of seizures? Arch Neurol 1998; 55:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/149\">",
"      Ben-Menachem E, French JA. VNS Therapy versus the latest antiepileptic drug. Epileptic Disord 2005; 7 Suppl 1:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/150\">",
"      Boon P, D'Hav&eacute; M, Van Walleghem P, et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia 2002; 43:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/151\">",
"      Forbes RB, Macdonald S, Eljamel S, Roberts RC. Cost-utility analysis of vagus nerve stimulators for adults with medically refractory epilepsy. Seizure 2003; 12:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/152\">",
"      Ben-Menachem E, Hellstr&ouml;m K, Verstappen D. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology 2002; 59:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/153\">",
"      Tecoma ES, Iragui VJ. Vagus nerve stimulation use and effect in epilepsy: what have we learned? Epilepsy Behav 2006; 8:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/154\">",
"      Janszky J, Hoppe M, Behne F, et al. Vagus nerve stimulation: predictors of seizure freedom. J Neurol Neurosurg Psychiatry 2005; 76:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/155\">",
"      Berg AT, Levy SR, Novotny EJ, Shinnar S. Predictors of intractable epilepsy in childhood: a case-control study. Epilepsia 1996; 37:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/7/19578/abstract/156\">",
"      DeGiorgio C, Heck C, Bunch S, et al. Vagus nerve stimulation for epilepsy: randomized comparison of three stimulation paradigms. Neurology 2005; 65:317.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2229 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-0DF129FE3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19578=[""].join("\n");
var outline_f19_7_19578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND THERAPEUTIC MECHANISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Partial-onset seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other seizure types and patient populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nonseizure outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SAFETY AND TOLERABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Common side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cardiac events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      End of battery life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL APPLICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2229\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2229|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/10/12452\" title=\"figure 1\">",
"      Vagal nerve stimulator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2229|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/38/4716\" title=\"table 1\">",
"      VNS settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2890?source=related_link\">",
"      Evaluation and management of drug-resistant epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=related_link\">",
"      Principles of magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=related_link\">",
"      Surgical therapy of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17512?source=related_link\">",
"      Treatment of seizures and epilepsy in the elderly patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_7_19579="Equipment for pleural manometry";
var content_f19_7_19579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Equipment needed for pleural manometry and large volume thoracentesis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Mask, protective eyewear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterile gowns, gloves, drapes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorhexidine 2 percent, or povidone-iodine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Local anesthetic (eg, lidocaine 1 or 2 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Needles (usually 25G 1.5 inch and 21G) and syringe (3 or 5 mL) for anesthetizing the skin and subcutaneous tissues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gauze pads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracentesis catheter (10 to 12 French)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stopcock (two stopcocks if an electronic system is used in addition to a water manometer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringe for fluid removal (30 to 50 mL) with luer lock tip",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two intravenous tubing extension sets and a 22G needle to use as resistor between them",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal saline (0.9 percent) to prefill intravenous tubing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ruler or measuring tape",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drainage bag",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bandage (eg, petroleum gauze, 4x4 gauze pads, elastic tape)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19579=[""].join("\n");
var outline_f19_7_19579=null;
var title_f19_7_19580="Differential diagnosis of HF-PEF";
var content_f19_7_19580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of heart failure with preserved left ventricular ejection fraction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diastolic heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Hypertensive heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Restrictive cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Infiltrative cardiomyopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Hypertrophic cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Noncompaction cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Coronary heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Miscellaneous factors: diabetes mellitus, chronic kidney disease, aging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Valvular heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Valvular stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Valvular regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Right heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Pulmonary hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Right ventricular infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Arrhythmogenic right ventricular cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pericardial disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Cardiac tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Constrictive pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Effusive-constrictive pericardial disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intracardiac mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Atrial myxoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High-output heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Episodic or reversible LV systolic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary vein stenosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol 2006; 47:500.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19580=[""].join("\n");
var outline_f19_7_19580=null;
var title_f19_7_19581="Myths about exertional heat illness";
var content_f19_7_19581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Myths about exertional heat illness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Misconception",
"       </td>",
"       <td class=\"subtitle1\">",
"        Explanation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Athletes stop sweating when they develop exertional heat stroke (EHS)",
"       </td>",
"       <td>",
"        Since EHS occurs during intense exercise in the heat, athletes are almost always sweating profusely when they collapse. This widely held but completely",
"        <strong>",
"         inaccurate",
"        </strong>",
"        belief about EHS can delay diagnosis and is dangerous.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Athletes must be severely dehydrated to develop EHS",
"       </td>",
"       <td>",
"        While dehydration may predispose athletes to exertional heat illness and can exacerbate EHS, it is",
"        <strong>",
"         not",
"        </strong>",
"        a necessary precondition. EHS can occur in as little as 20 minutes after the beginning of exercise, before severe fluid loss has occurred. Exercise intensity and environmental conditions (ie, heat and humidity) are the primary factors associated with EHS.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Body temperature can be accurately determined using external means",
"       </td>",
"       <td>",
"        No external temperature assessment devices currently available have been proven accurate in athletes exercising in intense heat with a significant degree of hyperthermia. External temperature devices, including oral, tympanic, temporal, forehead sticker, and axillary devices, should",
"        <strong>",
"         never",
"        </strong>",
"        be used to diagnose EHS. The only device that is practical and accurate under these conditions is the rectal thermistor.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Lucid mental status in a patient with severe heat illness means everything is okay",
"       </td>",
"       <td>",
"        Many patients with impending&nbsp;EHS appear lucid initially, only to progress to more severe disease. This initial period of normal mental function can mislead the clinician and obscure or delay the diagnosis. The lucid interval often coincides with minor central nervous system (CNS) dysfunction that is difficult to recognize.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Shivering delays cooling",
"       </td>",
"       <td>",
"        Shivering does occur when a normothermic individual is placed in a cold water bath. However, this is seldom the case with hyperthermic individuals and rapid cooling occurs even in the few patients who manifest a shivering response.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        The onset of exertional heat stroke (EHS) is unpredictable",
"       </td>",
"       <td>",
"        Several predisposing factors for EHS are well documented. They include: environmental conditions (high temperature and/or high humidity), high intensity exercise, lack of acclimatization, poor physical fitness, equipment preventing heat loss, large mass to surface area ratio (eg, obesity), sleep deprivation, dehydration, and fever.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cold water immersion puts the patient at risk of drowning",
"       </td>",
"       <td>",
"        With proper precautions, there is almost no risk of drowning. Precautions include: supervising the patient at",
"        <strong>",
"         all",
"        </strong>",
"        times, obtaining adequate help from teammates and colleagues, and placing a sheet under the patient's armpits and across their chest to hold them upright and prevent their head from falling under water.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cold water immersion is unsanitary",
"       </td>",
"       <td>",
"        While unsanitary conditions may be present due to vomiting or diarrhea, an unsanitary tub is an acceptable tradeoff when providing a life-saving intervention. A dirty tub is easily cleaned.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hypothermic afterdrop (continued cooling following immersion) can occur",
"       </td>",
"       <td>",
"        Hypothermic afterdrop may be a concern if the athlete is cooled too long. However, if a proper measurement device (ie, rectal thermistor or rectal thermometer) is used, core body temperature can be closely monitored during treatment to prevent such an afterdrop.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Peripheral vasoconstriction (PVC) delays cooling",
"       </td>",
"       <td>",
"        Although PVC may occur during cold water immersion, it has little impact compared to the large conductive and convective thermal transfer that rapidly cools the body. While initially PVC may increase core body temperature slightly even in an EHS patient, a rapid decrease in body temperature immediately follows.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Ice water immersion is uncomfortable for the patient",
"       </td>",
"       <td>",
"        The physical comfort of the patient and staff is a secondary concern in the face of a life-threatening illness like EHS. No significant harm is sustained by the patient during appropriately managed ice water immersion therapy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Recommendations are adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        The Korey Stringer Institute (ksi.uconn.edu).",
"       </li>",
"       <li>",
"        Casa DJ, McDermott BM, Lee EC, et al. \"Cold-water immersion: The gold standard for exertional heat stroke treatment,\" Exercise and Sports Science Reviews 2007; 35:141.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19581=[""].join("\n");
var outline_f19_7_19581=null;
var title_f19_7_19582="HD survival initial nutrition";
var content_f19_7_19582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Mortality risk in hemodialysis patients according to plasma albumin and creatinine concentrations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relative mortality risk in new patients begun on maintenance hemodialysis in 1986-1987 according to the plasma albumin (left) and creatinine (right) concentrations. The mortality risk varied inversely with both parameters. Asterisks refer to values that are significantly different from the reference ranges of 3.6 to 4.0 g/dL (36 to 40 g/L) for albumin and 10 to 11.9 mg/dL [884 to 1052 &micro;mol/L]) for creatinine. Lower albumin and creatinine levels presumably reflect the negative impact of malnutrition on patient survival.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from United States Renal Data Systems, Am J Kidney Dis 1992; 20(Suppl 2):32.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19582=[""].join("\n");
var outline_f19_7_19582=null;
var title_f19_7_19583="Smith Lemli Opitz genitalia";
var content_f19_7_19583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Smith-Lemli-Opitz Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immature, ambiguous genitalia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark DA. Atlas of Neonatology - A companion to Disease of the Newborn, 1st ed. WB Saunders Co., Philadelphia 2000. Copyright &copy; 2000 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_7_19583=[""].join("\n");
var outline_f19_7_19583=null;
